<SEC-DOCUMENT>0001140361-24-017676.txt : 20240403
<SEC-HEADER>0001140361-24-017676.hdr.sgml : 20240403
<ACCEPTANCE-DATETIME>20240403172747
ACCESSION NUMBER:		0001140361-24-017676
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20240403
DATE AS OF CHANGE:		20240403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aquestive Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001398733
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				208623253
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-278498
		FILM NUMBER:		24820252

	BUSINESS ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		908-941-1900

	MAIL ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MonoSol Rx, Inc.
		DATE OF NAME CHANGE:	20070507
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>ny20010746x1_s3.htm
<DESCRIPTION>FORM S-3
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="ny20010746x1_s3_100-regcov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 24pt; text-align: center;">As filed with the Securities and Exchange Commission on April&#160;3, 2024 </div><div class="regno" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 2pt; text-align: right;">Registration No. 333-&#8195;&#8195;&#8195;<font style="font-weight: normal;"> </font></div></div></div><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 9.5pt; text-align: center;">UNITED STATES <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Washington, D.C. 20549 </font></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 10.5pt; text-align: center;">FORM S-3 <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;">REGISTRATION STATEMENT <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt; font-style: italic;">UNDER</font><font style="font-size: 12pt; font-weight: normal;"> </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt; font-style: italic;">THE SECURITIES ACT OF 1933</font><font style="font-size: 12pt; font-weight: normal;"> </font></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">Aquestive Therapeutics, Inc. <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt;">(Exact name of registrant as specified in its charter) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 48.89%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.89%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">82-3827296 </div></td></tr><tr><td style="width: 48.89%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(State or other jurisdiction of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">incorporation or organization)</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(I.R.S. Employer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Identification Number)</div></td></tr></table><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">30 Technology Drive, <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Warren, New Jersey 07059 <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(908) 941-1900 <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Address, including zip code, and telephone number, including area code of registrant&#8217;s principal executive offices) </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">A. Ernest Toth, Jr. <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Chief Financial Officer <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aquestive Therapeutics, Inc. <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">30 Technology Drive, Warren, New Jersey 07059 (908) 941-1900 <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-style: italic; font-weight: bold; margin-top: 8.5pt; text-align: center;">Copies to: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 48.89%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">Lori J. Braender <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">SVP &#8211; General Counsel and Secretary <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">30 Technology Drive <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">Warren, New Jersey 07059</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.89%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">David S. Rosenthal <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">Anna Tomczyk <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">Dechert LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">1095 Avenue of the Americas <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">New York, New York 10036</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6.5pt; text-align: center;">From time to time after the effective date of this Registration Statement<font style="font-weight: normal;"> </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Approximate date of commencement of proposed sale to the public) </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the only securities being registered on this Form&#160;are being offered pursuant to dividend or interest reinvestment plans, please check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of the securities being registered on this Form&#160;are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. &#x2612; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&#160;462(e) under the Securities Act, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&#160;413(b) under the Securities Act, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Large accelerated filer</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.78%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 9pt;">&#x2610;</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 40%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accelerated filer</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.22%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 9pt;">&#x2610;</font><font style="font-size: 9pt;"> </font></div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-accelerated filer</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 40%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Smaller reporting company</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612; </div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 40%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Emerging growth company</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 9pt;">&#x2610;</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 4pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.<font style="font-weight: normal;"> </font></div></div><div class="block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_101-note_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">EXPLANATORY NOTE </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">This registration statement contains: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a base prospectus covering the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $250.0&#160;million of the registrant&#8217;s common stock, preferred stock, debt securities, warrants, rights and/or units&#894; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an equity distribution agreement prospectus covering the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of approximately $100.0&#160;million of the registrant&#8217;s common stock that may be issued and sold from time to time under an equity distribution agreement with Piper Sandler &amp; Co. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The equity distribution agreement prospectus immediately follow the base prospectus. The approximately $100.0&#160;million of common stock that may be offered, issued and sold by the registrant under the equity distribution agreement prospectus is included in the $250.0&#160;million of securities that may be offered, issued and sold by the registrant under the base prospectus.<font style="font-weight: normal;"> </font></div></div></div></div>
<!--End Page 2-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20010746x1_s3_102-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="h1" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><div style="font-family: Arial, Helvetica, sans-serif; text-align: left; margin-bottom: 12pt;">The information in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not soliciting offers to buy these securities in any state where such offer or sale is not permitted. </div>SUBJECT TO COMPLETION, DATED APRIL 3, 2024<font style="color: #000000;"> </font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">PROSPECTUS </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; text-align: center;"><img style="height: 57px; width: 224px;" src="logo_aquestivex1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 14.5pt; text-align: center;">Aquestive Pharmaceuticals, Inc.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 14pt;">$250,000,000</font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 14pt;">&#8195; </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Common Stock </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Preferred Stock </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Debt Securities </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Warrants </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Rights </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Units</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -2pt; text-align: center;"><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-top: 1pt; display: inline-block; margin-left: auto; margin-right: auto;"> </div> <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From time to time, we may offer up to $250,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable anti-dilution provisions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement.<font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our common stock is traded on the Nasdaq Global Market under the symbol &#8220;AQST.&#8221; On April&#160;2, 2024, the last reported sale price of our common stock was $4.14 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Global Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section titled &#8220;Plan of Distribution&#8221; in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. </div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 6.75pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;<u>Risk Factors</u>&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus as described on page <a href="#tRF">6</a> of this prospectus.<font style="font-style: normal; font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.<font style="font-weight: normal;"> </font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 6.75pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 26pt; text-align: center;">The date of this prospectus is &#8195;&#8195;&#8195;, 2024.</div></div></div></div>
<!--End Page 3-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_103-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS </div><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.51%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP">ABOUT THIS PROSPECTUS<font style="padding-left: 4.33pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tATP"><font style="padding-left: 5pt;">1</font> </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSUM">SUMMARY<font style="padding-left: 3.39pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tSUM"><font style="padding-left: 5pt;">2</font> </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">RISK FACTORS<font style="padding-left: 4.32pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tRF"><font style="padding-left: 5pt;">6</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSNR">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS<font style="padding-left: 0.19pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tSNR"><font style="padding-left: 5pt;">7</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUOP">USE OF PROCEEDS<font style="padding-left: 0.07pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tUOP">10</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOC">DESCRIPTION OF CAPITAL STOCK<font style="padding-left: 3.11pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tDOC"><font style="padding-left: 0.37pt;">11</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOD">DESCRIPTION OF DEBT SECURITIES<font style="padding-left: 4.16pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tDOD">15</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOW">DESCRIPTION OF WARRANTS<font style="padding-left: 0.27pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tDOW">22</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOR">DESCRIPTION OF RIGHTS<font style="padding-left: 3.98pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tDOR">24</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOU">DESCRIPTION OF UNITS<font style="padding-left: 0.64pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tDOU">26</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOD">PLAN OF DISTRIBUTION<font style="padding-left: 3.98pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tPOD">27</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">LEGAL MATTERS<font style="padding-left: 3.22pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tLM">30</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tE">EXPERTS<font style="padding-left: 1.77pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tE">30</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">WHERE YOU CAN FIND MORE INFORMATION<font style="padding-left: 3.84pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tWYC">30</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIOC">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE<font style="padding-left: 3.01pt;"></font></a></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><a href="#tIOC">31</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 4-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_104-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tATP"><!--Anchor--></a>ABOUT THIS PROSPECTUS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus is a part of a registration statement on Form&#160;S-3 that we filed with the Securities and Exchange Commission, or the SEC, utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate offering price of $250,000,000. This prospectus provides you with a general description of the securities we may offer. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading &#8220;Incorporation of Certain Information by Reference,&#8221; before investing in any of the securities offered. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor does this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even if this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus and the information incorporated herein by reference contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find More Information.&#8221; </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 5-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20010746x1_s3_105-summary_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSUM"><!--Anchor--></a>SUMMARY </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This summary highlights information contained in other parts of this prospectus or incorporated by reference into this prospectus from our filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;). As it is only a summary, it does not contain all of the information that you should consider before purchasing our securities and it is qualified in its entirety by, and should be read in conjunction with, the applicable prospectus supplement and the more detailed information appearing elsewhere or incorporated by reference into this prospectus. You should read the entire prospectus, the applicable prospectus supplement, the registration statement of which this prospectus is a part, and the information incorporated by reference herein in their entirety, including the &#8220;Risk Factors&#8221; and our financial statements and the related notes contained in and incorporated by reference into this prospectus, before purchasing our securities.<font style="font-style: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless the context indicates otherwise, references in this prospectus to &#8220;Aquestive,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Aquestive Therapeutics, Inc. and its consolidated subsidiaries.<font style="font-style: normal;"> </font></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; text-align: center;">Company Overview </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients&#8217; lives through innovative science and delivery technologies. We are developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. We have five licensed commercialized products which are marketed by our licensees in the U.S. and around the world. We are the exclusive manufacturer of these licensed products. Aquestive also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, and has proven drug development and commercialization capabilities. We are advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. We have also developed a product pipeline focused on treating diseases of the central nervous system. Our production facilities are located in Portage, Indiana, and our corporate headquarters and primary research laboratory facilities are based in Warren, New Jersey. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We manufacture licensed products at our facilities and anticipate that our current manufacturing capacity is sufficient for commercial quantities of our licensed products and product candidates currently in development. Our facilities have been inspected by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), the Australian Government Department of Health&#8217;s Therapeutics Goods Administration, and the Drug Enforcement Agency and are subject to inspection by all applicable health agencies, including the Brazilian Health Regulatory Agency and the European Medicines Agency. Not all collaborative or licensed products of Aquestive that may be commercially launched in the future will necessarily be manufactured by us, such as the case with KYNMOBI<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Corporate Information </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our principal executive offices are located at 30 Technology Drive, Warren, New Jersey 07059. Our website is www.aquestive.com. Except as otherwise specifically incorporated by reference in this prospectus, information contained in, or accessible through, our website is not a part of this prospectus, and you should not rely on any such information in deciding whether to purchase our securities. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Implications of Being a Smaller Reporting Company </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of December&#160;31, 2023, we are no longer an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 but are still a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. We will continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii) our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. We may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, (a) we may choose to present only the two most recent fiscal years of audited financial statements and only two years of related &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; in our Annual Report on Form&#160;10-K, (b) we are not required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended, on the effectiveness of our internal controls over financial </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 6-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20010746x1_s3_105-summary_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">reporting and (c) similar to emerging growth companies, we are subject to reduced disclosure obligations regarding executive compensation arrangements in our periodic reports, proxy statements and registration statements. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">The Securities We May Offer </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may offer shares of our common stock and preferred stock, various series of debt securities, warrants and rights to purchase shares of common stock or preferred stock, debt securities or units, as well as units to purchase any of such securities, from time to time under this prospectus, together with any applicable prospectus supplement and related free writing prospectus, at prices and on terms to be determined by market conditions at the time of offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">designation or classification&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">aggregate principal amount or aggregate offering price&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">maturity&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">original issue discount, if any&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">rates and times of payment of interest or dividends, if any&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">redemption, conversion, exchange or sinking fund terms, if any&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ranking&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictive covenants, if any&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">voting or other rights, if any&#894; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">important U.S. federal income tax considerations. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference into this prospectus. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may sell the securities directly to investors or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable prospectus supplement: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the names of those underwriters or agents&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">applicable fees, discounts and commissions to be paid to them&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">details regarding over-allotment options, if any&#894; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the estimated net proceeds to us. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Common Stock </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may offer shares of our common stock, par value $0.001 per share, either alone or underlying other registered securities convertible into or exercisable for our common stock. Holders of our common stock are entitled to dividends as our board of directors may declare from time to time out of legally available funds, subject to the preferential rights of the holders of any shares of our preferred stock that we may issue in the </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 7-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20010746x1_s3_105-summary_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">future. Currently, we do not pay any dividends and we do not have any issued and outstanding preferred stock. Each holder of our common stock is entitled to one vote per share. In this prospectus, we provide a general description of, among other things, the rights and restrictions that apply to holders of our common stock. Our common stock is described in greater detail in this prospectus under &#8220;Description of Capital Stock&#8212;Common Stock.&#8221; </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Preferred Stock </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may issue shares of preferred stock in one or more classes or series. Our board of directors or a committee designated by our board of directors will determine the dividend, voting and conversion rights and other provisions at the time of sale. The particular terms of each class or series of preferred stock, including redemption privileges, liquidation preferences, voting rights, dividend rights and/or conversion rights, will be more fully described in the applicable prospectus supplement relating to the preferred stock offered thereby. Our preferred stock is described in greater detail in this prospectus under &#8220;Description of Capital Stock&#8212;Preferred Stock.&#8221; </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Debt Securities </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may offer debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsubordinated debt that we may have and may be secured or unsecured. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all or some portion of our indebtedness. Any convertible debt securities that we issue will be convertible into or exchangeable for our common stock or other securities of ours. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The debt securities will be issued under one or more documents called indentures, which are contracts between us and a trustee for the holders of the debt securities. In this prospectus, we have summarized certain general features of the debt securities under &#8220;Description of Debt Securities.&#8221; We urge you, however, to read the prospectus supplements and any free writing prospectus that we may authorize to be provided to you related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. A form of an indenture has been filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of debt securities being offered will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Warrants </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may from time to time offer warrants for the purchase of our common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from those securities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The warrants will be evidenced by warrant certificates issued under one or more warrant agreements, which are contracts between us and an agent for the holders of the warrants. In this prospectus, we have summarized certain general features of the warrants under &#8220;Description of Warrants.&#8221; We urge you, however, to read the prospectus supplements and any free writing prospectus that we may authorize to be provided to you related to the series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement which includes this prospectus. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Rights </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may from time to time issue rights to purchase shares of our common stock or preferred stock, debt securities or units. The rights may be issued independently or together with other securities and may or may not be transferable by the persons purchasing or receiving the rights. In connection with any rights offering, we may enter into a standby underwriting or other arrangement with one or more underwriters or other persons pursuant to which such underwriters or other persons would purchase any offered securities remaining unsubscribed for after such rights offering. In connection with a rights offering to our stockholders, we would make available a prospectus supplement to our stockholders on or about the record date that we set for receiving rights in such rights offering. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 8-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20010746x1_s3_105-summary_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In this prospectus, we have summarized certain general features of the rights under &#8220;Description of Rights.&#8221; We urge you, however, to read the prospectus supplements and any free writing prospectus that we may authorize to be provided to you related to the series of rights being offered. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Units </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may offer units consisting of common stock, preferred stock, debt securities and/or warrants to purchase any of such securities in one or more series. In this prospectus, we have summarized certain general features of the units under &#8220;Description of Units.&#8221; We urge you, however, to read the prospectus supplements and any free writing prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the unit agreements that contain the terms of the units. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a current report on Form&#160;8-K that we file with the SEC, the form of unit agreement and any supplemental agreements that describe the terms of the series of units we are offering before the issuance of the related series of units. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will evidence each series of units by unit certificates that we will issue under a separate agreement. We will enter into the unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement relating to a particular series of units. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 9-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_106-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRF"><!--Anchor--></a>RISK FACTORS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, as updated by our annual, quarterly and other reports and documents that are incorporated by reference into this prospectus or the applicable prospectus supplement, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of these risk factors could have a material and adverse effect on our business, results of operations, financial position or cash flows, which may result in the loss of all or part of your investment. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 10-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_107-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSNR"><!--Anchor--></a>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus and the documents incorporated by reference contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section&#160;27A of the Securities Act and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)). These are based on our management&#8217;s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements may be found, among other places, in the Sections entitled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; incorporated by reference from our most recent Annual Report on Form&#160;10-K, as well as any amendments thereto, filed with the SEC. Also, documents we subsequently file with the SEC and incorporate by reference may contain forward-looking statements. Such risks and uncertainties include, but are not limited to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans, including those relating to Anaphylm&#8482; (epinephrine) Sublingual Film and Libervant&#8482; (diazepam) Buccal Film; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of delays in regulatory advancement through the FDA of Anaphylm, Libervant and our other drug candidates or failure to receive FDA approval at all; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that we may not overcome the seven-year orphan drug exclusivity granted by the FDA for the approved nasal spray product of another company in the U.S. in order for Libervant to be granted U.S.&#160;market access for any age group of patients; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of litigation brought by third parties relating to overcoming their orphan drug exclusivity of an FDA approved product should the FDA approve Libervant for U.S. market access for any age group of this epilepsy patient population; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk that a competing pediatric epilepsy product of Libervant will receive FDA approval prior to the Company&#8217;s receipt of FDA approval of the Libervant NDA for these epilepsy patients between two and five years of age; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk in obtaining market access for Libervant for other reasons; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk in obtaining market access from the FDA for our other product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks and uncertainties concerning the revenue stream from the monetization of our royalty rights for the product KYNMOBI<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, as well as the achievement of royalty targets worldwide or in any jurisdiction and certain other commercial targets required for contingent payments under the KYNMOBI<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> monetization transaction, and the Company may not receive any of the additional aggregate contingent payments under the monetization agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of development of a sales and marketing capability for future commercialization of our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of sufficient capital and cash resources, including access to available debt and equity financing, including under our at-the-market facility and the Common Stock Purchase Agreement entered into with Lincoln Park Capital Fund, LLC on April&#160;12, 2022, and from revenues from operations, to satisfy all of our short-term and longer-term cash requirements and other cash needs, at the times and in the amounts needed, including near-term debt amortization schedules; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of failure to satisfy all financial and other debt covenants and of any default under our debt facility; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">short-term and long-term liquidity and cash requirements, cash funding and cash burn; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk related to government and other claims against Indivior Inc. for which we license, manufacture and sell Suboxone<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and which accounts for the substantial part of our current operating revenues, including the risk related to the recent product liability multi-district litigation related to Suboxone<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks related to the outsourcing of certain operational and staff functions to third parties; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 11-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_107-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of the rate and degree of market acceptance of our product and product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the success of any competing products including generics; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of the size and growth of our product markets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks associated with intellectual property rights and infringement claims relating to our products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of unexpected patent developments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of legislation and regulatory actions and changes in laws or regulations affecting our business including relating to our products and product candidates and product pricing, reimbursement or access therefor; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of loss of significant customers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks related to claims and legal proceedings including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of product recalls and withdrawals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks related to any disruptions in our information technology networks and systems, including the impact of cyberattacks; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks related to adverse developments affecting the financial services industry; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks related to inflation and rising interest rates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks related to the impact of a health pandemic on our business, including with respect to our clinical trials and the site initiation, patient enrollment and timing and adequacy of those clinical trials, regulatory submissions and regulatory reviews and approvals of our product candidates, availability of pharmaceutical ingredients and other raw materials used in our products and product candidates, supply chain, manufacture and distribution of our products and product candidates; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks and uncertainties related to general economic, political (including the wars in Ukraine and Israel and other acts of war and terrorism), business, industry, regulatory and market conditions and other unusual items. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In some cases, forward-looking statements are identified by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not be different, and historic results referred to in our most recent Annual Report on Form&#160;10-K, may be interpreted differently in light of additional research and clinical and preclinical trials results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to (and expressly disclaim any such obligation to) update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this prospectus. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 12-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_107-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 13-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_108-use_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUOP"><!--Anchor--></a>USE OF PROCEEDS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby, if any, for working capital, capital expenditures and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these uses, we plan to invest these net proceeds in short-term, investment-grade securities. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 14-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDOC"><!--Anchor--></a>DESCRIPTION OF CAPITAL STOCK </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries. You should also refer to the amended and restated certificate of incorporation and the amended and restated bylaws, which are incorporated by reference as exhibits to the registration statement of which this prospectus is part.<font style="font-style: normal;"> </font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">General </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our amended and restated certificate of incorporation authorizes us to issue up to 250,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share, all of which remains undesignated. The following summary is qualified in its entirety by reference to our amended and restate certificate of incorporation, a copy of which is filed as an exhibit to our previous filings with the SEC and incorporated herein by reference. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Common Stock </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Outstanding Shares </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Voting Rights </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders. The affirmative vote of holders of at least 66<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup>&#8725;<font style="font-size: 7pt;">3</font>% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction, provided, however, that this restriction shall not apply to, and such 66<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup>&#8725;<font style="font-size: 7pt;">3</font>% vote shall not be required for, any such amendment, change or repeal approved by the affirmative vote of at least a majority of the then current duly elected board of directors, in which case such action shall require only the vote of shareholders as required under Delaware law. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Dividends </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to preferences that may apply to any outstanding preferred stock, holders of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate we will declare or pay any cash dividends for the foreseeable future. Further, any future debt agreements may also prohibit us from paying, or place restrictions on our ability to pay, dividends. Any return to stockholders will therefore be limited to the appreciation of their stock. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Liquidation </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Rights and Preferences </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 15-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Preferred Stock </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of the date of this prospectus, we had no shares of preferred stock issued or outstanding. Under our amended and restated certificate of incorporation, our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Anti-Takeover Effects of Provisions of Our Certificate of Incorporation and Our Bylaws </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our amended and restated certificate of incorporation and amended and restated bylaws contain certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of the board of directors and which may have the effect of delaying, deferring or preventing a future takeover or change in control of the company unless such takeover or change in control is approved by the board of directors. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These provisions include: </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Classified Board.<font style="font-style: normal; font-weight: normal;"> Our amended and restated certificate of incorporation provides that our board of directors </font><font style="font-style: normal; font-weight: normal;">is divided into three classes of directors, with the classes as nearly equal in number as possible. As a result, </font><font style="font-style: normal; font-weight: normal;">approximately one-third of our board of directors are elected each year. The classification of directors has the </font><font style="font-style: normal; font-weight: normal;">effect of making it more difficult for stockholders to change the composition of our board. Our amended and </font><font style="font-style: normal; font-weight: normal;">restated certificate of incorporation also provides that, subject to any rights of holders of preferred stock to elect </font><font style="font-style: normal; font-weight: normal;">additional directors under specified circumstances, the number of directors will be fixed exclusively pursuant to a </font><font style="font-style: normal; font-weight: normal;">resolution adopted by our board of directors. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Action by Written Consent; Special Meetings of Stockholders.<font style="font-style: normal; font-weight: normal;"> Our amended and restated certificate of </font><font style="font-style: normal; font-weight: normal;">incorporation provides that stockholder action can be taken only at an annual or special meeting of stockholders </font><font style="font-style: normal; font-weight: normal;">and cannot be taken by written consent in lieu of a meeting. Our amended and restated certificate of </font><font style="font-style: normal; font-weight: normal;">incorporation and our amended and restated bylaws also provide that, except as otherwise required by law, </font><font style="font-style: normal; font-weight: normal;">special meetings of the stockholders can be called only by or at the direction of the board of directors pursuant </font><font style="font-style: normal; font-weight: normal;">to a resolution adopted by a majority of the total number of directors. Stockholders are not permitted to call a </font><font style="font-style: normal; font-weight: normal;">special meeting or to require the board of directors to call a special meeting. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Removal of Directors.<font style="font-style: normal; font-weight: normal;"> Our amended and restated certificate of incorporation provides that our directors may </font><font style="font-style: normal; font-weight: normal;">be removed only for cause by the affirmative vote of at least 66</font><font style="font-style: normal; font-weight: normal;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></font><font style="font-style: normal; font-weight: normal;">&#8725;</font><font style="font-size: 7pt; font-style: normal; font-weight: normal;">3</font><font style="font-style: normal; font-weight: normal;">% of the votes that all our stockholders would </font><font style="font-style: normal; font-weight: normal;">be entitled to cast in an annual election of directors, voting together as a single class, at a meeting of the </font><font style="font-style: normal; font-weight: normal;">stockholders called for that purpose. This requirement of a supermajority vote to remove directors could enable a </font><font style="font-style: normal; font-weight: normal;">minority of our stockholders to prevent a change in the composition of our board. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Advance Notice Procedures.<font style="font-style: normal; font-weight: normal;"> Our amended and restated bylaws establish an advance notice procedure for </font><font style="font-style: normal; font-weight: normal;">stockholder proposals to be brought before an annual meeting of our stockholders, including proposed </font><font style="font-style: normal; font-weight: normal;">nominations of persons for election to the board of directors. Stockholders at an annual meeting are only able to </font><font style="font-style: normal; font-weight: normal;">consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the </font><font style="font-style: normal; font-weight: normal;">direction of the board of directors or by a stockholder who was a stockholder of record on the record date for the </font><font style="font-style: normal; font-weight: normal;">meeting, who is entitled to vote at the meeting and who has given our secretary timely written notice, in proper </font><font style="font-style: normal; font-weight: normal;">form, of the stockholder&#8217;s intention to bring that business before the meeting. Although the amended and restated </font><font style="font-style: normal; font-weight: normal;">bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of </font><font style="font-style: normal; font-weight: normal;">candidates or proposals regarding other business to be conducted at a special or annual meeting, the amended </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 16-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the company. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Super Majority Approval Requirements.<font style="font-style: normal; font-weight: normal;"> The Delaware General Corporation Law generally provides that the </font><font style="font-style: normal; font-weight: normal;">affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s </font><font style="font-style: normal; font-weight: normal;">certificate of incorporation or bylaws, unless either a corporation&#8217;s certificate of incorporation or bylaws requires </font><font style="font-style: normal; font-weight: normal;">a greater percentage. A majority vote of our board of directors or the affirmative vote of holders of at least </font><font style="font-style: normal; font-weight: normal;">66</font><font style="font-style: normal; font-weight: normal;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></font><font style="font-style: normal; font-weight: normal;">&#8725;</font><font style="font-size: 7pt; font-style: normal; font-weight: normal;">3</font><font style="font-style: normal; font-weight: normal;">% of the total votes of the outstanding shares of our capital stock entitled to vote with respect thereto, </font><font style="font-style: normal; font-weight: normal;">voting together as a single class, are required to amend, alter, change or repeal the amended and restated bylaws. </font><font style="font-style: normal; font-weight: normal;">In addition, the affirmative vote of the holders of at least 66</font><font style="font-style: normal; font-weight: normal;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></font><font style="font-style: normal; font-weight: normal;">&#8725;</font><font style="font-size: 7pt; font-style: normal; font-weight: normal;">3</font><font style="font-style: normal; font-weight: normal;">% of the total votes of the outstanding shares of </font><font style="font-style: normal; font-weight: normal;">our capital stock entitled to vote with respect thereto, voting together as a single class, are required to amend, </font><font style="font-style: normal; font-weight: normal;">alter, change or repeal, or to adopt any provisions inconsistent with, any of the provisions in our amended and </font><font style="font-style: normal; font-weight: normal;">restated certificate of incorporation relating to amendments to our amended and restated certificate of </font><font style="font-style: normal; font-weight: normal;">incorporation and amended and restated bylaws and as described under &#8220;Action by Written Consent; Special </font><font style="font-style: normal; font-weight: normal;">Meetings of Stockholders&#8221;, &#8220;Classified Board&#8221; and &#8220;Removal of Directors&#8221; above. This requirement of a </font><font style="font-style: normal; font-weight: normal;">supermajority vote to approve amendments to our amended and restated bylaws and amended and restated </font><font style="font-style: normal; font-weight: normal;">certificate of incorporation could enable a minority of our stockholders to exercise veto power over any such </font><font style="font-style: normal; font-weight: normal;">amendments. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Authorized but Unissued Shares.<font style="font-style: normal; font-weight: normal;"> Our authorized but unissued shares of common stock and preferred stock </font><font style="font-style: normal; font-weight: normal;">are available for future issuance without stockholder approval. These additional shares may be utilized for a </font><font style="font-style: normal; font-weight: normal;">variety of corporate purposes, including future public offerings to raise additional capital and corporate </font><font style="font-style: normal; font-weight: normal;">acquisitions. The existence of authorized but unissued shares of common stock and preferred stock could render </font><font style="font-style: normal; font-weight: normal;">more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy </font><font style="font-style: normal; font-weight: normal;">contest, tender offer, merger or otherwise. For example, if in the due exercise of its fiduciary obligations, our </font><font style="font-style: normal; font-weight: normal;">board of directors were to determine that a takeover proposal is not in the best interests of us or our </font><font style="font-style: normal; font-weight: normal;">stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder </font><font style="font-style: normal; font-weight: normal;">approval in one or more private offerings or other transactions that might dilute the voting or other rights of the </font><font style="font-style: normal; font-weight: normal;">proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated </font><font style="font-style: normal; font-weight: normal;">certificate of incorporation grants our board of directors broad power to establish the rights and preferences of </font><font style="font-style: normal; font-weight: normal;">authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the </font><font style="font-style: normal; font-weight: normal;">amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may </font><font style="font-style: normal; font-weight: normal;">also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of </font><font style="font-style: normal; font-weight: normal;">delaying, deterring or preventing a change in control of us. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Exclusive Forum.<font style="font-style: normal; font-weight: normal;"> Our amended and restated certificate of incorporation provides that, subject to limited </font><font style="font-style: normal; font-weight: normal;">exceptions, the state or federal courts located in the State of Delaware are the sole and exclusive forum for </font><font style="font-style: normal; font-weight: normal;">(i)&#160;any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a </font><font style="font-style: normal; font-weight: normal;">fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any </font><font style="font-style: normal; font-weight: normal;">action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, </font><font style="font-style: normal; font-weight: normal;">our amended and restated certificate of incorporation or our amended and restated bylaws, or (iv) any other </font><font style="font-style: normal; font-weight: normal;">action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum </font><font style="font-style: normal; font-weight: normal;">provision would not apply to suits brought to enforce any liability or duty created by the Securities Act or the </font><font style="font-style: normal; font-weight: normal;">Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any </font><font style="font-style: normal; font-weight: normal;">such claims may be based upon federal law claims, Section&#160;27 of the Exchange Act creates exclusive federal </font><font style="font-style: normal; font-weight: normal;">jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and </font><font style="font-style: normal; font-weight: normal;">regulations thereunder. Furthermore, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal </font><font style="font-style: normal; font-weight: normal;">and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules </font><font style="font-style: normal; font-weight: normal;">and regulations thereunder. Our amended and restated certificate of incorporation also provides that any person or </font><font style="font-style: normal; font-weight: normal;">entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice </font><font style="font-style: normal; font-weight: normal;">of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the </font><font style="font-style: normal; font-weight: normal;">choice of forum provision contained in our amended and restated certificate of incorporation is inapplicable or </font><font style="font-style: normal; font-weight: normal;">unenforceable if it is challenged in a proceeding or otherwise. Any person or entity purchasing or otherwise </font><font style="font-style: normal; font-weight: normal;">acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to </font><font style="font-style: normal; font-weight: normal;">the provisions of our amended and restated certificate of incorporation described above. Although we believe </font><font style="font-style: normal; font-weight: normal;">these provisions benefit us by providing increased consistency in the application of Delaware law for the </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 17-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with one or more actions or proceedings described above, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Section&#160;203 of the Delaware General Corporation Law </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law, or Section&#160;203. In general, Section&#160;203 prohibits a publicly-held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#8217;s voting stock. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: before the stockholder became interested, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 75% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#8217; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The transfer agent and registrar for our common stock is Computershare. The transfer agent&#8217;s address is 1290 Avenue of the Americas, 9th Floor, New York, NY 10104, and its telephone number is (212) 805-7100. The transfer agent for any series of stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Listing on the Nasdaq Global Market </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;AQST.&#8221; </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 18-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDOD"><!--Anchor--></a>DESCRIPTION OF DEBT SECURITIES </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following description, together with the additional information we include in any applicable prospectus supplements or free writing prospectuses, summarizes the material terms and provisions of the debt securities that we may offer under this prospectus. We may issue debt securities, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any future debt securities we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement or free writing prospectus. The terms of any debt securities we offer under a prospectus supplement may differ from the terms we describe below. As of the date of this prospectus, we have no outstanding registered debt securities. Unless the context requires otherwise, whenever we refer to the &#8220;indenture,&#8221; we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may offer senior debt securities or subordinated debt securities under the indenture and any supplemental indentures that we will enter into with the trustee named in the indenture. We have filed a form of the indenture as an exhibit to the registration statement, of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The indenture will be qualified under the Trust Indenture Act of 1939, as amended (the &#8220;Trust Indenture Act&#8221;). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following summaries of material provisions of the indenture are subject to, and qualified in their entirety by reference to, all of the provisions of the indenture and any supplemental indentures applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">General </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the manner provided in an officer&#8217;s certificate or by a supplemental indenture. Debt securities may be issued in separate series without limitation as to aggregate principal amount. We may specify a maximum aggregate principal amount for the debt securities of any series. We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the title of the series of debt securities&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any limit upon the aggregate principal amount that may be issued&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the maturity date or dates&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the form of the debt securities of the series&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the applicability of any guarantees&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our right, if any, to defer payment of interest and the maximum length of any such deferral period&#894; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 19-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities&#894; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities&#894; and the depositary for such global security or securities&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#8217; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions to or changes in the provisions relating to satisfaction and discharge of the indenture&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and the terms and conditions upon which the election may be made&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any restrictions on transfer, sale or assignment of the debt securities of the series&#894; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 20-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Conversion or Exchange Rights </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will set forth in the applicable prospectus supplement the terms under which a series of debt securities may be convertible into or exchangeable for our common stock, our preferred stock or other securities (including securities of a third party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third party) that the holders of the series of debt securities receive would be subject to adjustment. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Consolidation, Merger or Sale </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indenture or the debt securities, as appropriate. If the debt securities are convertible into or exchangeable for our other securities or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into securities that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Events of Default under the Indenture </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been extended&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we fail to observe or perform any other covenant contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive notice from the trustee or we and the trustee receive notice from the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series&#894; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if specified events of bankruptcy, insolvency or reorganization occur. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default arises due to the occurrence of certain specified bankruptcy, insolvency or reorganization events, the unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br></div></div></div>
<!--End Page 21-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the terms of the indenture, if an event of default under the indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under the indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the direction so given by the holder is not in conflict with any law or the applicable indenture&#894; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The indenture provides that if an event of default has occurred and is continuing, the trustee will be required in the exercise of its powers to use the degree of care that a prudent person would use in the conduct of its own affairs. The trustee, however, may refuse to follow any direction that conflicts with law or the indenture, or that the trustee determines is unduly prejudicial to the rights of any other holder of the relevant series of debt securities, or that would involve the trustee in personal liability. Prior to taking any action under the indenture, the trustee will be entitled to indemnification against all costs, expenses and liabilities that would be incurred by taking or not taking such action. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, a holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the holder has given written notice to the trustee of a continuing event of default with respect to that series&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made a written request and such holders have offered reasonable indemnity to the trustee or security satisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting the proceeding as trustee&#894; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the trustee does not institute the proceeding and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Modification of Indenture&#894; Waiver </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the terms of the indenture for any series of debt securities that we may issue, we and the trustee may change the indenture without the consent of any holders with respect to the following specific matters: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to cure any ambiguity, defect or inconsistency in the indenture&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to comply with the provisions described above under &#8220;Description of Debt Securities&#8212;Consolidation, Merger or Sale&#894;&#8221; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">18<br></div></div></div>
<!--End Page 22-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#8220;Description of Debt Securities&#8212;General&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to provide for uncertificated debt securities and to make all appropriate changes for such purpose&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to add such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture&#894; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">However, subject to the terms of the indenture for any series of debt securities that we may issue or otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may only make the following changes with the consent of each holder of any outstanding debt securities affected: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">extending the fixed maturity of any debt securities of any series&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities&#894; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Discharge </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The indenture may provide that, subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we may elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">register the transfer or exchange of debt securities of the series&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">replace stolen, lost or mutilated debt securities of the series&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">maintain paying agencies&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">hold monies for payment in trust&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">recover excess money held by the trustee&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compensate and indemnify the trustee&#894; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">appoint any successor trustee. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, and any premium and interest on, the debt securities of the series on the dates payments are due. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Form, Exchange and Transfer </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">19<br></div></div></div>
<!--End Page 23-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depositary named by us and identified in a prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms related to any book-entry securities will be set forth in the applicable prospectus supplement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we elect to redeem the debt securities of any series, we will not be required to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing&#894; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Information Concerning the Trustee </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The trustee, other than during the occurrence and continuance of an event of default under the indenture, undertakes to perform only those duties as are specifically set forth in the indenture and is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. However, upon an event of default under the indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Payment and Paying Agents </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest payment. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">20<br></div></div></div>
<!--End Page 24-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Governing Law </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The indenture and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Ranking Debt Securities </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The subordinated debt securities that we may offer will be unsecured and will be subordinate and junior in priority of payment to certain other indebtedness to the extent described in a prospectus supplement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The senior debt securities that we may offer will be unsecured and will rank equally in right of payment to all our other senior unsecured debt. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">21<br></div></div></div>
<!--End Page 25-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDOW"><!--Anchor--></a>DESCRIPTION OF WARRANTS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a current report on Form&#160;8-K that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, if any, that describes the terms of the particular series of warrants we are offering before the issuance of the related series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. We urge you to read the applicable prospectus supplement and any applicable free writing prospectus related to the particular series of warrants that we sell under this prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">General </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will describe in the applicable prospectus supplement the terms relating to a series of warrants, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the title of such securities&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the offering and exercise price or prices and aggregate number of warrants offered&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the currency or currencies for which the warrants may be purchased&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the designation and terms of the securities with which the warrants are issued, and the number of warrants issued with each such security or each principal amount of such security&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the date on and after which the warrants and the related securities will be separately transferable&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms of any rights to redeem or call the warrants&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms of any rights to force the exercise of the warrants&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the dates on which the right to exercise the warrants will commence and expire&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the manner in which the warrant agreements and warrants may be modified&#894; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">22<br></div></div></div>
<!--End Page 26-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a discussion of any material or special U.S. federal income tax consequences of holding or exercising the warrants&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms of the securities issuable upon exercise of the warrants&#894; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture&#894; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Exercise of Warrants </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of the warrants may exercise the warrants by delivering the warrant certificate or agreement representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate or agreement and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon receipt of the required payment and the warrant certificate or agreement properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate or agreement are exercised, then we will issue a new warrant certificate or agreement for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Governing Law </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the laws of the State of New York. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Enforceability of Rights by Holders of Warrants </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">23<br></div></div></div>
<!--End Page 27-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 28-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDOR"><!--Anchor--></a>DESCRIPTION OF RIGHTS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a general description of the terms of the rights we may issue from time to time unless we provide otherwise in the applicable prospectus supplement. Particular terms of any rights we offer will be described in the prospectus supplement relating to such rights. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">General </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may issue rights to purchase common stock, preferred stock, debt securities or units. Rights may be issued independently or together with other securities and may or may not be transferable by the person purchasing or receiving the rights. In connection with any rights offering to our stockholders, we may enter into a standby underwriting, backstop or other arrangement with one or more underwriters or other persons pursuant to which such underwriters or other persons would purchase any offered securities remaining unsubscribed for after such rights offering. In connection with a rights offering to our stockholders, we would distribute certificates evidencing the rights and a prospectus supplement to our stockholders on or about the record date that we set for receiving rights in such rights offering. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The applicable prospectus supplement will describe the following terms of any rights we may issue, including some or all of the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the title and aggregate number of the rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the subscription price or a formula for the determination of the subscription price for the rights and the currency or currencies in which the subscription price may be payable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the designation and terms of the securities with which the rights are issued and the number of rights issued with each such security or each principal amount of such security; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number or a formula for the determination of the number of the rights issued to each stockholder; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the extent to which the rights are transferable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of rights to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one right; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of rights to purchase common stock or preferred stock, the type of stock and number of shares of stock purchasable upon exercise of one right; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the date on which the right to exercise the rights will commence, and the date on which the rights will expire (subject to any extension); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the minimum or maximum amount of the rights that may be exercised at any one time; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the extent to which such rights include an over-subscription privilege with respect to unsubscribed securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the procedures for adjusting the subscription price and number of shares of common stock or preferred stock purchasable upon the exercise of each right upon the occurrence of certain events, including stock splits, reverse stock splits, combinations, subdivisions or reclassifications of common stock or preferred stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effect on the rights of any merger, consolidation, sale or other disposition of our business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms of any rights to redeem or call the rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">information with respect to book-entry procedures, if any; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms of the securities issuable upon exercise of the rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the material terms of any standby underwriting, backstop or other purchase arrangement that we may enter into in connection with the rights offering; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, a discussion of certain U.S. Federal income tax considerations; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other terms of the rights, including terms, procedures and limitations relating to the exchange and exercise of the rights. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">24<br></div></div></div>
<!--End Page 28-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 29-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Exercise of Rights </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each right will entitle the holder to purchase for cash or other consideration such shares of stock or principal amount of securities at the subscription price as shall in each case be set forth in, or be determinable as set forth in, the prospectus supplement relating to the rights offered thereby. Rights may be exercised as set forth in the applicable prospectus supplement beginning on the date specified therein and continuing until the close of business on the expiration date set forth in the prospectus supplement relating to the rights offered thereby. After the close of business on the expiration date, unexercised rights will become void. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon receipt of payment and a subscription certificate properly completed and duly executed at the corporate trust office of the subscription agent or any other office indicated in the prospectus supplement, we will, as soon as practicable, forward the securities purchasable upon such exercise. If less than all of the rights represented by such subscription certificate are exercised, a new subscription certificate will be issued for the remaining rights. If we so indicate in the applicable prospectus supplement, holders of the rights may surrender securities as all or part of the exercise price for rights. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may determine to offer any unsubscribed offered securities directly to stockholders, persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby underwriting, backstop or other arrangements, as set forth in the applicable prospectus supplement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to exercising their rights, holders of rights will not have any of the rights of holders of the securities purchasable upon subscription, including, in the case of rights to purchase common stock or preferred stock, the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise any voting rights or, in the case of rights to purchase debt securities, the right to receive principal, premium, if any, or interest payments, on the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">25<br></div></div></div>
<!--End Page 29-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 30-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_109-description_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDOU"><!--Anchor--></a>DESCRIPTION OF UNITS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the units that we may offer under this prospectus. While the terms we have summarized below will apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a current report on Form&#160;8-K that we file with the SEC, the form of unit agreement that describes the terms of the series of units we are offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular series of units that we sell under this prospectus, as well as the complete unit agreement and any supplemental agreements that contain the terms of the units. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">General </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may issue units comprised of one or more debt securities, shares of common stock, shares of preferred stock and warrants in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will describe in the applicable prospectus supplement the terms of the series of units, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any provisions of the governing unit agreement that differ from those described below; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The provisions described in this section, as well as those described under &#8220;Description of Capital Stock,&#8221; &#8220;Description of Debt Securities&#8221; and &#8220;Description of Warrants&#8221; will apply to each unit and to any common stock, preferred stock, debt security or warrant included in each unit, respectively. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Issuance in Series </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may issue units in such amounts and in numerous distinct series as we determine. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Enforceability of Rights by Holders of Units </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We, the unit agents and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any purpose and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">26<br></div></div></div>
<!--End Page 30-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 31-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_110-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPOD"><!--Anchor--></a>PLAN OF DISTRIBUTION </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may sell the securities, from time to time, to or through underwriters or dealers, through agents or remarketing firms, or directly to one or more purchasers pursuant to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">underwritten public offerings; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">negotiated transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">block trades; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;At the Market Offerings,&#8221; within the meaning of Rule&#160;415(a)(4) of the Securities Act, into an existing trading market, at prevailing market prices; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through a combination of these methods. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may sell the securities to or through one or more underwriters or dealers (acting as principal or agent), through agents, or directly to one or more purchasers. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may distribute securities from time to time in one or more transactions: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at a fixed price or prices, which may be changed; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at market prices prevailing at the time of sale; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at prices related to such prevailing market prices; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at negotiated prices. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the name or names of the underwriters, dealers or agents, if any; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the securities are to be offered through the selling efforts of brokers or dealers, the plan of distribution and the terms of any agreement, arrangement, or understanding entered into with broker(s) or dealer(s) prior to the effective date of the registration statement, and, if known, the identity of any broker(s) or dealer(s) who will participate in the offering and the amount to be offered through each; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive from the sale; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if any of the securities being registered are to be offered otherwise than for cash, the general purposes of the distribution, the basis upon which the securities are to be offered, the amount of compensation and other expenses of distribution, and by whom they are to be borne; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any delayed delivery arrangements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any over-allotment or other options under which underwriters may purchase additional securities from us; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any public offering price; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any discounts, commissions or concessions allowed or reallowed or paid to dealers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the identity and relationships of any finders, if applicable; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any securities exchange or market on which the securities may be listed. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">27<br></div></div></div>
<!--End Page 31-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 32-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_110-plan_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Unless otherwise indicated in the prospectus supplement, subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters, dealers or agents with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, dealer or agent, the nature of any such relationship. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may use a remarketing firm to offer the securities in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own account or as agents for us. These remarketing firms will offer or sell the securities pursuant to the terms of the securities. A prospectus supplement will identify any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing firm&#8217;s compensation. Remarketing firms may be deemed to be underwriters in connection the securities they remarket. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we offer and sell securities through a dealer, we or an underwriter will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. The name of the dealer and the terms of the transaction will be set forth in the applicable prospectus supplement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions payable to the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, the agent will act on a best-efforts basis for the period of its appointment. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Dealers and agents participating in the distribution of the securities may be deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting discounts. If such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may sell securities directly to one or more purchasers without using underwriters or agents. Underwriters, dealers and agents that participate in the distribution of the securities may be underwriters as defined in the Securities Act, and any discounts or commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may provide agents, underwriters and dealers with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents, underwriters or dealers may make with respect to these liabilities. Agents, underwriters and dealers, or their respective affiliates, may engage in transactions with, or perform services for, us in the ordinary course of business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The securities we offer may be new issues of securities and may have no established trading market. The securities may or may not be listed on a securities exchange. Underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We can make no assurance as to the liquidity of, or the existence of trading markets for, any of the securities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">28<br></div></div></div>
<!--End Page 32-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 33-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_110-plan_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any underwriters that are qualified market makers on the Nasdaq Global Market may engage in passive market making transactions in the common stock on the Nasdaq Global Market in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">29<br></div></div></div>
<!--End Page 33-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 34-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_111-legal_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLM"><!--Anchor--></a>LEGAL MATTERS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Dechert LLP will pass for us upon the validity of the securities being offered by this prospectus and any applicable prospectus supplement. Additional legal matters may be passed upon for us or any underwriters, dealers or agents by counsel that we will name in the applicable prospectus supplement. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tE"><!--Anchor--></a>EXPERTS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The consolidated financial statements of Aquestive Therapeutics, Inc. as of December 31, 2023 and 2022, and for each of the years in the two-year period ended December 31, 2023, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have filed with the SEC a registration statement on Form&#160;S-3 under the Securities Act, with respect to the securities being offered by this prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to herein are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We file electronically with the SEC annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K, proxy statements and other information and amendments to those reports filed or furnished pursuant to Section&#160;13 or 15(d) of the Exchange Act. The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Copies of these reports, proxy and information statements and other information may be obtained by electronic request at the following e-mail address: publicinfo@sec.gov. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We make available, free of charge and through our Internet web site at www.aquestive.com, our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and any amendments to any such reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Copies of our Code of Business Conduct and Ethics and our Corporate Governance Guidelines may be accessed free of charge by visiting our website at www.aquestive.com under &#8220;Investors&#8221; at &#8220;Corporate Governance: Governance Documents&#8221; or by requesting a copy via an e-mail addressed to investorrelations@aquestive.com or by written request addressed to our Corporate Secretary at our principal executive offices. To the extent required by applicable law and regulation, we intend to post on our website any amendment to, or waiver under, a provision of the Code of Business Conduct and Ethics that applies to our executive officers and directors within the time period required. The information set forth on, or connected to, our website is expressly not incorporated by reference into, and does not constitute a part of, this prospectus. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">30<br></div></div></div>
<!--End Page 34-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 35-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_112-incorp_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tIOC"><!--Anchor--></a>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The SEC allows us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is 001-38599. The documents incorporated by reference into this prospectus contain important information that you should read about us. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following documents are incorporated by reference into this document: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1398733/000162828024009010/aqst-20231231.htm">March&#160;5, 2024</a>&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our Definitive Proxy Statement on Schedule 14A, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1398733/000114036123021673/ny20007004x2_def14a.htm">April&#160;28, 2023</a> (to the extent incorporated by reference into Part&#160;III of our Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2022); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our Current Reports on Form&#160;8-K filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1398733/000162828024011308/aqst-20240314.htm">March&#160;15, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1398733/000114036124014613/ny20024600x3_8-k.htm">March&#160;21, 2024</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1398733/000162828024013888/aqst-20240401.htm">April&#160;1, 2024</a> (to the extent the information in such report is filed and not furnished); and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the description of our common stock contained in our Registration Statement on Form&#160;8-A, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1398733/000114036118033010/s002128x10_8a12b.htm">July&#160;20, 2018</a>, as the description therein has been updated and superseded by the description of our securities contained in Exhibit&#160;4.7 to our Annual Report on Form&#160;10-K for the fiscal&#160;year ended December&#160;31, 2019, as filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1398733/000114036120005499/ex4_7.htm">March&#160;11, 2020</a>. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item&#160;2.02 or Item&#160;7.01 of Form&#160;8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii) after the date of this prospectus but prior to the termination of the offering. These documents include periodic reports, such as Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q and Current Reports on Form&#160;8-K, as well as proxy statements. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to Aquestive Therapeutics, Inc., Attn: Corporate Secretary, 30 Technology Dr.&#160;South, Warren, NJ 07059&#894; telephone: (908) 941-1900. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">31<br></div></div></div>
<!--End Page 35-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 36-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20010746x1_s3_113-bcv_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 456pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 78.75pt; text-align: center;"><img style="height: 57px; width: 224px;" src="logo_aquestivex1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 32.5pt; text-align: center;">$250,000,000 </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 30.5pt; text-align: center;">Common Stock <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred Stock <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;">Debt Securities <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;">Warrants <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;">Units </div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 79.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">PROSPECTUS </div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 19.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 146.5pt; text-align: center;">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</div></div></div><div class="block-frill" style="width: 456pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 36-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 37-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20010746x1_s3_200-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="fpara" style="color: #FF0000; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><div style="font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left; margin-bottom: 12pt;">The information in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not soliciting offers to buy these securities in any state where such offer or sale is not permitted.</div>SUBJECT TO COMPLETION, DATED APRIL 3, 2024<font style="color: #000000;"> </font></div><div class="h2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">PROSPECTUS </div><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 16pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Up to $100,000,000</div><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 22.75pt; margin-left: 0pt; text-align: left;"><img style="height: 57px; width: 224px;" src="logo_aquestivex1.jpg"><br></div><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 16pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Common Stock</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #49718D; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 6pt;"> </div></div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We previously entered into an Equity Distribution Agreement with Piper Sandler &amp; Co., or Piper Sandler, dated September&#160;11, 2019, as amended on March 26, 2021, or the Amended Equity Distribution Agreement, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the Amended Equity Distribution Agreement, which does not have a limit on the amount that can be sold pursuant thereto, we may offer and sell shares of our common stock having an aggregate offering price of up&#160;to $100.0 million from time to time through Piper Sandler, acting as sales agent, pursuant to this prospectus. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;AQST.&#8221; The last reported sale price of our common stock on the Nasdaq Global Market on April 2, 2024 was $4.14 per share. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Sales of our common stock, if any, under this prospectus may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Piper Sandler is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices on mutually agreed terms between Piper Sandler and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The compensation to Piper Sandler for sales of common stock sold pursuant to the Amended Equity Distribution Agreement will be an amount up to 3.0% of the gross sales price per share of common stock sold under the Amended Equity Distribution Agreement. In connection with the sale of the common stock on our behalf, Piper Sandler will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation of Piper Sandler will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Piper Sandler with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.</div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 8pt; text-align: center;"><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #49718D; margin-top: 6pt; display: inline-block; margin-left: auto; margin-right: auto;"> </div> <br></div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Investing in our common stock involves a high degree of risk. You should read this prospectus and the documents incorporated by reference herein before you make your investment decision. See &#8220;<u>Risk </u><u>Factors</u>&#8221; beginning on page S-<a href="#tRF1">5</a> of this prospectus and in the documents incorporated by reference herein, including our annual report on Form&#160;10-K, to read about risks that you should consider before purchasing shares of our common stock.</div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 8pt; text-align: center;"><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #49718D; margin-top: 6pt; display: inline-block; margin-left: auto; margin-right: auto;"> </div> <br></div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus are truthful or complete. Any representation to the contrary is a criminal offense.<font style="font-weight: normal;"> </font></div><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 18pt; font-weight: bold; margin-top: 42.5pt; text-align: center;">Piper Sandler </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 24pt; text-align: center;">The date of this prospectus is &#8195;&#8195;&#8195;, 2024.<font style="font-weight: normal;"> </font></div></div></div></div>
<!--End Page 37-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 38-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_201-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS </div><div class="h2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Prospectus </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP1">ABOUT THIS PROSPECTUS<font style="padding-left: 0.95pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP1"><font style="padding-left: 5.56pt;">S-</font>1 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSUM1">SUMMARY<font style="padding-left: 1.28pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSUM1"><font style="padding-left: 5.56pt;">S-</font>2 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTO1">THE OFFERING<font style="padding-left: 3.11pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTO1"><font style="padding-left: 5.56pt;">S-</font>3 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF1">RISK FACTORS<font style="padding-left: 2.03pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF1"><font style="padding-left: 5.56pt;">S-</font>5 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSNR1">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS<font style="padding-left: 4.81pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSNR1"><font style="padding-left: 5.56pt;">S-</font>7 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUOP1">USE OF PROCEEDS<font style="padding-left: 3.11pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUOP1">S-10 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tD1">DILUTION<font style="padding-left: 3.16pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tD1">S-11 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOC1">DESCRIPTION OF COMMON STOCK<font style="padding-left: 1.52pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOC1">S-13 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOD1">PLAN OF DISTRIBUTION<font style="padding-left: 4.3pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOD1">S-17 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM1">LEGAL MATTERS<font style="padding-left: 0.01pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM1">S-19 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tE1">EXPERTS<font style="padding-left: 0.09pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tE1">S-19 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC1">WHERE YOU CAN FIND MORE INFORMATION<font style="padding-left: 4.51pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC1">S-19 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIOC1">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE<font style="padding-left: 3.59pt;"></font></a></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIOC1">S-20</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-i<br></div></div></div>
<!--End Page 38-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 39-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_202-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tATP1"><!--Anchor--></a>ABOUT THIS PROSPECTUS </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission, or the SEC, utilizing a &#8220;shelf&#8221; registration process, and relates to the offering of our common stock. Before buying any of the shares of common stock that we are offering, we urge you to carefully read this prospectus all of the information incorporated by reference herein, as well as the additional information described under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus. These documents contain important information that you should consider when making your investment decision. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus describes the terms of this offering of common stock and also adds to and updates information contained in the documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference into this prospectus that was filed with the Securities and Exchange Commission, or the SEC, before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference into this prospectus&#8212;the statement in the document having the later date modifies or supersedes the earlier statement. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">You should rely only on the information contained in or incorporated by reference in this prospectus, any applicable prospectus supplement and any free writing prospectus that we may authorize for use in connection with this offering. Neither we nor Piper Sandler have authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor Piper Sandler are making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus, any applicable prospectus supplement, the documents incorporated by reference herein and therein and any free writing prospectus that we have authorized for use in connection with this offering is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, any applicable prospectus supplement, the documents incorporated by reference herein and therein and any free writing prospectus that we have authorized for use in connection with this offering in their entirety before making an investment decision. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-1<br></div></div></div>
<!--End Page 39-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 40-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20010746x1_s3_203-summary_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 492pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #49718D; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 12pt;"><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSUM1"><!--Anchor--></a>SUMMARY </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">This summary highlights information contained in other parts of this prospectus or incorporated by reference herein from our filings with the SEC. As it is only a summary, it does not contain all of the information that you should consider before purchasing our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere or incorporated by reference into this prospectus. You should read the entire prospectus, any applicable prospectus supplement, the registration statement of which this prospectus is a part, and the information incorporated by reference in its entirety, including the sections titled &#8220;Risk Factors&#8221; and our financial statements and the related notes contained in and incorporated by reference into this prospectus, before purchasing our securities.<font style="font-style: normal;"> </font></div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless the context indicates otherwise, references in this prospectus to &#8220;Aquestive,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Aquestive Therapeutics, Inc. and its consolidated subsidiaries.<font style="font-style: normal;"> </font></div><div class="h2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Company Overview </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients&#8217; lives through innovative science and delivery technologies. We are developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. We have five licensed commercialized products which are marketed by our licensees in the U.S. and around the world. We are the exclusive manufacturer of these licensed products. Aquestive also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, and has proven drug development and commercialization capabilities. We are advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. We have also developed a product pipeline focused on treating diseases of the central nervous system. Our production facilities are located in Portage, Indiana, and our corporate headquarters and primary research laboratory facilities are based in Warren, New Jersey. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We manufacture licensed products at our facilities and anticipate that our current manufacturing capacity is sufficient for commercial quantities of our licensed products and product candidates currently in development. Our facilities have been inspected by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), the Australian Government Department of Health&#8217;s Therapeutics Goods Administration, and the Drug Enforcement Agency and are subject to inspection by all applicable health agencies, including the Brazilian Health Regulatory Agency and the European Medicines Agency. Not all collaborative or licensed products of Aquestive that may be commercially launched in the future will necessarily be manufactured by us, such as the case with KYNMOBI<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>. </div><div class="h2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Corporate Information </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our principal executive offices are located at 30 Technology Drive, Warren, New Jersey 07059. Our website is www.aquestive.com. Except as otherwise specifically incorporated by reference in this prospectus, information contained in, or accessible through, our website is not a part of this prospectus, and you should not rely on any such information in deciding whether to purchase our securities. </div><div class="h2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Implications of Being a Smaller Reporting Company </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2023, we are no longer an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 but are still a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i) the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii) our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. We may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, (a) we may choose to present only the two most recent fiscal years of audited financial statements and only two years of related &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; in our Annual Report on Form&#160;10-K, (b) we are not required to comply with the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-2<br></div></div></div>
<!--End Page 40-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 41-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20010746x1_s3_203-summary_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 492pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #49718D; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 12pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended, on the effectiveness of our internal controls over financial reporting and (c) similar to emerging growth companies, we are subject to reduced disclosure obligations regarding executive compensation arrangements in our periodic reports, proxy statements and registration statements. </div><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a name="tTO1"><!--Anchor--></a>THE OFFERING</div><div class="sum1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Common stock offered by us<font style="font-weight: normal; padding-left: 4.25pt;"></font></div><div class="sum2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">Shares of common stock having an aggregate offering price of up to $100.0&#160;million sold from time to time pursuant to this prospectus. </div><div class="sum1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 6pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Common stock to be outstanding after this offering<font style="font-weight: normal; padding-left: 1.34pt;"></font></div><div class="sum2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">Up to 92,687,674 shares (as more fully described in the notes following this table), assuming sales of 24,154,589 shares of our common stock in this offering at an offering price of $4.14 per share, which was the last reported sale price of our common stock on the Nasdaq Global Market on April&#160;2, 2024. The actual number of shares issued will vary depending on the sales price under this offering. </div><div class="sum1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Plan of Distribution<font style="font-weight: normal; padding-left: 1.11pt;"></font></div><div class="sum2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">&#8220;At the market offering&#8221; that may be made from time to time, if at all, through our sales agent, Piper Sandler. See &#8220;Plan of Distribution&#8221; on page S-<a href="#tPOD1">17</a>. </div><div class="sum1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Use of Proceeds<font style="font-weight: normal; padding-left: 0.91pt;"></font></div><div class="sum2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">We currently intend to use the net proceeds from this offering, if any, primarily for working capital, capital expenditures and general corporate purposes. See &#8220;Use of Proceeds&#8221; within this prospectus on page S-<a href="#tUOP1">10</a>. </div><div class="sum1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Risk Factors<font style="font-weight: normal; padding-left: 3.35pt;"></font></div><div class="sum2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">Investing in our common stock involves significant risks. See &#8220;Risk Factors&#8221; beginning on page S-<a href="#tRF1">5</a> of this prospectus, and under similar headings in other documents incorporated by reference into this prospectus, for a discussion of factors that you should read and consider before investing in our common stock. </div><div class="sum1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Nasdaq listing symbol<font style="font-weight: normal; padding-left: 3.12pt;"></font></div><div class="sum2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">&#8220;AQST&#8221;</div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The number of shares of our common stock that will be outstanding immediately after this offering as shown above is based on 68,533,085 shares of common stock outstanding as of December 31, 2023. <br></div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The number of shares of common stock outstanding as of December 31, 2023, as used throughout this prospectus, unless otherwise indicated, does not take into account (i) 4,557,220 shares of common stock issued subsequent to December&#160;31, 2023 and prior to this offering pursuant to our ATM Facility (defined below), (ii)&#160;16,666,667 shares of common stock issued in an underwritten public offering on March&#160;22, 2024, pursuant to an underwriting agreement (the &#8220;Underwriting Agreement&#8221;), by and among us and Leerink Partners LLC and Piper Sandler &amp; Co., as representatives of the several underwriters named therein (the &#8220;Underwriters&#8221;), dated March&#160;19, 2024 and up to 2,500,000 shares of common stock issuable to the Underwriters pursuant to the Underwriters&#8217; 30-day option to purchase additional shares of common stock pursuant to the Underwriting Agreement, (iii) exercise of our outstanding options and the proceeds from such issuances, and (iv) issuances of shares upon the vesting of our restricted stock units, and also excludes: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">5,733,064 shares of common stock issuable upon exercise of outstanding options pursuant to our stock incentive plans at a weighted average option exercise price of $5.58 per share as of December&#160;31, 2023&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">1,948,313 shares of common stock issuable upon vesting of restricted stock units outstanding under our stock incentive plans as of December&#160;31, 2023&#894; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-3<br></div></div></div>
<!--End Page 41-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 42-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20010746x1_s3_203-summary_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 492pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #49718D; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 12pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">Up to 1,998,000 shares of common stock issuable under performance stock units outstanding under our 2018 Equity Incentive Plan as of December&#160;31, 2023 upon the satisfaction of performance criteria&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">4,624,977 shares of common stock issuable upon exercise of outstanding warrants as December&#160;31, 2023: 1,571,429 of which are exercisable at an exercise price of $4.25 per share, 143,000 of which are exercisable at an exercise price of $5.38 per share, 160,548 of which are exercisable at an exercise price of $0.96 per share, and 2,750,000 shares of which are exercisable at an exercise price of $2.60&#160;per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">947,950 shares of common stock reserved for future issuance under the 2018 Equity Incentive Plan as of December&#160;31, 2023; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">1,000,000 shares of common stock reserved for future issuance under the 2022 Inducement Equity Incentive Plan as of December&#160;31, 2023; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">39,018 shares of common stock available for future purchases under our Employee Stock Purchase Plan as of December&#160;31, 2023; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">Up to 214,129 commitment shares issuable to Lincoln Park Capital Fund LLC pursuant to the Purchase Agreement, dated April&#160;22, 2022 (the &#8220;Lincoln Park Purchase Agreement&#8221;), in connection with future purchases under the Lincoln Park Purchase Agreement. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-4<br></div></div></div>
<!--End Page 42-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 43-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_204-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRF1"><!--Anchor--></a>RISK FACTORS </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Investing in our Common Stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in the documents incorporated by reference in this prospectus and any applicable prospectus supplement, as well as other information we include or incorporate by reference into this prospectus and any applicable prospectus supplement, before making an investment decision. Our business, financial condition or results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of any of these risks, and you may lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks described in the documents incorporated herein by reference, including our most recent Annual Report on Form&#160;10-K for the year ended December 31, 2023, which is on file with the SEC and are incorporated by reference into this prospectus, and other documents we file with the SEC that are deemed incorporated by reference into this prospectus.<font style="font-style: normal;"> </font></div><div class="h2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Risks Related to this Offering </div><div class="frisk" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Resales of our common stock in the public market during this offering by our stockholders may cause the market price of our common stock to fall. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may issue common stock from time to time in connection with this offering. This issuance from time to time of these new shares of our common stock, or our ability to issue these shares of common stock in this offering, could result in resales of our common stock by our current stockholders concerned about the potential dilution of their holdings. In turn, these resales could have the effect of depressing the market price for our common stock. </div><div class="frisk" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">There may be future sales or other dilution of our equity, which may adversely affect the market price of our common stock. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We are generally not restricted from issuing additional common stock, including any securities that are convertible into or exchangeable for, or that represent the right to receive, common stock. The market price of our common stock could decline as a result of sales of common stock or securities that are convertible into or exchangeable for, or that represent the right to receive, common stock after this offering or the perception that such sales could occur. </div><div class="frisk" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We have broad discretion in how we use the net proceeds of this offering, and we may not use these proceeds effectively or in ways with which you agree. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our management will have broad discretion as to the application of the net proceeds, if any, of this offering and could use them for purposes other than those contemplated at the time of this offering. Our stockholders may not agree with the manner in which our management chooses to allocate and spend the net proceeds. Moreover, our management may use the net proceeds for corporate purposes that may not increase the market price of our common stock. </div><div class="frisk" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Purchasers will experience immediate dilution in the book value per share of the common stock purchased in the offering. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The expected offering price of our common stock will be substantially higher than the net tangible book value (deficit) per share of our outstanding common stock. As a result, based on our capitalization as of December 31, 2023, investors purchasing shares in this offering would incur immediate dilution of $4.258 per share of common stock purchased, based on an assumed public offering price of our common stock of $4.140 per share, the last reported sale price of the common stock on April 2, 2024. In addition to this offering, subject to market conditions and other factors, it is likely that we will pursue additional financings in the future, as we continue to build our business. In future years, we will likely need to raise significant additional capital to finance our operations and to fund clinical trials, regulatory submissions and the development, manufacture and marketing of other products under development and new product opportunities. Accordingly, we may conduct substantial future offerings of equity or debt securities. The exercise of outstanding options and warrants and future equity issuances, including future public offerings </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-5<br></div></div></div>
<!--End Page 43-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 44-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_204-risk_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">or future private placements of equity securities and any additional shares issued in connection with acquisitions, will result in dilution to investors. In addition, the market price of our common stock could fall as a result of resales of any of these shares of common stock due to an increased number of shares available for sale in the market. </div><div class="frisk" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The actual number of shares we will issue under the Amended Equity Distribution Agreement with Piper Sandler, at any one time or in total, is uncertain. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Subject to certain limitations in the Amended Equity Distribution Agreement with Piper Sandler and compliance with applicable law, we have the discretion to deliver placement notices to Piper Sandler at any time throughout the term of the Amended Equity Distribution Agreement. The number of shares that are sold by Piper Sandler after delivering a placement notice will fluctuate based on the market price of the common stock during the sales period and limits we set with Piper Sandler. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-6<br></div></div></div>
<!--End Page 44-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 45-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_205-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSNR1"><!--Anchor--></a>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus and the documents that we incorporate by reference in each contain &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section&#160;27A of the Securities Act and Section&#160;2 1E of the Exchange Act). These are based on our management&#8217;s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements may be found, among other places, in the Sections entitled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; incorporated by reference from our most recent Annual Report on Form&#160;10-K and Quarterly Reports on Form&#160;10-Q, as well as any amendments thereto, filed with the SEC. Also, documents we subsequently file with the SEC and incorporate by reference may contain forward-looking statements. Such risks and uncertainties include, but are not limited to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans, including those relating to Anaphylm&#8482; (epinephrine) Sublingual Film and Libervant&#8482; (diazepam) Buccal Film; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of delays in regulatory advancement through the FDA of Anaphylm, Libervant and our other drug candidates or failure to receive FDA approval at all; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">the risk that we may not overcome the seven-year orphan drug exclusivity granted by the FDA for the approved nasal spray product of another company in the U.S. in order for Libervant to be granted U.S.&#160;market access for any age group of patients; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of litigation brought by third parties relating to overcoming their orphan drug exclusivity of an FDA approved product should the FDA approve Libervant for U.S. market access for any age group of this epilepsy patient population; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk that a competing pediatric epilepsy product of Libervant will receive FDA approval prior to the Company&#8217;s receipt of FDA approval of the Libervant NDA for these epilepsy patients between two and five years of age; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk in obtaining market access for Libervant for other reasons; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk in obtaining market access from the FDA for our other product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risks and uncertainties concerning the revenue stream from the monetization of our royalty rights for the product KYNMOBI<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, as well as the achievement of royalty targets worldwide or in any jurisdiction and certain other commercial targets required for contingent payments under the KYNMOBI<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> monetization transaction, and the Company may not receive any of the additional aggregate contingent payments under the monetization agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of development of a sales and marketing capability for future commercialization of our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of sufficient capital and cash resources, including access to available debt and equity financing, including under our ATM Facility and the Common Stock Purchase Agreement entered into with Lincoln Park Capital Fund, LLC on April&#160;12, 2022, and from revenues from operations, to satisfy all of our short-term and longer-term cash requirements and other cash needs, at the times and in the amounts needed, including near-term debt amortization schedules; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of failure to satisfy all financial and other debt covenants and of any default under our debt facility; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">short-term and long-term liquidity and cash requirements, cash funding and cash burn; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-7<br></div></div></div>
<!--End Page 45-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 46-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_205-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk related to government and other claims against Indivior Inc. for which we license, manufacture and sell Suboxone<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and which accounts for the substantial part of our current operating revenues, including the risk related to the recent product liability multi-district litigation related to Suboxone<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risks related to the outsourcing of certain operational and staff functions to third parties; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of the rate and degree of market acceptance of our product and product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of the success of any competing products including generics; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of the size and growth of our product markets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risks associated with intellectual property rights and infringement claims relating to our products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of unexpected patent developments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of legislation and regulatory actions and changes in laws or regulations affecting our business including relating to our products and product candidates and product pricing, reimbursement or access therefor; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of loss of significant customers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risks related to claims and legal proceedings including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of product recalls and withdrawals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risks related to any disruptions in our information technology networks and systems, including the impact of cyberattacks; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">adverse developments affecting the financial services industry; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risks related to inflation and rising interest rates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risks related to the impact of a health pandemic on our business, including with respect to our clinical trials and the site initiation, patient enrollment and timing and adequacy of those clinical trials, regulatory submissions and regulatory reviews and approvals of our product candidates, availability of pharmaceutical ingredients and other raw materials used in our products and product candidates, supply chain, manufacture and distribution of our products and product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">risks and uncertainties related to general economic, political (including the wars in Ukraine and Israel and other acts of war and terrorism), business, industry, regulatory and market conditions and other unusual items; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">other uncertainties affecting us including those described in the &#8220;Risk Factors&#8221; section of this prospectus, and in our most recent Annual Report on Form&#160;10-K filed with the SEC; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">use of our existing cash and cash equivalents and the anticipated use of net proceeds from this offering. </div></td></tr></table><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In some cases, forward-looking statements are identified by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from those </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-8<br></div></div></div>
<!--End Page 46-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 47-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_205-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">anticipated by the forward-looking statements. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not be different, and historic results referred to in our most recent Annual Report on Form&#160;10-K, may be interpreted differently in light of additional research and clinical and preclinical trials results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to (and expressly disclaim any such obligation to) update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this prospectus. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-9<br></div></div></div>
<!--End Page 47-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 48-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_206-use_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUOP1"><!--Anchor--></a>USE OF PROCEEDS </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may offer and sell shares of our common stock having an aggregate offering price of up to $100.0&#160;million from time to time through Piper Sandler pursuant to this prospectus. We intend to use the net proceeds, if any, from the sale of the common stock under this prospectus for working capital, capital expenditures and general corporate purposes. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of the date of this prospectus, we cannot specify with certainty all of the particular uses of the proceeds from this offering. Accordingly, our management will retain broad discretion over the use of such proceeds. Pending the use of the net proceeds from this offering, we intend to invest the net proceeds in investment-grade, interest-bearing instruments. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-10<br></div></div></div>
<!--End Page 48-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 49-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_206-use_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tD1"><!--Anchor--></a>DILUTION </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the public offering price per share of our common stock and the net tangible book value per share of our common stock upon consummation of this offering. Dilution results from the fact that the public offering price is substantially in excess of the book value per share attributable to the existing stockholders for the presently outstanding stock. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The net tangible book value (deficit) of our common stock as of December 31, 2023, was approximately $(107.8) million, or approximately $(1.572) per share. Net tangible book value (deficit) per share represents the amount of our total tangible assets, excluding goodwill and intangible assets, less total liabilities divided by the total number of shares of our common stock outstanding. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">After giving effect to the sale of shares of our common stock in an assumed maximum offering of $100.0 million at an assumed offering price of $4.140 per share, the last reported sale price of our common stock on April 2, 2024 on the Nasdaq Global Market, and after deducting estimated commissions and estimated offering expenses of approximately $3.1 million, our as adjusted net tangible book value as of December&#160;31, 2023 would have been approximately $(10.9) million, or approximately $(0.118) per share. This represents an immediate increase in net tangible book value of approximately $1.455 per share to our existing stockholders and an immediate dilution in as adjusted net tangible book value of approximately $4.258 per share to purchasers of our common stock in this offering, as illustrated by the following table: </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assumed offering price per share<font style="padding-left: 4.62pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">4.14</font>0 </div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net tangible book value (deficit) per share as of December&#160;31, 2023<font style="padding-left: 2.96pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$(1.572)</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase in net tangible book value per share attributable to new investors<font style="padding-left: 2.41pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 33.89pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 33.89pt;">1.455</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As adjusted net tangible book value per share after this offering<font style="padding-left: 2.4pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 33.89pt;">$(0.118</font><font style="min-width: 33.89pt;">) </font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net dilution per share to new investors participating in this offering<font style="padding-left: 4.05pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 33.89pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 33.89pt;">4.258</font></div></td></tr></table><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The table above assumes for illustrative purposes only an aggregate of 24,154,589 shares of our common stock are sold at a price of $4.140 per share, the last reported sale price of our common stock on the Nasdaq Global Market on April 2, 2024, for aggregate gross proceeds of $100.0 million. The shares, if any, sold in this offering will be sold from time to time at various prices. An increase of $1.000 per share in the price at which the shares are sold from the assumed offering price of $4.140 per share shown in the table above, assuming all of our common stock in the aggregate amount of $100.0 million is sold at that price, would decrease our adjusted net tangible book value per share after the offering to $(0.124) per share and would increase the dilution in net tangible book value per share to new investors in this offering to $5.264 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.000 per share in the price at which the shares are sold from the assumed offering price of $4.140 per share shown in the table above, assuming all of our common stock in the aggregate amount of $100.0&#160;million is sold at that price, would increase our adjusted net tangible book value per share after the offering to $(0.109) per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $3.249 per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The calculations above are based upon 68,533,085 shares of common stock outstanding as of December&#160;31, 2023 and do not take into account (i) 4,557,220 shares of common stock issued subsequent to December&#160;31, 2023 and prior to this offering pursuant to our ATM Facility, (ii) 16,666,667 shares of common stock issued in an underwritten public offering on March&#160;22, 2024, pursuant to the Underwriting Agreement and up to 2,500,000&#160;shares of common stock issuable to the Underwriters pursuant to the Underwriters&#8217; 30-day option to purchase additional shares of common stock pursuant to the Underwriting Agreement, (iii) exercise of our outstanding options and the proceeds from such issuances, and (vi) issuances of shares upon the vesting of our restricted stock units, and exclude: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">5,733,064 shares of common stock issuable upon exercise of outstanding options pursuant to our stock incentive plans at a weighted average option exercise price of $5.58 per share as of December&#160;31, 2023&#894; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-11<br></div></div></div>
<!--End Page 49-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 50-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_206-use_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">1,948,313 shares of common stock issuable upon vesting of restricted stock units outstanding under our stock incentive plans as of December&#160;31, 2023&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">Up to 1,998,000 shares of common stock issuable under performance stock units outstanding under our 2018 Equity Incentive Plan as of December&#160;31, 2023 upon the satisfaction of performance criteria&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">4,624,977 shares of common stock issuable upon exercise of outstanding warrants as December&#160;31, 2023: 1,571,429 of which are exercisable at an exercise price of $4.25 per share, 143,000 of which are exercisable at an exercise price of $5.38 per share, 160,548 of which are exercisable at an exercise price of $0.96 per share, and 2,750,000 shares of which are exercisable at an exercise price of $2.60&#160;per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">947,950 shares of common stock reserved for future issuance under the 2018 Equity Incentive Plan as of December&#160;31, 2023; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">1,000,000 shares of common stock reserved for future issuance under the 2022 Inducement Equity Incentive Plan as of December&#160;31, 2023; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">39,018 shares of common stock available for future purchases under our Employee Stock Purchase Plan as of December&#160;31, 2023; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">Up to 214,129 commitment shares issuable to Lincoln Park Capital Fund LLC pursuant to the Lincoln Park Purchase Agreement, in connection with future purchases under the Lincoln Park Purchase Agreement. </div></td></tr></table><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">To the extent that outstanding options or warrants outstanding as of December 31, 2022 have been or may be exercised or other shares are issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-12<br></div></div></div>
<!--End Page 50-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 51-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_207-description_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDOC1"><!--Anchor--></a>DESCRIPTION OF COMMON STOCK </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following description of our common stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries. You should also refer to the amended and restated certificate of incorporation and the amended and restated bylaws, which are incorporated by reference as exhibits to the registration statement of which this prospectus is part. </div><div class="h2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">General </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our amended and restated certificate of incorporation authorizes us to issue up to 250,000,000 shares of common stock, $0.001 par value per share. The following summary is qualified in its entirety by reference to our amended and restate certificate of incorporation, a copy of which is filed as an exhibit to our previous filings with the SEC and incorporated herein by reference. </div><div class="h2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Common Stock </div><div class="h3" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Outstanding Shares </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </div><div class="h3" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Voting Rights </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders. The affirmative vote of holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction, provided, however, that this restriction shall not apply to, and such 66 2/3% vote shall not be required for, any such amendment, change or repeal approved by the affirmative vote of at least a majority of the then current duly elected board of directors, in which case such action shall require only the vote of shareholders as required under Delaware law. </div><div class="h3" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Dividends </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Subject to preferences that may apply to any outstanding preferred stock, holders of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate we will declare or pay any cash dividends for the foreseeable future. Further, any future debt agreements may also prohibit us from paying, or place restrictions on our ability to pay, dividends. Any return to stockholders will therefore be limited to the appreciation of their stock. </div><div class="h3" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Liquidation </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock. </div><div class="h3" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Rights and Preferences </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-13<br></div></div></div>
<!--End Page 51-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 52-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_207-description_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Anti-Takeover Effects of Provisions of Our Certificate of Incorporation and Our Bylaws </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our amended and restated certificate of incorporation and amended and restated bylaws contain certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of the board of directors and which may have the effect of delaying, deferring or preventing a future takeover or change in control of the company unless such takeover or change in control is approved by the board of directors. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">These provisions include: </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Classified Board<font style="font-style: normal; font-weight: normal;">. Our amended and restated certificate of incorporation provides that our board of </font><font style="font-style: normal; font-weight: normal;">directors is divided into three classes of directors, with the classes as nearly equal in number as possible. As </font><font style="font-style: normal; font-weight: normal;">a result, approximately one-third of our board of directors are elected each year. The classification of </font><font style="font-style: normal; font-weight: normal;">directors has the effect of making it more difficult for stockholders to change the composition of our board. </font><font style="font-style: normal; font-weight: normal;">Our amended and restated certificate of incorporation also provides that, subject to any rights of holders of </font><font style="font-style: normal; font-weight: normal;">preferred stock to elect additional directors under specified circumstances, the number of directors will be </font><font style="font-style: normal; font-weight: normal;">fixed exclusively pursuant to a resolution adopted by our board of directors. </font></div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Action by Written Consent; Special Meetings of Stockholders<font style="font-style: normal; font-weight: normal;">. Our amended and restated certificate of </font><font style="font-style: normal; font-weight: normal;">incorporation provides that stockholder action can be taken only at an annual or special meeting of </font><font style="font-style: normal; font-weight: normal;">stockholders and cannot be taken by written consent in lieu of a meeting. Our amended and restated </font><font style="font-style: normal; font-weight: normal;">certificate of incorporation and our amended and restated bylaws also provide that, except as otherwise </font><font style="font-style: normal; font-weight: normal;">required by law, special meetings of the stockholders can be called only by or at the direction of the board </font><font style="font-style: normal; font-weight: normal;">of directors pursuant to a resolution adopted by a majority of the total number of directors. Stockholders </font><font style="font-style: normal; font-weight: normal;">are not permitted to call a special meeting or to require the board of directors to call a special meeting. </font></div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Removal of Directors<font style="font-style: normal; font-weight: normal;">. Our amended and restated certificate of incorporation provides that our directors </font><font style="font-style: normal; font-weight: normal;">may be removed only for cause by the affirmative vote of at least 66 2/3% of the votes that all our </font><font style="font-style: normal; font-weight: normal;">stockholders would be entitled to cast in an annual election of directors, voting together as a single class, at </font><font style="font-style: normal; font-weight: normal;">a meeting of the stockholders called for that purpose. This requirement of a supermajority vote to remove </font><font style="font-style: normal; font-weight: normal;">directors could enable a minority of our stockholders to prevent a change in the composition of our board. </font></div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Advance Notice Procedures<font style="font-style: normal; font-weight: normal;">. Our amended and restated bylaws establish an advance notice procedure for </font><font style="font-style: normal; font-weight: normal;">stockholder proposals to be brought before an annual meeting of our stockholders, including proposed </font><font style="font-style: normal; font-weight: normal;">nominations of persons for election to the board of directors. Stockholders at an annual meeting are only </font><font style="font-style: normal; font-weight: normal;">able to consider proposals or nominations specified in the notice of meeting or brought before the meeting </font><font style="font-style: normal; font-weight: normal;">by or at the direction of the board of directors or by a stockholder who was a stockholder of record on the </font><font style="font-style: normal; font-weight: normal;">record date for the meeting, who is entitled to vote at the meeting and who has given our secretary timely </font><font style="font-style: normal; font-weight: normal;">written notice, in proper form, of the stockholder&#8217;s intention to bring that business before the meeting. </font><font style="font-style: normal; font-weight: normal;">Although the amended and restated bylaws do not give the board of directors the power to approve or </font><font style="font-style: normal; font-weight: normal;">disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at </font><font style="font-style: normal; font-weight: normal;">a special or annual meeting, the amended and restated bylaws may have the effect of precluding the conduct </font><font style="font-style: normal; font-weight: normal;">of certain business at a meeting if the proper procedures are not followed or may discourage or deter a </font><font style="font-style: normal; font-weight: normal;">potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise </font><font style="font-style: normal; font-weight: normal;">attempting to obtain control of the company. </font></div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Super Majority Approval Requirements<font style="font-style: normal; font-weight: normal;">. The Delaware General Corporation Law generally provides that </font><font style="font-style: normal; font-weight: normal;">the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a </font><font style="font-style: normal; font-weight: normal;">corporation&#8217;s certificate of incorporation or bylaws, unless either a corporation&#8217;s certificate of incorporation </font><font style="font-style: normal; font-weight: normal;">or bylaws requires a greater percentage. A majority vote of our board of directors or the affirmative vote of </font><font style="font-style: normal; font-weight: normal;">holders of at least 66&#160;2/3% of the total votes of the outstanding shares of our capital stock entitled to vote </font><font style="font-style: normal; font-weight: normal;">with respect thereto, voting together as a single class, are required to amend, alter, change or repeal the </font><font style="font-style: normal; font-weight: normal;">amended and restated bylaws. In addition, the affirmative vote of the holders of at least 66 2/3% of the </font><font style="font-style: normal; font-weight: normal;">total votes of the outstanding shares of our capital stock entitled to vote with respect thereto, voting </font><font style="font-style: normal; font-weight: normal;">together as a single class, are required to amend, alter, change or repeal, or to adopt any provisions </font><font style="font-style: normal; font-weight: normal;">inconsistent with, any of the provisions in our amended and restated certificate of incorporation relating to </font><font style="font-style: normal; font-weight: normal;">amendments to our amended and restated certificate of incorporation and amended and restated bylaws and </font><font style="font-style: normal; font-weight: normal;">as described under &#8220;Action by Written Consent; Special Meetings of Stockholders&#8221;, &#8220;Classified Board&#8221; and </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-14<br></div></div></div>
<!--End Page 52-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 53-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_207-description_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">&#8220;Removal of Directors&#8221; above. This requirement of a supermajority vote to approve amendments to our amended and restated bylaws and amended and restated certificate of incorporation could enable a minority of our stockholders to exercise veto power over any such amendments. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Authorized but Unissued Shares<font style="font-style: normal; font-weight: normal;">. Our authorized but unissued shares of common stock and preferred stock </font><font style="font-style: normal; font-weight: normal;">are available for future issuance without stockholder approval. These additional shares may be utilized for a </font><font style="font-style: normal; font-weight: normal;">variety of corporate purposes, including future public offerings to raise additional capital and corporate </font><font style="font-style: normal; font-weight: normal;">acquisitions. The existence of authorized but unissued shares of common stock and preferred stock could </font><font style="font-style: normal; font-weight: normal;">render more difficult or discourage an attempt to obtain control of a majority of our common stock by </font><font style="font-style: normal; font-weight: normal;">means of a proxy contest, tender offer, merger or otherwise. For example, if in the due exercise of its </font><font style="font-style: normal; font-weight: normal;">fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best </font><font style="font-style: normal; font-weight: normal;">interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued </font><font style="font-style: normal; font-weight: normal;">without stockholder approval in one or more private offerings or other transactions that might dilute the </font><font style="font-style: normal; font-weight: normal;">voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this </font><font style="font-style: normal; font-weight: normal;">regard, our amended and restated certificate of incorporation grants our board of directors broad power to </font><font style="font-style: normal; font-weight: normal;">establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of </font><font style="font-style: normal; font-weight: normal;">shares of preferred stock could decrease the amount of earnings and assets available for distribution to </font><font style="font-style: normal; font-weight: normal;">holders of shares of common stock. The issuance may also adversely affect the rights and powers, including </font><font style="font-style: normal; font-weight: normal;">voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in </font><font style="font-style: normal; font-weight: normal;">control of us. </font></div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Exclusive Forum<font style="font-style: normal; font-weight: normal;">. Our amended and restated certificate of incorporation provides that, subject to limited </font><font style="font-style: normal; font-weight: normal;">exceptions, the state or federal courts located in the State of Delaware are the sole and exclusive forum for </font><font style="font-style: normal; font-weight: normal;">(i)&#160;any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a </font><font style="font-style: normal; font-weight: normal;">fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any </font><font style="font-style: normal; font-weight: normal;">action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation </font><font style="font-style: normal; font-weight: normal;">Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or (iv) any </font><font style="font-style: normal; font-weight: normal;">other action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive </font><font style="font-style: normal; font-weight: normal;">forum provision would not apply to suits brought to enforce any liability or duty created by the Securities </font><font style="font-style: normal; font-weight: normal;">Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the </font><font style="font-style: normal; font-weight: normal;">extent that any such claims may be based upon federal law claims, Section&#160;27 of the Exchange Act creates </font><font style="font-style: normal; font-weight: normal;">exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange </font><font style="font-style: normal; font-weight: normal;">Act or the rules and regulations thereunder. Furthermore, Section&#160;22 of the Securities Act creates concurrent </font><font style="font-style: normal; font-weight: normal;">jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the </font><font style="font-style: normal; font-weight: normal;">Securities Act or the rules and regulations thereunder. Our amended and restated certificate of incorporation </font><font style="font-style: normal; font-weight: normal;">also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our </font><font style="font-style: normal; font-weight: normal;">capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is </font><font style="font-style: normal; font-weight: normal;">possible that a court of law could rule that the choice of forum provision contained in our amended and </font><font style="font-style: normal; font-weight: normal;">restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or </font><font style="font-style: normal; font-weight: normal;">otherwise. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock </font><font style="font-style: normal; font-weight: normal;">shall be deemed to have notice of and to have consented to the provisions of our amended and restated </font><font style="font-style: normal; font-weight: normal;">certificate of incorporation described above. Although we believe these provisions benefit us by providing </font><font style="font-style: normal; font-weight: normal;">increased consistency in the application of Delaware law for the specified types of actions and proceedings, </font><font style="font-style: normal; font-weight: normal;">the provisions may have the effect of discouraging lawsuits against our directors and officers. The </font><font style="font-style: normal; font-weight: normal;">enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has </font><font style="font-style: normal; font-weight: normal;">been challenged in legal proceedings, and it is possible that, in connection with one or more actions or </font><font style="font-style: normal; font-weight: normal;">proceedings described above, a court could find the choice of forum provisions contained in our amended </font><font style="font-style: normal; font-weight: normal;">and restated certificate of incorporation to be inapplicable or unenforceable. </font></div><div class="h2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Section&#160;203 of the Delaware General Corporation Law </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law, or Section&#160;203. In general, Section&#160;203 prohibits a publicly-held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-15<br></div></div></div>
<!--End Page 53-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 54-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_207-description_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#8217;s voting stock. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: before the stockholder became interested, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 75% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#8217; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </div><div class="h2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The transfer agent and registrar for our common stock is Computershare. The transfer agent&#8217;s address is 1290&#160;Avenue of the Americas, 9th Floor, New York, NY 10104, and its telephone number is (212) 805-7100. The transfer agent for any series of stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series. </div><div class="h2" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Listing on the Nasdaq Global Market </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;AQST.&#8221; </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-16<br></div></div></div>
<!--End Page 54-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 55-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_208-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPOD1"><!--Anchor--></a>PLAN OF DISTRIBUTION </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left; line-height: 12pt;">We previously entered into the Amended Equity Distribution Agreement with Piper Sandler, pursuant to which we may offer and sell shares of our common stock from time to time through Piper Sandler, acting as sales agent. This prospectus registers shares of common stock having an aggregate offering price of up to $100.0&#160;million that we may offer and sell from time to time. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left; line-height: 12pt;">Piper Sandler will use commercially reasonable efforts to sell on our behalf all of the shares of our common stock requested to be sold by us, consistent with its normal trading and sales practices, under the terms and subject to the conditions set forth in the Amended Equity Distribution Agreement. We may instruct the sales agent not to sell our common stock if the sales cannot be effected at or above the price designated by us in any instruction. We or the sales agent may suspend the offering of our common stock upon proper notice and subject to other conditions, as further described in the Amended Equity Distribution Agreement. A copy of the Amended Equity Distribution Agreement is incorporated by reference into the registration statement of which this prospectus forms a part. Additionally, we have agreed to not make any sales of our common stock under the Amended Equity Distribution Agreement until the expiration or waiver of a 60-day lock-up period ending May 18, 2024, pursuant to the underwriting agreement, dated March 19, 2024, by and among us and Leerink Partners LLC and Piper Sandler. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left; line-height: 11.5pt;">Piper Sandler may sell our common stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) promulgated under the Securities Act, including sales made directly on or through the Nasdaq Capital Market or on any other existing trading market for our common stock. Piper Sandler will provide written confirmation to us following the close of trading on the Nasdaq Capital Market each day in which our common stock is sold under the Amended Equity Distribution Agreement. Each such confirmation will include the number of shares of our common stock sold on such day, the net proceeds to us and the compensation payable by us to Piper Sandler in connection with such sales. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left; line-height: 11.5pt;">We will pay Piper Sandler commissions for its services in acting as sales agent in the sale of our common stock. Piper Sandler will be entitled to compensation in an amount up to 3.0% of the gross sales price of all common stock sold through it as sales agent under the Amended Equity Distribution Agreement. We have also agreed to reimburse Piper Sandler for the out-of-pocket reasonable fees and disbursements of its legal counsel, in an amount not to exceed $50,000 in connection with the execution of the Amended Equity Distribution Agreement. We estimate that the total expenses for this offering, excluding compensation payable to Piper Sandler under the terms of the Amended Equity Distribution Agreement, will be approximately $140,000. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left; line-height: 11.5pt;">Settlement for sales of our common stock will occur on the second business day following the date on which any such sales are made, or on some other date that is agreed upon by us and Piper Sandler in connection with a particular transaction, in return for payment of the net proceeds to us. Pursuant to Rule&#160;15c6-1 of the Exchange Act, settlement for any securities offered under this prospectus supplement on or after May&#160;28, 2024, may occur on the first business day that is also a trading day following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left; line-height: 11.5pt;">We will report at least quarterly the number of shares of our common stock sold through Piper Sandler, as sales agent, under the Amended Equity Distribution Agreement, the net proceeds to us and the compensation paid by us to Piper Sandler in connection with such sales. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left; line-height: 11.5pt;">Piper Sandler and its affiliates have from time to time provided, and may in the future provide, various investment banking, commercial banking, fiduciary and advisory services for us for which they have received, and may in the future receive, customary fees and expenses. Piper Sandler and its affiliates may from time to time engage in other transactions with and perform services for us in the ordinary course of their business. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left; line-height: 11.5pt;">In connection with the sale of our common stock on our behalf, Piper Sandler will be deemed to be an underwriter within the meaning of the Securities Act, and the compensation paid by us to Piper Sandler will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Piper Sandler against specified liabilities, including liabilities under the Securities Act, or to contribute to payments that Piper Sandler may be required to make because of such liabilities. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left; line-height: 11.5pt;">The offering of our common stock pursuant to the Amended Equity Distribution Agreement will terminate upon the termination of the Amended Equity Distribution Agreement. The Amended Equity Distribution </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-17<br></div></div></div>
<!--End Page 55-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 56-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_208-plan_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Agreement may be terminated by Piper Sandler or us at any time on the close of business on the date of receipt of written notice, and by Piper Sandler at any time in certain circumstances, including any suspension or limitation on the trading of our common stock on the Nasdaq Capital Market, as further described therein. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-18<br></div></div></div>
<!--End Page 56-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 57-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_209-legal_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLM1"><!--Anchor--></a>LEGAL MATTERS </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Certain legal matters in connection with this offering will be passed upon for us by Dechert LLP. Piper Sandler &amp; Co. is being represented in connection with this offering by Cooley LLP, New York, New York. </div><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tE1"><!--Anchor--></a>EXPERTS </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The consolidated financial statements of Aquestive Therapeutics, Inc. as of December 31, 2023 and 2022, and for each of the years in the two-year period ended December 31, 2023, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </div><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tWYC1"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus is part of the registration statement on Form&#160;S-3 we filed with the Commission under the Securities Act and does not contain all the information set forth or incorporated by reference in the registration statement. For further information with respect to us and the securities offered by this prospectus, we refer you to the registration statement and its exhibits. Whenever a reference is made in this prospectus as to the contents of any contract or any other document referred to herein, such references are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We file electronically with the SEC annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K, proxy statements and other information and amendments to those reports filed or furnished pursuant to Section&#160;13 or 15(d) of the Exchange Act. The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Copies of these reports, proxy and information statements and other information may be obtained by electronic request at the following e-mail address: publicinfo@sec.gov. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We make available, free of charge and through our Internet web site at www.aquestive.com, our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and any amendments to any such reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Copies of our Code of Business Conduct and Ethics and our Corporate Governance Guidelines may be accessed free of charge by visiting our website at www.aquestive.com under &#8220;Investors&#8221; at &#8220;Corporate Governance: Governance Documents&#8221; or by requesting a copy via an e-mail addressed to investorrelations@aquestive.com or by written request addressed to our Corporate Secretary at our principal executive offices. To the extent required by applicable law and regulation, we intend to post on our website any amendment to, or waiver under, a provision of the Code of Business Conduct and Ethics that applies to our executive officers and directors within the time period required. The information set forth on, or connected to, our website is expressly not incorporated by reference into, and does not constitute a part of, this prospectus. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-19<br></div></div></div>
<!--End Page 57-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 58-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_210-incorp_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tIOC1"><!--Anchor--></a>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The SEC allows us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is 001-38599. The documents incorporated by reference into this prospectus contain important information that you should read about us. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The following documents are incorporated by reference into this document: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1398733/000162828024009010/aqst-20231231.htm">March&#160;5, 2024</a>&#894; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">our Definitive Proxy Statement on Schedule 14A, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1398733/000114036123021673/ny20007004x2_def14a.htm">April&#160;28, 2023</a> (to the extent incorporated by reference into Part&#160;III of our Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2022); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">our Current Reports on Form&#160;8-K filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1398733/000162828024011308/aqst-20240314.htm">March&#160;15, 2024</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1398733/000114036124014613/ny20024600x3_8-k.htm">March&#160;21, 2024</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1398733/000162828024013888/aqst-20240401.htm">April&#160;1, 2024</a> (to the extent the information in such reports is filed and not furnished)&#894; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; text-align: left;">the description of our common stock contained in our Registration Statement on Form&#160;8-A, filed with the SEC on July&#160;20, 2018, as the description therein has been updated and superseded by the description of our securities contained in Exhibit&#160;4.7 to our Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2019, as filed with the SEC on<a href="https://www.sec.gov/Archives/edgar/data/1398733/000114036120005499/ex4_7.htm"> March&#160;11, 2020</a>. </div></td></tr></table><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item&#160;2.02 or Item&#160;7.01 of Form&#160;8-K and exhibits filed on such form that are related to such items) that are hereafter filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act until all of the securities offered by this prospectus have been sold or we otherwise terminate the offering of these securities. These documents include periodic reports, such as Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q and Current Reports on Form&#160;8-K, as well as proxy statements. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to Aquestive Therapeutics, Inc., Attn: Corporate Secretary, 30 Technology Dr.&#160;South, Warren, NJ 07059&#894; telephone: (908) 941-1900. </div><div class="fpara" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #49718D; font-family: Arial, Helvetica, sans-serif; font-size: 10pt; margin-top: 9pt; text-align: center;">S-20<br></div></div></div>
<!--End Page 58-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 59-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20010746x1_s3_300-bcv_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 456pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 82.75pt; text-align: center;">Up to $100,000,000 </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 65.25pt; text-align: center;"><img style="height: 57px; width: 224px;" src="logo_aquestivex1.jpg"><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 55.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">Common Stock</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12.5pt; text-align: center;"><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-top: 12pt; display: inline-block; margin-left: auto; margin-right: auto;"> </div> <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 56.5pt; text-align: center;">PROSPECTUS </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 102.5pt; text-align: center;">Piper Sandler </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 102.5pt; text-align: center;">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2024</div></div></div><div class="block-frill" style="width: 456pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 59-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 60-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_301-part2_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PART II </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; text-align: center;">INFORMATION NOT REQUIRED IN THE PROSPECTUS </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#160;14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Other Expenses of Issuance and Distribution </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth the estimated costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the offering of the securities being registered. All the amounts shown are estimates, except for the SEC registration fee and FINRA filing fee. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SEC registration fee<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$19,590 </div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FINRA filing fee<font style="padding-left: 2.52pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$38,000 </div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting fees and expenses<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32.5pt;">* </font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legal fees and expenses<font style="padding-left: 3.11pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32.5pt;">* </font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transfer agent fees and expenses<font style="padding-left: 2.38pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32.5pt;">* </font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trustee fees and expenses<font style="padding-left: 1.24pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32.5pt;">* </font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Printing and miscellaneous expenses<font style="padding-left: 3.11pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32.5pt;">* </font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32.5pt;">*</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">These fees cannot be estimated at this time, as they are calculated based on the securities offered and the number of issuances. In accordance with Rule&#160;430B, an estimate of the aggregate expenses in connection with the sale and distribution of the securities being offered will be included in the applicable prospectus supplement</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#160;15.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Indemnification of Officers and Directors </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Registrant is incorporated under the laws of the State of Delaware. Section&#160;145 of the Delaware&#160;General Corporation Law provides that a Delaware corporation may indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such person as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses which such officer or director has actually and reasonably incurred. The Registrant&#8217;s amended and restated certificate of incorporation and amended and restated bylaws provide for the indemnification of our directors and officers to the fullest extent permitted under the Delaware General Corporation Law. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section&#160;102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transaction from which the director derives an improper personal benefit; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unlawful payment of dividends or redemption of shares; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">breach of a director's duty of loyalty to the corporation or its stockholders. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-1<br></div></div></div>
<!--End Page 60-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 61-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_301-part2_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Registrant&#8217;s amended and restated certificate of incorporation includes such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding in advance of its final disposition shall be paid by the Registrant upon delivery to the Registrant of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified by the Registrant. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As permitted by the Delaware General Corporation Law, the Registrant has entered into indemnification agreements with its directors and executive officers. These agreements, among other things, require the Registrant to indemnify each director and officer to the fullest extent permitted by law and advance expenses to each indemnitee in connection with any proceeding in which indemnification is available. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Registrant has an insurance policy covering our officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, or otherwise. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#160;16.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Exhibits and Financial Statement Schedules </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A list of exhibits filed with this registration statement on Form&#160;S-3 is set forth on the Exhibit&#160;Index and is incorporated herein by reference. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#160;17.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Undertakings </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The undersigned registrant hereby undertakes: </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(1)&#8195;To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(i)&#8195;To include any prospectus required by Section&#160;10(a)(3) of the Securities Act&#894; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(ii)&#8195;To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement&#894; and </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(iii)&#8195;To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement&#894; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">provided, however<font style="font-style: normal;">, that the undertakings set forth in paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if </font><font style="font-style: normal;">the information required to be included in a post-effective amendment by those paragraphs is contained in reports </font><font style="font-style: normal;">filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities </font><font style="font-style: normal;">Exchange Act of 1934, as amended, or the Exchange Act, that are incorporated by reference in this registration </font><font style="font-style: normal;">statement or are contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of this registration </font><font style="font-style: normal;">statement. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(2)&#8195;That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font> offering thereof. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(3)&#8195;To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(4)&#8195;That, for the purpose of determining liability under the Securities Act to any purchaser: </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(i)&#8195;Each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement&#894; and </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(ii)&#8195;Each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&#160;430B relating to an offering made pursuant to Rule&#160;415(a)(1)(i), </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-2<br></div></div></div>
<!--End Page 61-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 62-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_301-part2_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">(vii), or (x) for the purpose of providing the information required by Section&#160;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font> offering thereof. <font style="font-style: italic;">Provided, however</font>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(5)&#8195;That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: (i) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424&#894; (ii) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant&#894; (iii) the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant&#894; and (iv) any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(6)&#8195;That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font> offering thereof. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(7)&#8195;To file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section&#160;310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the SEC under Section&#160;305(b)(2) of the Trust Indenture Act. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted against the registrant by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-3<br></div></div></div>
<!--End Page 62-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 63-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_302-exhibit_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">EXHIBIT INDEX </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 7.69%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 91.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description of Document </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.1*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Underwriting Agreement. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1398733/000114036119016535/ex1_2.htm">1.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity Distribution Agreement, dated September&#160;11, 2019, by and between Aquestive Therapeutics,&#160;Inc. and Piper Sandler &amp; Co. (filed as Exhibit&#160;1.2 to the Registration Statement on Form&#160;S-3&#160;(333-233716) of the Company, as filed on September&#160;11, 2019, and incorporated by reference herein). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1398733/000114036121010128/nt10022087x3_ex10-1.htm">1.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendment No. 1 to the Equity Distribution Agreement, dated March&#160;26, 2021, by and between Aquestive Therapeutics, Inc. and Piper Sandler &amp; Co. (filed as Exhibit&#160;10.1 to the Current Report on Form&#160;8-K of the Company, as filed on March&#160;26, 2021, and incorporated by reference herein). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1398733/000114036118033895/s002128x30_ex3-1.htm">3.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated Certificate of Incorporation of Aquestive Therapeutics, Inc., dated as of July&#160;27, 2018 (filed as Exhibit&#160;3.1 to the Current Report on Form&#160;8-K of the Company, as filed on July&#160;27, 2018, and incorporated by reference herein). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1398733/000114036118030141/s002128x4_ex3-6.htm">3.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated Bylaws of Aquestive Therapeutics, Inc. (filed as Exhibit&#160;3.6 to the Registration Statement on Form&#160;S-1 of the Company (File No. 333-225924), as filed on June&#160;27, 2018, and incorporated by reference herein). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1398733/000114036118030141/s002128x4_ex4-1.htm">4.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Common Stock Certificate of Aquestive Therapeutics, Inc. (filed as Exhibit&#160;4.1 to the Registration Statement on Form&#160;S-1 of the Company (File No. 333-225924), as filed on June&#160;27, 2018, and incorporated by reference herein). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.2*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of certificate of designation with respect to any preferred stock issued hereunder and the related form of preferred stock certificate </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20010746x1_ex4-3.htm">4.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of indenture to be entered into between registrant and a trustee acceptable to the registrant. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.4*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of warrant agreement. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.5*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of warrant certificate. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.6*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of debt security. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.7*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of rights certificate. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.8*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of unit agreement. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.9*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of unit certificate. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20010746x1_ex5-1.htm">5.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion of Dechert LLP. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20010746x1_ex5-2.htm">5.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion of Dechert LLP. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20010746x1_ex23-1.htm">23.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of KPMG LLP. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20010746x1_ex5-1.htm">23.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Dechert LLP (included in its Opinion filed as Exhibit&#160;5.1 hereto). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20010746x1_ex5-2.htm">23.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Dechert LLP (included in its Opinion filed as Exhibit&#160;5.2 hereto). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOA">24.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Powers of Attorney (included on signature page). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">25.1**</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Statement of Eligibility of Trustee under the Indenture. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20010746x1_ex107.htm">107</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filing Fee Table</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">To be filed, if applicable, by amendment or as an exhibit to a document filed under the Securities Exchange Act of 1934, as amended, and incorporated by reference herein. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">**<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">To be filed separately pursuant to Section&#160;305(b)(2) of the Trust Indenture Act of 1939, as amended, and the appropriate rules and regulations thereunder.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-4<br></div></div></div>
<!--End Page 63-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 64-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_303-sig_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">SIGNATURES </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&#160;S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the County of Somerset, State of New Jersey, on the 3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> day of April, 2024. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 53.85%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">AQUESTIVE THERAPEUTICS, INC. </div></td></tr><tr><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Daniel Barber </div></td></tr><tr><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Daniel Barber </div></td></tr><tr><td style="width: 43.59%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-5<br></div></div></div>
<!--End Page 64-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 65-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20010746x1_s3_303-sig_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPOA"><!--Anchor--></a>POWER OF ATTORNEY </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel Barber and A. Ernest Toth, Jr., and each of them, as their true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement and sign any registration statement for the same offering covered by the registration statement that is to be effective upon filing pursuant to Rule&#160;462 promulgated under the Securities Act of 1933, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 30.77%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name and Signature</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date </div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Daniel Barber</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Member of the Board of Directors <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Principal Executive Officer)</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;3, 2024 </div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Daniel Barber </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ A. Ernest Toth, Jr.</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Senior Vice President, Chief Financial Officer<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Principal Financial and Accounting Officer)</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;3, 2024 </div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A. Ernest Toth, Jr. </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Santo J. Costa</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chairman of the Board of Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;3, 2024 </div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Santo J. Costa</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ John S. Cochran</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Member of the Board of Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;3, 2024 </div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">John S. Cochran.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Gregory B. Brown</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Member of the Board of Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;3, 2024 </div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gregory B. Brown, M.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Abigail L. Jenkins</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Member of the Board of Directors </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;3, 2024 </div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Abigail L. Jenkins </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Julie Krop</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Member of the Board of Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;3, 2024 </div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Julie Krop, M.D. </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Timothy E. Morris</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Member of the Board of Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;3, 2024 </div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Timothy E. Morris</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Marco Taglietti</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Member of the Board of Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;3, 2024 </div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marco Taglietti, M.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-6<br></div></div></div>
<!--End Page 65-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>ny20010746x1_ex4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 4.3</b></font></p>
  <p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AQUESTIVE THERAPEUTICS, INC.,</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AS ISSUER,</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[TRUSTEE],</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AS TRUSTEE,</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDENTURE</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DATED AS OF , 20</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DEBT SECURITIES</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE OF CONTENTS</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="padding: 0.25pt; background-color: White; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td colspan="2" style="padding: 0.25pt; background-color: White; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="padding: 0.25pt; text-align: right; background-color: White; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE I DEFINITIONS</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; width: 1%; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; width: 10%; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 1.1</font></td>
        <td style="vertical-align: top; width: 79%; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions of Terms</font></td>
        <td style="vertical-align: bottom; width: 10%; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND
            EXCHANGE OF SECURITIES</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation and Terms of Securities</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.2</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities and Trustee&#8217;s Certificate</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.3</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominations: Provisions for Payment</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.4</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution and Authentications</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.5</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration of Transfer and Exchange</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.6</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Temporary Securities</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.7</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutilated, Destroyed, Lost or Stolen Securities</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.8</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancellation</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.9</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits of Indenture</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.10</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authenticating Agent</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.11</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global Securities</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE III REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemption</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.2</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Redemption</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.3</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment Upon Redemption</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.4</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sinking Fund</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.5</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfaction of Sinking Fund Payments with Securities</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.6</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemption of Securities for Sinking Fund</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE IV COVENANTS</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Principal, Premium and Interest</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.2</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance of Office or Agency</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.3</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paying Agents</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.4</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment to Fill Vacancy in Office of Trustee</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.5</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Consolidation Provisions</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE V SECURITYHOLDERS&#8217; LISTS AND REPORTS BY THE COMPANY AND THE
            TRUSTEE</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company to Furnish Trustee Names and Addresses of Securityholders</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.2</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preservation of Information; Communications With Securityholders</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.3</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reports by the Company</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.4</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reports by the Trustee</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE VI REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF
            DEFAULT</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Events of Default</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.2</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collection of Indebtedness and Suits for Enforcement by Trustee</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.3</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application of Moneys Collected</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.4</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitation on Suits</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.5</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights and Remedies Cumulative; Delay or Omission Not Waiver</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.6</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control by Securityholders</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.7</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undertaking to Pay Costs</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE VII CONCERNING THE TRUSTEE</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Duties and Responsibilities of Trustee</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.2</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Rights of Trustee</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</font></td>
      </tr>

  </table>
  <!-- Field: /Rule-Page -->
  <p style="margin: 0"></p>
  <p style="margin: 0"><font style="font-size: 8pt"><br>
    </font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif; width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.3</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif; width: 79%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trustee Not Responsible for Recitals or Issuance or Securities</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.4</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May Hold Securities</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.5</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moneys Held in Trust</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.6</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation and Reimbursement</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.7</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reliance on Officer&#8217;s Certificate</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.8</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disqualification; Conflicting Interests</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.9</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Trustee Required; Eligibility</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.10</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resignation and Removal; Appointment of Successor</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.11</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptance of Appointment By Successor</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.12</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger, Conversion, Consolidation or Succession to Business</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.13</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferential Collection of Claims Against the Company</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.14</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Default</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE VIII CONCERNING THE SECURITYHOLDERS</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 8.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence of Action by Securityholders</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 8.2</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proof of Execution by Securityholders</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 8.3</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Who May Be Deemed Owners</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 8.4</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Securities Owned by Company Disregarded</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 8.5</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actions Binding on Future Securityholders</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE IX SUPPLEMENTAL INDENTURES</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental Indentures Without the Consent of Securityholders</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.2</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental Indentures With Consent of Securityholders</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.3</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of Supplemental Indentures</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.4</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Affected by Supplemental Indentures</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.5</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution of Supplemental Indentures</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE X SUCCESSOR ENTITY</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company May Consolidate, Etc.</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.2</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successor Entity Substituted</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.3</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence of Consolidation, Etc. to Trustee</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE XI SATISFACTION AND DISCHARGE</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 11.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfaction and Discharge of Indenture</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 11.2</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discharge of Obligations</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 11.3</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposited Moneys to be Held in Trust</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 11.4</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Moneys Held by Paying Agents</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 11.5</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment to Company</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</font></td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE XII IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS</font></p>
        </td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 12.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Recourse</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td colspan="3" style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE XIII MISCELLANEOUS PROVISIONS</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</font></td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <!--PROfilePageNumberReset%LCR%3%%%-->
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif; width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif; width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.1</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif; width: 79%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect on Successors and Assigns</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif; width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.2</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actions by Successor</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.3</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surrender of Company Powers</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.4</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.5</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing Law</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.6</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment of Securities as Debt</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.7</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificates and Opinions as to Conditions Precedent</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.8</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments on Business Days</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.9</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conflict with Trust Indenture Act</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.10</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</font></td>
      </tr>
      <tr style="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.11</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separability</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</font></td>
      </tr>
      <tr style="background-color: White; font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 13.12</font></td>
        <td style="vertical-align: top; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance Certificates</font></td>
        <td style="vertical-align: bottom; padding: 0.25pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</font></td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">iii</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <!--PROfilePageNumberReset%Num%1%%%-->
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDENTURE</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDENTURE, dated as of [ ], 20[ ], among AQUESTIVE THERAPEUTICS, INC., a Delaware corporation
      (the &#8220;Company&#8221;), and [TRUSTEE], as trustee (the &#8220;Trustee&#8221;):</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and
      delivery of this Indenture to provide for the issuance of debt securities (hereinafter referred to as the &#8220;Securities&#8221;), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as
      registered Securities without coupons, to be authenticated by the certificate of the Trustee;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS, to provide the terms and conditions upon which the Securities are to be
      authenticated, issued and delivered, the Company has duly authorized the execution of this Indenture; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS, all things necessary to make this Indenture a valid agreement of the Company, in
      accordance with its terms, have been done.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW, THEREFORE, in consideration of the premises and the purchase of the Securities by the
      holders thereof, it is mutually covenanted and agreed as follows for the equal and ratable benefit of the holders of Securities:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE I</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DEFINITIONS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 1.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Definitions of Terms.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The terms defined in this Section (except as in this Indenture or any indenture supplemental
      hereto otherwise expressly provided or unless the context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section and shall include the plural as
      well as the singular. All other terms used in this Indenture that are defined in the Trust Indenture Act of 1939, as amended, or that are by reference in such Act defined in the Securities Act of 1933, as amended (except as herein or any indenture
      supplemental hereto otherwise expressly provided or unless the context otherwise requires), shall have the meanings assigned to such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the execution of this
      instrument.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Authenticating Agent&#8221; means an authenticating agent with respect to all or any of the series
      of Securities appointed by the Trustee pursuant to Section 2.10.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Bankruptcy Law&#8221; means Title 11, U.S. Code, or any similar federal or state law for the
      relief of debtors.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Board of Directors&#8221; means the Board of Directors of the Company or any duly authorized
      committee of such Board.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Board Resolution&#8221; means a copy of a resolution certified by the Secretary or an Assistant
      Secretary of the Company to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Business Day&#8221; means, with respect to any series of Securities, any day other than a day on
      which federal or state banking institutions in the Borough of Manhattan, the City of New York, or in the city of the Corporate Trust Office of the Trustee, are authorized or obligated by law, executive order or regulation to close.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Certificate&#8221; means a certificate signed by any Officer. The Certificate need not comply with
      the provisions of Section 13.07.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Company&#8221; means Aquestive Therapeutics, Inc., a corporation duly organized and existing under
      the laws of the State of Delaware, and, subject to the provisions of Article Ten, shall also include its successors and assigns.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">1</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Corporate Trust Office&#8221; means the office of the Trustee at which, at any particular time,
      its corporate trust business shall be principally administered, which office at the date hereof is located at [ ].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Custodian&#8221; means any receiver, trustee, assignee, liquidator or similar official under any
      Bankruptcy Law.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Default&#8221; means any event, act or condition that with notice or lapse of time, or both, would
      constitute an Event of Default.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Defaulted Interest&#8221; has the meaning set forth in Section 2.03.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Depositary&#8221; means, with respect to Securities of any series for which the Company shall
      determine that such Securities will be issued as a Global Security, The Depository Trust Company, another clearing agency, or any successor registered as a clearing agency under the Exchange Act, or other applicable statute or regulation, which, in
      each case, shall be designated by the Company pursuant to either Section 2.01 or 2.11.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Event of Default&#8221; means, with respect to Securities of a particular series, any event
      specified in Section 6.01, continued for the period of time, if any, therein designated.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Exchange Act&#8221; means the Securities and Exchange Act of 1934, as amended.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Global Security&#8221; means, with respect to any series of Securities, a Security executed by the
      Company and delivered by the Trustee to the Depositary or pursuant to the Depositary&#8217;s instruction, all in accordance with the Indenture, which shall be registered in the name of the Depositary or its nominee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Governmental Obligations&#8221; means securities that are (a) direct obligations of the United
      States of America for the payment of which its full faith and credit is pledged or (b) obligations of a Person controlled or supervised by and acting as an agency or instrumentality of the United States of America, the payment of which is
      unconditionally guaranteed as a full faith and credit obligation by the United States of America that, in either case, are not callable or redeemable at the option of the issuer thereof at any time prior to the stated maturity of the Securities, and
      shall also include a depositary receipt issued by a bank or trust company as custodian with respect to any such Governmental Obligation or a specific payment of principal of or interest on any such Governmental Obligation held by such custodian for
      the account of the holder of such depositary receipt; provided, however, that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received
      by the custodian in respect of the Governmental Obligation or the specific payment of principal of or interest on the Governmental Obligation evidenced by such depositary receipt.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and other words of similar import, refer to this
      Indenture as a whole and not to any particular Article, Section or other subdivision.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Indenture&#8221; means this instrument as originally executed or as it may from time to time be
      supplemented or amended by one or more indentures supplemental hereto entered into in accordance with the terms hereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Interest Payment Date&#8221;, when used with respect to any installment of interest on a Security
      of a particular series, means the date specified in such Security or in a Board Resolution or in an indenture supplemental hereto with respect to such series as the fixed date on which an installment of interest with respect to Securities of that
      series is due and payable.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Officer&#8221; means, with respect to the Company, the chairman of the Board of Directors, a chief
      executive officer, a president, a chief financial officer, a chief operating officer, any executive vice president, any senior vice president, any vice president, the treasurer or any assistant treasurer, the controller or any assistant controller or
      the secretary or any assistant secretary.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Officer&#8217;s Certificate&#8221; means a certificate signed by any Officer. Each such certificate
      shall include the statements provided for in Section 13.07, if and to the extent required by the provisions thereof.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">2</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Opinion of Counsel&#8221; means an opinion in writing subject to customary exceptions of legal
      counsel, who may be an employee of or counsel for the Company, that is delivered to the Trustee in accordance with the terms hereof. Each such opinion shall include the statements provided for in Section 13.07, if and to the extent required by the
      provisions thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Outstanding&#8221;, when used with reference to Securities of any series, means, subject to the
      provisions of Section 8.04, as of any particular time, all Securities of that series theretofore authenticated and delivered by the Trustee under this Indenture, except (a) Securities theretofore canceled by the Trustee or any paying agent, or
      delivered to the Trustee or any paying agent for cancellation or that have previously been canceled; (b) Securities or portions thereof for the payment or redemption of which moneys or Governmental Obligations in the necessary amount shall have been
      deposited in trust with the Trustee or with any paying agent (other than the Company) or shall have been set aside and segregated in trust by the Company (if the Company shall act as its own paying agent); provided, however, that if such Securities
      or portions of such Securities are to be redeemed prior to the maturity thereof, notice of such redemption shall have been given as provided in Article Three, or provision satisfactory to the Trustee shall have been made for giving such notice; and
      (c) Securities in lieu of or in substitution for which other Securities shall have been authenticated and delivered pursuant to the terms of Section 2.07.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Person&#8221; means any individual, corporation, partnership, joint venture, joint-stock company,
      limited liability company, association, trust, unincorporated organization, any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Predecessor Security&#8221; of any particular Security means every previous Security evidencing
      all or a portion of the same debt as that evidenced by such particular Security; and, for the purposes of this definition, any Security authenticated and delivered under Section 2.07 in lieu of a lost, destroyed or stolen Security shall be deemed to
      evidence the same debt as the lost, destroyed or stolen Security.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Responsible Officer&#8221; when used with respect to the Trustee means the chairman of its board
      of directors, the chief executive officer, the president, any vice president, the secretary, the treasurer, any trust officer, any corporate trust officer or any other officer or assistant officer of the Trustee customarily performing functions
      similar to those performed by the Persons who at the time shall be such officers, respectively, or to whom any corporate trust matter is referred because of his or her knowledge of and familiarity with the particular subject.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Securities&#8221; means the debt securities authenticated and delivered under this Indenture.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Securityholder&#8221;, &#8220;holder of Securities&#8221;, &#8220;registered holder&#8221;, or other similar term, means
      the Person or Persons in whose name or names a particular Security shall be registered on the books of the Company kept for that purpose in accordance with the terms of this Indenture.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Security Register&#8221; and &#8220;Security Registrar&#8221; shall have the meanings as set forth in Section
      2.05.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Subsidiary&#8221; means, with respect to any Person, (i) any corporation at least a majority of
      whose outstanding Voting Stock shall at the time be owned, directly or indirectly, by such Person or by one or more of its Subsidiaries or by such Person and one or more of its Subsidiaries, any general partnership, joint venture or similar entity,
      at least a majority of whose outstanding partnership or similar interests shall at the time be owned by such Person, or by one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries and (iii) any limited partnership of
      which such Person or any of its Subsidiaries is a general partner.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Trustee&#8221; means [_________________], and, subject to the provisions of Article Seven, shall
      also include its successors and assigns, and, if at any time there is more than one Person acting in such capacity hereunder, &#8220;Trustee&#8221; shall mean each such Person. The term &#8220;Trustee&#8221; as used with respect to a particular series of the Securities
      shall mean the trustee with respect to that series.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Trust Indenture Act&#8221; means the Trust Indenture Act of 1939, as amended.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Voting Stock&#8221;, as applied to stock of any Person, means shares, interests, participations or
      other equivalents in the equity interest (however designated) in such Person having ordinary voting power for the election of a majority of the directors (or the equivalent) of such Person, other than shares, interests, participations or other
      equivalents having such power only by reason of the occurrence of a contingency.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">3</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE II</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND EXCHANGE OF SECURITIES</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Designation and Terms of Securities.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The aggregate principal amount of Securities that may be authenticated and delivered under
      this Indenture is unlimited. The Securities may be issued in one or more series up to the aggregate principal amount of Securities of that series from time to time authorized by or pursuant to a Board Resolution or pursuant to one or more indentures
      supplemental hereto. Prior to the initial issuance of Securities of any series, there shall be established in or pursuant to a Board Resolution, and set forth in an Officer&#8217;s Certificate, or established in one or more indentures supplemental hereto:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) the title of the Securities of the series (which shall distinguish the Securities of that
      series from all other Securities);</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) any limit upon the aggregate principal amount of the Securities of that series that may
      be authenticated and delivered under this Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of that series);</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the date or dates on which the principal of the Securities of the series is payable,
      any original issue discount that may apply to the Securities of that series upon their issuance, the principal amount due at maturity, and the place(s) of payment;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) the rate or rates at which the Securities of the series shall bear interest or the
      manner of calculation of such rate or rates, if any</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) the date or dates from which such interest shall accrue, the Interest Payment Dates on
      which such interest will be payable or the manner of determination of such Interest Payment Dates, the place(s) of payment, and the record date for the determination of holders to whom interest is payable on any such Interest Payment Dates or the
      manner of determination of such record dates;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi) the right, if any, to extend the interest payment periods and the duration of such
      extension;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii) the period or periods within which, the price or prices at which and the terms and
      conditions upon which Securities of the series may be redeemed, in whole or in part, at the option of the Company;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii) the obligation, if any, of the Company to redeem or purchase Securities of the series
      pursuant to any sinking fund, mandatory redemption, or analogous provisions (including payments made in cash in satisfaction of future sinking fund obligations) or at the option of a holder thereof and the period or periods within which, the price or
      prices at which, and the terms and conditions upon which, Securities of the series shall be redeemed or purchased, in whole or in part, pursuant to such obligation;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix) the form of the Securities of the series including the form of the Certificate of
      Authentication for such series;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x) if other than denominations of one thousand U.S. dollars ($1,000) or any integral
      multiple thereof, the denominations in which the Securities of the series shall be issuable;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi) any and all other terms (including terms, to the extent applicable, relating to any
      auction or remarketing of the Securities of that series and any security for the obligations of the Company with respect to such Securities) with respect to such series (which terms shall not be inconsistent with the terms of this Indenture, as
      amended by any supplemental indenture) including any terms which may be required by or advisable under United States laws or regulations or advisable in connection with the marketing of Securities of that series;</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">4</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii) whether the Securities are issuable as a Global Security and, in such case, the terms
      and the identity of the Depositary for such series;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii) whether the Securities will be convertible into or exchangeable for shares of common
      stock, preferred stock or other securities of the Company or any other Person and, if so, the terms and conditions upon which such Securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it
      will be calculated and may be adjusted, any mandatory or optional (at the Company&#8217;s option or the holders&#8217; option) conversion or exchange features, and the applicable conversion or exchange period;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv) if other than the principal amount thereof, the portion of the principal amount of
      Securities of the series which shall be payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.01;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv) any additional or different Events of Default or restrictive covenants (which may
      include, among other restrictions, restrictions on the Company&#8217;s ability or the ability of the Company&#8217;s Subsidiaries to: incur additional indebtedness; issue additional securities; create liens; pay dividends or make distributions in respect of the
      capital stock of the Company or the Company&#8217;s Subsidiaries; redeem capital stock; place restrictions on the Company&#8217;s Subsidiaries&#8217; ability to pay dividends, make distributions or transfer assets; make investments or other restricted payments; sell
      or otherwise dispose of assets; enter into sale- leaseback transactions; engage in transactions with stockholders or affiliates; issue or sell stock of the Company&#8217;s Subsidiaries; or effect a consolidation or merger) or financial covenants (which may
      include, among other financial covenants, financial covenants that require the Company and its Subsidiaries to maintain specified interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios) provided for with respect to
      the Securities of the series;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi) if other than dollars, the coin or currency in which the Securities of the series are
      denominated (including, but not limited to, foreign currency);</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii) the terms and conditions, if any, upon which the Company shall pay amounts in addition
      to the stated interest, premium, if any and principal amounts of the Securities of the series to any Securityholder that is not a &#8220;United States person&#8221; for federal tax purposes; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii) any restrictions on transfer, sale or assignment of the Securities of the series.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Securities of any one series shall be substantially identical except as may otherwise be
      provided in or pursuant to any such Board Resolution or in any indentures supplemental hereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any of the terms of the series are established by action taken pursuant to a Board
      Resolution of the Company, a copy of an appropriate record of such action shall be certified by the secretary or an assistant secretary of the Company and delivered to the Trustee at or prior to the delivery of the Officer&#8217;s Certificate of the
      Company setting forth the terms of the series.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities of any particular series may be issued at various times, with different dates on
      which the principal or any installment of principal is payable, with different rates of interest, if any, or different methods by which rates of interest may be determined, with different dates on which such interest may be payable and with different
      redemption dates.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.2</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form of Securities and Trustee&#8217;s Certificate.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Securities of any series and the Trustee&#8217;s certificate of authentication to be borne by
      such Securities shall be substantially of the tenor and purport as set forth in one or more indentures supplemental hereto or as provided in a Board Resolution, and set forth in an Officer&#8217;s Certificate, and they may have such letters, numbers or
      other marks of identification or designation and such legends or endorsements printed, lithographed or engraved thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Indenture, or as may be required to
      comply with any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange on which Securities of that series may be listed, or to conform to usage.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">5</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.3</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Denominations: Provisions for Payment.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Securities shall be issuable as registered Securities and in the denominations of one
      thousand U.S. dollars ($1,000) or any integral multiple thereof, subject to Section 2.01(a)(10).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Securities of a particular series shall bear interest payable on the dates and at the
      rate specified with respect to that series. Subject to Section 2.01(a)(16), the principal of and the interest on the Securities of any series, as well as any premium thereon in case of redemption thereof prior to maturity, shall be payable in the
      coin or currency of the United States of America that at the time is legal tender for public and private debt, at the office or agency of the Company maintained for that purpose. Each Security shall be dated the date of its authentication. Interest
      on the Securities shall be computed on the basis of a 360-day year composed of twelve 30-day months.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The interest installment on any Security that is payable, and is punctually paid or duly
      provided for, on any Interest Payment Date for Securities of that series shall be paid to the Person in whose name said Security (or one or more Predecessor Securities) is registered at the close of business on the regular record date for such
      interest installment. In the event that any Security of a particular series or portion thereof is called for redemption and the redemption date is subsequent to a regular record date with respect to any Interest Payment Date and prior to such
      Interest Payment Date, interest on such Security will be paid upon presentation and surrender of such Security as provided in Section 3.03.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any interest on any Security that is payable, but is not punctually paid or duly provided
      for, on any Interest Payment Date for Securities of the same series (herein called &#8220;Defaulted Interest&#8221;) shall forthwith cease to be payable to the registered holder on the relevant regular record date by virtue of having been such holder; and such
      Defaulted Interest shall be paid by the Company, at its election, as provided in clause (1) or clause (2) below:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) The Company may make payment of any Defaulted Interest on Securities to the Persons in
      whose names such Securities (or their respective Predecessor Securities) are registered at the close of business on a special record date for the payment of such Defaulted Interest, which shall be fixed in the following manner: the Company shall
      notify the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each such Security and the date of the proposed payment, and at the same time the Company shall deposit with the Trustee an amount of money equal to the
      aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit prior to the date of the proposed payment, such money when deposited to be held in trust for the
      benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Trustee shall fix a special record date for the payment of such Defaulted Interest which shall not be more than 15 nor less than 10 days prior to the
      date of the proposed payment and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment. The Trustee shall promptly notify the Company of such special record date and, in the name and at the expense of the
      Company, shall cause notice of the proposed payment of such Defaulted Interest and the special record date therefor to be mailed, first class postage prepaid, to each Securityholder at his or her address as it appears in the Security Register (as
      hereinafter defined), not less than 10 days prior to such special record date. Notice of the proposed payment of such Defaulted Interest and the special record date therefor having been mailed as aforesaid, such Defaulted Interest shall be paid to
      the Persons in whose names such Securities (or their respective Predecessor Securities) are registered on such special record date.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) The Company may make payment of any Defaulted Interest on any Securities in any other
      lawful manner not inconsistent with the requirements of any securities exchange on which such Securities may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the proposed
      payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise set forth in a Board Resolution or one or more indentures supplemental
      hereto establishing the terms of any series of Securities pursuant to Section 2.01 hereof, the term &#8220;regular record date&#8221; as used in this Section with respect to a series of Securities and any Interest Payment Date for such series shall mean either
      the fifteenth day of the month immediately preceding the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the first day of a month, or the first day of
      the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the fifteenth day of a month, whether or not such date is a Business Day.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">6</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the foregoing provisions of this Section, each Security of a series delivered
      under this Indenture upon transfer of or in exchange for or in lieu of any other Security of such series shall carry the rights to interest accrued and unpaid, and to accrue, that were carried by such other Security.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.4</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution and Authentications.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Securities shall be signed on behalf of the Company by one of its Officers. Signatures
      may be in the form of a manual or facsimile signature. The Company may use the facsimile signature of any Person who shall have been an Officer, notwithstanding the fact that at the time the Securities shall be authenticated and delivered or disposed
      of such Person shall have ceased to be such an officer of the Company. The Securities may contain such notations, legends or endorsements required by law, stock exchange rule or usage. Each Security shall be dated the date of its authentication by
      the Trustee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Security shall not be valid until authenticated manually by an authorized signatory of the
      Trustee, or by an Authenticating Agent. Such signature shall be conclusive evidence that the Security so authenticated has been duly authenticated and delivered hereunder and that the holder is entitled to the benefits of this Indenture. At any time
      and from time to time after the execution and delivery of this Indenture, the Company may deliver Securities of any series executed by the Company to the Trustee for authentication, together with a written order of the Company for the authentication
      and delivery of such Securities, signed by an Officer, and the Trustee in accordance with such written order shall authenticate and deliver such Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In authenticating such Securities and accepting the additional responsibilities under this
      Indenture in relation to such Securities, the Trustee shall be entitled to receive, if requested, and (subject to Section 7.01) shall be fully protected in relying upon, an Opinion of Counsel stating that the form and terms thereof have been
      established in conformity with the provisions of this Indenture.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Trustee shall not be required to authenticate such Securities if the issue of such
      Securities pursuant to this Indenture will affect the Trustee&#8217;s own rights, duties or immunities under the Securities and this Indenture or otherwise in a manner that is not reasonably acceptable to the Trustee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.5</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration of Transfer and Exchange.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Securities of any series may be exchanged upon presentation thereof at the office or agency
      of the Company designated for such purpose, for other Securities of such series of authorized denominations, and for a like aggregate principal amount, upon payment of a sum sufficient to cover any tax or other governmental charge in relation
      thereto, all as provided in this Section. In respect of any Securities so surrendered for exchange, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in exchange therefor the Security or Securities of
      the same series that the Securityholder making the exchange shall be entitled to receive, bearing numbers not contemporaneously outstanding.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The Company shall keep, or cause to be kept, at its office or agency designated for such
      purpose a register or registers (herein referred to as the &#8220;Security Register&#8221;) in which, subject to such reasonable regulations as it may prescribe, the Company shall register the Securities and the transfers of Securities as in this Article
      provided and which at all reasonable times shall be open for inspection by the Trustee. The registrar for the purpose of registering Securities and transfer of Securities as herein provided shall be appointed as authorized by Board Resolution (the
      &#8220;Security Registrar&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon surrender for transfer of any Security at the office or agency of the Company designated
      for such purpose, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in the name of the transferee or transferees a new Security or Securities of the same series as the Security presented for a like
      aggregate principal amount.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">7</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Securities presented or surrendered for exchange or registration of transfer, as provided
      in this Section, shall be accompanied (if so required by the Company or the Security Registrar) by a written instrument or instruments of transfer, in form satisfactory to the Company or the Security Registrar, duly executed by the registered holder
      or by such holder&#8217;s duly authorized attorney in writing.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth
      in an Officer&#8217;s Certificate, or established in one or more indentures supplemental to this Indenture, no service charge shall be made for any exchange or registration of transfer of Securities, or issue of new Securities in case of partial redemption
      of any series, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge in relation thereto, other than exchanges pursuant to Section 2.06, Section 3.03(b) and Section 9.04 not involving any transfer.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) The Company shall not be required (i) to issue, exchange or register the transfer of any
      Securities during a period beginning at the opening of business 15 days before the day of the mailing of a notice of redemption of less than all the Outstanding Securities of the same series and ending at the close of business on the day of such
      mailing, nor (ii) to register the transfer of or exchange any Securities of any series or portions thereof called for redemption, other than the unredeemed portion of any such Securities being redeemed in part. The provisions of this Section 2.05
      are, with respect to any Global Security, subject to Section 2.11 hereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.6</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Temporary Securities.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending the preparation of definitive Securities of any series, the Company may execute, and
      the Trustee shall authenticate and deliver, temporary Securities (printed, lithographed or typewritten) of any authorized denomination. Such temporary Securities shall be substantially in the form of the definitive Securities in lieu of which they
      are issued, but with such omissions, insertions and variations as may be appropriate for temporary Securities, all as may be determined by the Company. Every temporary Security of any series shall be executed by the Company and be authenticated by
      the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive Securities of such series. Without unnecessary delay the Company will execute and will furnish definitive Securities of such series and
      thereupon any or all temporary Securities of such series may be surrendered in exchange therefor (without charge to the holders), at the office or agency of the Company designated for the purpose, and the Trustee shall authenticate and such office or
      agency shall deliver in exchange for such temporary Securities an equal aggregate principal amount of definitive Securities of such series, unless the Company advises the Trustee to the effect that definitive Securities need not be executed and
      furnished until further notice from the Company. Until so exchanged, the temporary Securities of such series shall be entitled to the same benefits under this Indenture as definitive Securities of such series authenticated and delivered hereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.7</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mutilated, Destroyed, Lost or Stolen Securities.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In case any temporary or definitive Security shall become mutilated or be destroyed, lost or
      stolen, the Company (subject to the next succeeding sentence) shall execute, and upon the Company&#8217;s request the Trustee (subject as aforesaid) shall authenticate and deliver, a new Security of the same series, bearing a number not contemporaneously
      outstanding, in exchange and substitution for the mutilated Security, or in lieu of and in substitution for the Security so destroyed, lost or stolen. In every case the applicant for a substituted Security shall furnish to the Company and the Trustee
      such security or indemnity as may be required by them to save each of them harmless, and, in every case of destruction, loss or theft, the applicant shall also furnish to the Company and the Trustee evidence to their satisfaction of the destruction,
      loss or theft of the applicant&#8217;s Security and of the ownership thereof. The Trustee may authenticate any such substituted Security and deliver the same upon the written request or authorization of any officer of the Company. Upon the issuance of any
      substituted Security, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected
      therewith.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In case any Security that has matured or is about to mature shall become mutilated or be
      destroyed, lost or stolen, the Company may, instead of issuing a substitute Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated Security) if the applicant for such payment shall furnish to
      the Company and the Trustee such security or indemnity as they may require to save them harmless, and, in case of destruction, loss or theft, evidence to the satisfaction of the Company and the Trustee of the destruction, loss or theft of such
      Security and of the ownership thereof.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">8</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every replacement Security issued pursuant to the provisions of this Section shall constitute
      an additional contractual obligation of the Company whether or not the mutilated, destroyed, lost or stolen Security shall be found at any time, or be enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally and
      proportionately with any and all other Securities of the same series duly issued hereunder. All Securities shall be held and owned upon the express condition that the foregoing provisions are exclusive with respect to the replacement or payment of
      mutilated, destroyed, lost or stolen Securities, and shall preclude (to the extent lawful) any and all other rights or remedies, notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the replacement or
      payment of negotiable instruments or other securities without their surrender.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.8</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cancellation.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Securities surrendered for the purpose of payment, redemption, exchange or registration
      of transfer shall, if surrendered to the Company or any paying agent, be delivered to the Trustee for cancellation, or, if surrendered to the Trustee, shall be cancelled by it, and no Securities shall be issued in lieu thereof except as expressly
      required or permitted by any of the provisions of this Indenture. On request of the Company at the time of such surrender, the Trustee shall deliver to the Company canceled Securities held by the Trustee. In the absence of such request the Trustee
      may dispose of canceled Securities in accordance with its standard procedures and deliver a certificate of disposition to the Company. If the Company shall otherwise acquire any of the Securities, however, such acquisition shall not operate as a
      redemption or satisfaction of the indebtedness represented by such Securities unless and until the same are delivered to the Trustee for cancellation.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.9</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Benefits of Indenture.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing in this Indenture or in the Securities, express or implied, shall give or be
      construed to give to any Person, other than the parties hereto and the holders of the Securities any legal or equitable right, remedy or claim under or in respect of this Indenture, or under any covenant, condition or provision herein contained; all
      such covenants, conditions and provisions being for the sole benefit of the parties hereto and of the holders of the Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.10</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Authenticating Agent.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">So long as any of the Securities of any series remain Outstanding there may be an
      Authenticating Agent for any or all such series of Securities which the Trustee shall have the right to appoint. Said Authenticating Agent shall be authorized to act on behalf of the Trustee to authenticate Securities of such series issued upon
      exchange, transfer or partial redemption thereof, and Securities so authenticated shall be entitled to the benefits of this Indenture and shall be valid and obligatory for all purposes as if authenticated by the Trustee hereunder. All references in
      this Indenture to the authentication of Securities by the Trustee shall be deemed to include authentication by an Authenticating Agent for such series. Each Authenticating Agent shall be acceptable to the Company and shall be a corporation that has a
      combined capital and surplus, as most recently reported or determined by it, sufficient under the laws of any jurisdiction under which it is organized or in which it is doing business to conduct a trust business, and that is otherwise authorized
      under such laws to conduct such business and is subject to supervision or examination by federal or state authorities. If at any time any Authenticating Agent shall cease to be eligible in accordance with these provisions, it shall resign
      immediately.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Authenticating Agent may at any time resign by giving written notice of resignation to
      the Trustee and to the Company. The Trustee may at any time (and upon request by the Company shall) terminate the agency of any Authenticating Agent by giving written notice of termination to such Authenticating Agent and to the Company. Upon
      resignation, termination or cessation of eligibility of any Authenticating Agent, the Trustee may appoint an eligible successor Authenticating Agent acceptable to the Company. Any successor Authenticating Agent, upon acceptance of its appointment
      hereunder, shall become vested with all the rights, powers and duties of its predecessor hereunder as if originally named as an Authenticating Agent pursuant hereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 2.11</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Global Securities.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) If the Company shall establish pursuant to Section 2.01 that the Securities of a particular
      series are to be issued as a Global Security, then the Company shall execute and the Trustee shall, in accordance with Section 2.04, authenticate and deliver, a Global Security that (i) shall represent, and shall be denominated in an amount equal to
      the aggregate principal amount of, all of the Outstanding Securities of such series, (ii) shall be registered in the name of the Depositary or its nominee, (iii) shall be delivered by the Trustee to the Depositary or pursuant to the Depositary&#8217;s
      instruction and (iv) shall bear a legend substantially to the following effect: &#8220;Except as otherwise provided in Section 2.11 of the Indenture, this Security may be transferred, in whole but not in part, only to another nominee of the Depositary or
      to a successor Depositary or to a nominee of such successor Depositary.&#8221;</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">9</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Notwithstanding the provisions of Section 2.05, the Global Security of a series may be
      transferred, in whole but not in part and in the manner provided in Section 2.05, only to another nominee of the Depositary for such series, or to a successor Depositary for such series selected or approved by the Company or to a nominee of such
      successor Depositary.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) If at any time the Depositary for a series of the Securities notifies the Company that it
      is unwilling or unable to continue as Depositary for such series or if at any time the Depositary for such series shall no longer be registered or in good standing under the Exchange Act, or other applicable statute or regulation, and a successor
      Depositary for such series is not appointed by the Company within 90 days after the Company receives such notice or becomes aware of such condition, as the case may be, or if an Event of Default has occurred and is continuing and the Company has
      received a request from the Depositary or from the Trustee, this Section 2.11 shall no longer be applicable to the Securities of such series and the Company will execute, and subject to Section 2.04, the Trustee will authenticate and deliver the
      Securities of such series in definitive registered form without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. In
      addition, the Company may at any time determine that the Securities of any series shall no longer be represented by a Global Security and that the provisions of this Section 2.11 shall no longer apply to the Securities of such series. In such event
      the Company will execute and, subject to Section 2.04, the Trustee, upon receipt of an Officer&#8217;s Certificate evidencing such determination by the Company, will authenticate and deliver the Securities of such series in definitive registered form
      without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. Upon the exchange of the Global Security for such Securities
      in definitive registered form without coupons, in authorized denominations, the Global Security shall be canceled by the Trustee. Such Securities in definitive registered form issued in exchange for the Global Security pursuant to this Section
      2.11(c) shall be registered in such names and in such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Trustee. The Trustee shall deliver such Securities to
      the Depositary for delivery to the Persons in whose names such Securities are so registered.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE III</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 3.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Redemption.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may redeem the Securities of any series issued hereunder on and after the dates
      and in accordance with the terms established for such series pursuant to Section 2.01 hereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 3.2</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notice of Redemption.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) In case the Company shall desire to exercise such right to redeem all or, as the case may
      be, a portion of the Securities of any series in accordance with any right the Company reserved for itself to do so pursuant to Section 2.01 hereof, the Company shall, or shall cause the Trustee to, give notice of such redemption to holders of the
      Securities of such series to be redeemed by mailing, first class postage prepaid, a notice of such redemption not less than 30 days and not more than 90 days before the date fixed for redemption of that series to such holders at their last addresses
      as they shall appear upon the Security Register, unless a shorter period is specified in the Securities to be redeemed. Any notice that is mailed in the manner herein provided shall be conclusively presumed to have been duly given, whether or not the
      registered holder receives the notice. In any case, failure duly to give such notice to the holder of any Security of any series designated for redemption in whole or in part, or any defect in the notice, shall not affect the validity of the
      proceedings for the redemption of any other Securities of such series or any other series. In the case of any redemption of Securities prior to the expiration of any restriction on such redemption provided in the terms of such Securities or elsewhere
      in this Indenture, the Company shall furnish the Trustee with an Officer&#8217;s Certificate evidencing compliance with any such restriction.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">10</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each such notice of redemption shall specify the date fixed for redemption and the redemption
      price at which Securities of that series are to be redeemed, and shall state that payment of the redemption price of such Securities to be redeemed will be made at the office or agency of the Company, upon presentation and surrender of such
      Securities, that interest accrued to the date fixed for redemption will be paid as specified in said notice, that from and after said date interest will cease to accrue and that the redemption is from a sinking fund, if such is the case. If less than
      all the Securities of a series are to be redeemed, the notice to the holders of Securities of that series to be redeemed in part shall specify the particular Securities to be so redeemed.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In case any Security is to be redeemed in part only, the notice that relates to such Security
      shall state the portion of the principal amount thereof to be redeemed, and shall state that on and after the redemption date, upon surrender of such Security, a new Security or Securities of such series in principal amount equal to the unredeemed
      portion thereof will be issued.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) If less than all the Securities of a series are to be redeemed, the Company shall give
      the Trustee at least 45 days&#8217; notice (unless a shorter notice shall be satisfactory to the Trustee) in advance of the date fixed for redemption as to the aggregate principal amount of Securities of the series to be redeemed, and thereupon the Trustee
      shall select, by lot or in such other manner as it shall deem appropriate and fair in its discretion and that may provide for the selection of a portion or portions (equal to one thousand U.S. dollars ($1,000) or any integral multiple thereof) of the
      principal amount of such Securities of a denomination larger than $1,000, the Securities to be redeemed and shall thereafter promptly notify the Company in writing of the numbers of the Securities to be redeemed, in whole or in part. The Company may,
      if and whenever it shall so elect, by delivery of instructions signed on its behalf by an Officer, instruct the Trustee or any paying agent to call all or any part of the Securities of a particular series for redemption and to give notice of
      redemption in the manner set forth in this Section, such notice to be in the name of the Company or its own name as the Trustee or such paying agent may deem advisable. In any case in which notice of redemption is to be given by the Trustee or any
      such paying agent, the Company shall deliver or cause to be delivered to, or permit to remain with, the Trustee or such paying agent, as the case may be, such Security Register, transfer books or other records, or suitable copies or extracts
      therefrom, sufficient to enable the Trustee or such paying agent to give any notice by mail that may be required under the provisions of this Section</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Section 3.3</b></font></td>
        <td style="font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment Upon Redemption.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) If the giving of notice of redemption shall have been completed as above provided, the
      Securities or portions of Securities of the series to be redeemed specified in such notice shall become due and payable on the date and at the place stated in such notice at the applicable redemption price, together with interest accrued to the date
      fixed for redemption and interest on such Securities or portions of Securities shall cease to accrue on and after the date fixed for redemption, unless the Company shall default in the payment of such redemption price and accrued interest with
      respect to any such Security or portion thereof. On presentation and surrender of such Securities on or after the date fixed for redemption at the place of payment specified in the notice, said Securities shall be paid and redeemed at the applicable
      redemption price for such series, together with interest accrued thereon to the date fixed for redemption (but if the date fixed for redemption is an interest payment date, the interest installment payable on such date shall be payable to the
      registered holder at the close of business on the applicable record date pursuant to Section 2.03).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Upon presentation of any Security of such series that is to be redeemed in part only, the
      Company shall execute and the Trustee shall authenticate and the office or agency where the Security is presented shall deliver to the holder thereof, at the expense of the Company, a new Security of the same series of authorized denominations in
      principal amount equal to the unredeemed portion of the Security so presented.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" border="0" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 3.4</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sinking Fund.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions of Sections 3.04, 3.05 and 3.06 shall be applicable to any sinking fund for
      the retirement of Securities of a series, except as otherwise specified as contemplated by Section 2.01 for Securities of such series.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The minimum amount of any sinking fund payment provided for by the terms of Securities of any
      series is herein referred to as a &#8220;mandatory sinking fund payment,&#8221; and any payment in excess of such minimum amount provided for by the terms of Securities of any series is herein referred to as an &#8220;optional sinking fund payment&#8221;. If provided for by
      the terms of Securities of any series, the cash amount of any sinking fund payment may be subject to reduction as provided in Section 3.05. Each sinking fund payment shall be applied to the redemption of Securities of any series as provided for by
      the terms of Securities of such series.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">11</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 3.5</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Satisfaction of Sinking Fund Payments with Securities.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company (i) may deliver Outstanding Securities of a series and (ii) may apply as a credit
      Securities of a series that have been redeemed either at the election of the Company pursuant to the terms of such Securities or through the application of permitted optional sinking fund payments pursuant to the terms of such Securities, in each
      case in satisfaction of all or any part of any sinking fund payment with respect to the Securities of such series required to be made pursuant to the terms of such Securities as provided for by the terms of such series, provided that such Securities
      have not been previously so credited. Such Securities shall be received and credited for such purpose by the Trustee at the redemption price specified in such Securities for redemption through operation of the sinking fund and the amount of such
      sinking fund payment shall be reduced accordingly.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 3.6</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Redemption of Securities for Sinking Fund.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not less than 45 days prior to each sinking fund payment date for any series of Securities
      (unless a shorter period shall be satisfactory to the Trustee), the Company will deliver to the Trustee an Officer&#8217;s Certificate specifying the amount of the next ensuing sinking fund payment for that series pursuant to the terms of the series, the
      portion thereof, if any, that is to be satisfied by delivering and crediting Securities of that series pursuant to Section 3.05 and the basis for such credit and will, together with such Officer&#8217;s Certificate, deliver to the Trustee any Securities to
      be so delivered. Not less than 30 days before each such sinking fund payment date the Trustee shall select the Securities to be redeemed upon such sinking fund payment date in the manner specified in Section 3.02 and cause notice of the redemption
      thereof to be given in the name of and at the expense of the Company in the manner provided in Section 3.02. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Section 3.03.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE IV</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVENANTS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 4.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment of Principal, Premium and Interest.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will duly and punctually pay or cause to be paid the principal of (and premium,
      if any) and interest on the Securities of that series at the time and place and in the manner provided herein and established with respect to such Securities. Payments of principal on the Securities may be made at the time provided herein and
      established with respect to such Securities by U.S. dollar check drawn on and mailed to the address of the Securityholder entitled thereto as such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account
      (such wire transfer to be made only to a Securityholder of an aggregate principal amount of Securities of the applicable series in excess of U.S. $2,000,000 and only if such Securityholder shall have furnished wire instructions to the Trustee no
      later than 15 days prior to the relevant payment date). Payments of interest on the Securities may be made at the time provided herein and established with respect to such Securities by U.S. dollar check mailed to the address of the Securityholder
      entitled thereto as such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account (such a wire transfer to be made only to a Securityholder of an aggregate principal amount of Securities of the applicable
      series in excess of U.S. $2,000,000 and only if such Securityholder shall have furnished wire instructions in writing to the Security Registrar and the Trustee no later than 15 days prior to the relevant payment date.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 4.2</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maintenance of Office or Agency.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">So long as any series of the Securities remain Outstanding, the Company agrees to maintain an
      office or agency with respect to each such series and at such other location or locations as may be designated as provided in this Section 4.02, where (i) Securities of that series may be presented for payment, (ii) Securities of that series may be
      presented as herein above authorized for registration of transfer and exchange, and (iii) notices and demands to or upon the Company in respect of the Securities of that series and this Indenture may be given or served, such designation to continue
      with respect to such office or agency until the Company shall, by written notice signed by any officer authorized to sign an Officer&#8217;s Certificate and delivered to the Trustee, designate some other office or agency for such purposes or any of them.
      If at any time the Company shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, notices and demands may be made or served at the Corporate Trust Office of the
      Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, notices and demands. The Company initially appoints the Corporate Trust Office of the Trustee as its paying agent with respect to the Securities.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">12</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 4.3</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paying Agents.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) If the Company shall appoint one or more paying agents for all or any series of the
      Securities, other than the Trustee, the Company will cause each such paying agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) that it will hold all sums held by it as such agent for the payment of the principal of
      (and premium, if any) or interest on the Securities of that series (whether such sums have been paid to it by the Company or by any other obligor of such Securities) in trust for the benefit of the Persons entitled thereto;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) that it will give the Trustee notice of any failure by the Company (or by any other
      obligor of such Securities) to make any payment of the principal of (and premium, if any) or interest on the Securities of that series when the same shall be due and payable;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) that it will, at any time during the continuance of any failure referred to in the
      preceding paragraph (a)(2) above, upon the written request of the Trustee, forthwith pay to the Trustee all sums so held in trust by such paying agent; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) that it will perform all other duties of paying agent as set forth in this Indenture.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) If the Company shall act as its own paying agent with respect to any series of the
      Securities, it will on or before each due date of the principal of (and premium, if any) or interest on Securities of that series, set aside, segregate and hold in trust for the benefit of the Persons entitled thereto a sum sufficient to pay such
      principal (and premium, if any) or interest so becoming due on Securities of that series until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will promptly notify the Trustee of such action, or any failure (by
      it or any other obligor on such Securities) to take such action. Whenever the Company shall have one or more paying agents for any series of Securities, it will, prior to each due date of the principal of (and premium, if any) or interest on any
      Securities of that series, deposit with the paying agent a sum sufficient to pay the principal (and premium, if any) or interest so becoming due, such sum to be held in trust for the benefit of the Persons entitled to such principal, premium or
      interest, and (unless such paying agent is the Trustee) the Company will promptly notify the Trustee of this action or failure so to act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Notwithstanding anything in this Section to the contrary, (i) the agreement to hold sums in
      trust as provided in this Section is subject to the provisions of Section 11.05, and (ii) the Company may at any time, for the purpose of obtaining the satisfaction and discharge of this Indenture or for any other purpose, pay, or direct any paying
      agent to pay, to the Trustee all sums held in trust by the Company or such paying agent, such sums to be held by the Trustee upon the same terms and conditions as those upon which such sums were held by the Company or such paying agent; and, upon
      such payment by the Company or any paying agent to the Trustee, the Company or such paying agent shall be released from all further liability with respect to such money.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 4.4</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Appointment to Fill Vacancy in Office of Trustee.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will
      appoint, in the manner provided in Section 7.10, a Trustee, so that there shall at all times be a Trustee hereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 4.5</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif">
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compliance with Consolidation Provisions.&#160;</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will not, while any of the Securities remain Outstanding, consolidate with or
      merge into any other Person, in either case where the Company is not the survivor of such transaction, or sell or convey all or substantially all of its property to any other Person unless the provisions of Article Ten hereof are complied with.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">13</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE V</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITYHOLDERS&#8217; LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 5.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company to Furnish Trustee Names and Addresses of Securityholders.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will furnish or cause to be furnished to the Trustee (a) within 15 days after
      each regular record date (as defined in Section 2.03) a list, in such form as the Trustee may reasonably require, of the names and addresses of the holders of each series of Securities as of such regular record date, provided that the Company shall
      not be obligated to furnish or cause to furnish such list at any time that the list shall not differ in any respect from the most recent list furnished to the Trustee by the Company and (b) at such other times as the Trustee may request in writing
      within 30 days after the receipt by the Company of any such request, a list of similar form and content as of a date not more than 15 days prior to the time such list is furnished; provided, however, that, in either case, no such list need be
      furnished for any series for which the Trustee shall be the Security Registrar.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 5.2</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preservation of Information; Communications With Securityholders.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The Trustee shall preserve, in as current a form as is reasonably practicable, all
      information as to the names and addresses of the holders of Securities contained in the most recent list furnished to it as provided in Section 5.01 and as to the names and addresses of holders of Securities received by the Trustee in its capacity as
      Security Registrar (if acting in such capacity).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The Trustee may destroy any list furnished to it as provided in Section 5.01 upon receipt
      of a new list so furnished.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 99%; font: 10pt Times New Roman, Times, Serif">
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Securityholders may communicate as provided in Section 312(b) of the Trust
              Indenture Act with other Securityholders with respect to their rights under this Indenture or under the Securities, and, in connection with any such communications, the Trustee shall satisfy its obligations under Section 312(b) of the Trust
              Indenture Act in accordance with the provisions of Section 312(b) of the Trust Indenture Act.</font></p>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Reports by the Company&#160;</b></font></p>
        </td>
        <td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company covenants and agrees to provide (which delivery may be via electronic mail) to
      the Trustee, after the Company files the same with the Securities and Exchange Commission, copies of the annual reports and of the information, documents and other reports (or copies of such portions of any of the foregoing as the Securities and
      Exchange Commission may from time to time by rules and regulations prescribe) that the Company files with the Securities and Exchange Commission pursuant to Section 13 or Section 15(d) of the Exchange Act; provided, however, the Company shall not be
      required to deliver to the Trustee any materials for which the Company has sought and received confidential treatment by the Securities and Exchange Commission; and provided further, so long as such filings by the Company are available on the
      Securities and Exchange Commission&#8217;s Electronic Data Gathering, Analysis and Retrieval System (EDGAR), such filings shall be deemed to have been filed with the Trustee for purposes of this Section 5.03 without any further action required by the
      Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 5.4</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reports by the Trustee.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) If required by Section 313(a) of the Trust Indenture Act, the Trustee, within sixty (60)
      days after each May 1, shall transmit by mail, first class postage prepaid, to the Securityholders, as their names and addresses appear upon the Security Register, a brief report dated as of such May 1, which complies with Section 313(a) of the Trust
      Indenture Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The Trustee shall comply with Section 313(b) and 313(c) of the Trust Indenture Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) A copy of each such report shall, at the time of such transmission to Securityholders, be
      filed by the Trustee with the Company, with each securities exchange upon which any Securities are listed (if so listed) and also with the Securities and Exchange Commission. The Company agrees to notify the Trustee when any Securities become listed
      on any securities exchange.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">14</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE VI</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 6.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Events of Default.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Whenever used herein with respect to Securities of a particular series, &#8220;Event of Default&#8221;
      means any one or more of the following events that has occurred and is continuing:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) the Company defaults in the payment of any installment of interest upon any of the
      Securities of that series, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by the Company in accordance with the terms of
      any indenture supplemental hereto shall not constitute a default in the payment of interest for this purpose;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) the Company defaults in the payment of the principal of (or premium, if any, on) any of
      the Securities of that series as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to that series;
      provided, however, that a valid extension of the maturity of such Securities in accordance with the terms of any indenture supplemental hereto shall not constitute a default in the payment of principal or premium, if any;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the Company fails to observe or perform any other of its covenants or agreements with
      respect to that series contained in this Indenture or otherwise established with respect to that series of Securities pursuant to Section 2.01 hereof (other than a covenant or agreement that has been expressly included in this Indenture solely for
      the benefit of one or more series of Securities other than such series) for a period of 90 days after the date on which written notice of such failure, requiring the same to be remedied and stating that such notice is a &#8220;Notice of Default&#8221; hereunder,
      shall have been given to the Company by the Trustee, by registered or certified mail, or to the Company and the Trustee by the holders of at least 25% in principal amount of the Securities of that series at the time Outstanding;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) the Company pursuant to or within the meaning of any Bankruptcy Law (i) commences a
      voluntary case, (ii) consents to the entry of an order for relief against it in an involuntary case, (iii) consents to the appointment of a Custodian of it or for all or substantially all of its property or (iv) makes a general assignment for the
      benefit of its creditors; or</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) a court of competent jurisdiction enters an order under any Bankruptcy Law that (i) is
      for relief against the Company in an involuntary case, (ii) appoints a Custodian of the Company for all or substantially all of its property or (iii) orders the liquidation of the Company, and the order or decree remains unstayed and in effect for 90
      days.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) In each and every such case (other than an Event of Default specified in clause (4) or
      clause (5) above), unless the principal of all the Securities of that series shall have already become due and payable, either the Trustee or the holders of not less than 25% in aggregate principal amount of the Securities of that series then
      Outstanding hereunder, by notice in writing to the Company (and to the Trustee if given by such Securityholders), may declare the principal of (and premium, if any, on) and accrued and unpaid interest on all the Securities of that series to be due
      and payable immediately, and upon any such declaration the same shall become and shall be immediately due and payable. If an Event of Default specified in clause (4) or clause (5) above occurs, the principal of and accrued and unpaid interest on all
      the Securities of that series shall automatically be immediately due and payable without any declaration or other act on the part of the Trustee or the holders of the Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) At any time after the principal of (and premium, if any, on) and accrued and unpaid
      interest on the Securities of that series shall have been so declared due and payable, and before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the holders of a majority in
      aggregate principal amount of the Securities of that series then Outstanding hereunder, by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if: (i) the Company has paid or deposited with the
      Trustee a sum sufficient to pay all matured installments of interest upon all the Securities of that series and the principal of (and premium, if any, on) any and all Securities of that series that shall have become due otherwise than by acceleration
      (with interest upon such principal and premium, if any, and, to the extent that such payment is enforceable under applicable law, upon overdue installments of interest, at the rate per annum expressed in the Securities of that series to the date of
      such payment or deposit) and the amount payable to the Trustee under Section 7.06, and (ii) any and all Events of Default under the Indenture with respect to such series, other than the nonpayment of principal on (and premium, if any, on) and accrued
      and unpaid interest on Securities of that series that shall not have become due by their terms, shall have been remedied or waived as provided in Section 6.06.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">15</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No such rescission and annulment shall extend to or shall affect any subsequent default or
      impair any right consequent thereon.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) In case the Trustee shall have proceeded to enforce any right with respect to Securities of
      that series under this Indenture and such proceedings shall have been discontinued or abandoned because of such rescission or annulment or for any other reason or shall have been determined adversely to the Trustee, then and in every such case,
      subject to any determination in such proceedings, the Company and the Trustee shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of the Company and the Trustee shall continue as though
      no such proceedings had been taken.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 6.2</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collection of Indebtedness and Suits for Enforcement by Trustee.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The Company covenants that (i) in case it shall default in the payment of any installment
      of interest on any of the Securities of a series, or in any payment required by any sinking or analogous fund established with respect to that series as and when the same shall have become due and payable, and such default shall have continued for a
      period of 90 days, or (ii) in case it shall default in the payment of the principal of (or premium, if any, on) any of the Securities of a series when the same shall have become due and payable, whether upon maturity of the Securities of a series or
      upon redemption or upon declaration or otherwise then, upon demand of the Trustee, the Company will pay to the Trustee, for the benefit of the holders of the Securities of that series, the whole amount that then shall have been become due and payable
      on all such Securities for principal (and premium, if any) or interest, or both, as the case may be, with interest upon the overdue principal (and premium, if any) and (to the extent that payment of such interest is enforceable under applicable law)
      upon overdue installments of interest at the rate per annum expressed in the Securities of that series; and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, and the amount payable to the
      Trustee under Section 7.06.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) If the Company shall fail to pay such amounts forthwith upon such demand, the Trustee, in
      its own name and as trustee of an express trust, shall be entitled and empowered to institute any action or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceeding to judgment
      or final decree, and may enforce any such judgment or final decree against the Company or other obligor upon the Securities of that series and collect the moneys adjudged or decreed to be payable in the manner provided by law or equity out of the
      property of the Company or other obligor upon the Securities of that series, wherever situated.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) In case of any receivership, insolvency, liquidation, bankruptcy, reorganization,
      readjustment, arrangement, composition or judicial proceedings affecting the Company, or its creditors or property, the Trustee shall have power to intervene in such proceedings and take any action therein that may be permitted by the court and shall
      (except as may be otherwise provided by law) be entitled to file such proofs of claim and other papers and documents as may be necessary or advisable in order to have the claims of the Trustee and of the holders of Securities of such series allowed
      for the entire amount due and payable by the Company under the Indenture at the date of institution of such proceedings and for any additional amount that may become due and payable by the Company after such date, and to collect and receive any
      moneys or other property payable or deliverable on any such claim, and to distribute the same after the deduction of the amount payable to the Trustee under Section 7.06; and any receiver, assignee or trustee in bankruptcy or reorganization is hereby
      authorized by each of the holders of Securities of such series to make such payments to the Trustee, and, in the event that the Trustee shall consent to the making of such payments directly to such Securityholders, to pay to the Trustee any amount
      due it under Section 7.06.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) All rights of action and of asserting claims under this Indenture, or under any of the
      terms established with respect to Securities of that series, may be enforced by the Trustee without the possession of any of such Securities, or the production thereof at any trial or other proceeding relative thereto, and any such suit or proceeding
      instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for payment to the Trustee of any amounts due under Section 7.06, be for the ratable benefit of the holders
      of the Securities of such series.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">16</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In case of an Event of Default hereunder, the Trustee may in its discretion proceed to
      protect and enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights, either at law or in equity or in bankruptcy or otherwise,
      whether for the specific enforcement of any covenant or agreement contained in the Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested in the Trustee by this Indenture or
      by law.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing contained herein shall be deemed to authorize the Trustee to authorize or consent to
      or accept or adopt on behalf of any Securityholder any plan of reorganization, arrangement, adjustment or composition affecting the Securities of that series or the rights of any holder thereof or to authorize the Trustee to vote in respect of the
      claim of any Securityholder in any such proceeding.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 6.3</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application of Moneys Collected.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any moneys collected by the Trustee pursuant to this Article with respect to a particular
      series of Securities shall be applied in the following order, at the date or dates fixed by the Trustee and, in case of the distribution of such moneys on account of principal (or premium, if any) or interest, upon presentation of the Securities of
      that series, and notation thereon of the payment, if only partially paid, and upon surrender thereof if fully paid:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST: To the payment of reasonable costs and expenses of collection and of all amounts
      payable to the Trustee under Section 7.06;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECOND: To the payment of the amounts then due and unpaid upon Securities of such series for
      principal (and premium, if any) and interest, in respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for
      principal (and premium, if any) and interest, respectively; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIRD: To the payment of the remainder, if any, to the Company or any other Person lawfully
      entitled thereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 6.4</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitation on Suits.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No holder of any Security of any series shall have any right by virtue or by availing of any
      provision of this Indenture to institute any suit, action or proceeding in equity or at law upon or under or with respect to this Indenture or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless (i) such holder
      previously shall have given to the Trustee written notice of an Event of Default and of the continuance thereof with respect to the Securities of such series specifying such Event of Default, as hereinbefore provided; (ii) the holders of not less
      than 25% in aggregate principal amount of the Securities of such series then Outstanding shall have made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder; (iii) such holder or holders
      shall have offered to the Trustee such reasonable indemnity as it may require against the costs, expenses and liabilities to be incurred therein or thereby; (iv) the Trustee for 90 days after its receipt of such notice, request and offer of
      indemnity, shall have failed to institute any such action, suit or proceeding and (v) during such 90 day period, the holders of a majority in principal amount of the Securities of that series do not give the Trustee a direction inconsistent with the
      request.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding anything contained herein to the contrary or any other provisions of this
      Indenture, the right of any holder of any Security to receive payment of the principal of (and premium, if any) and interest on such Security, as therein provided, on or after the respective due dates expressed in such Security (or in the case of
      redemption, on the redemption date), or to institute suit for the enforcement of any such payment on or after such respective dates or redemption date, shall not be impaired or affected without the consent of such holder and by accepting a Security
      hereunder it is expressly understood, intended and covenanted by the taker and holder of every Security of such series with every other such taker and holder and the Trustee, that no one or more holders of Securities of such series shall have any
      right in any manner whatsoever by virtue or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of the holders of any other of such Securities, or to obtain or seek to obtain priority over or preference to any
      other such holder, or to enforce any right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all holders of Securities of such series. For the protection and enforcement of the provisions of
      this Section, each and every Securityholder and the Trustee shall be entitled to such relief as can be given either at law or in equity.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">17</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 6.5</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights and Remedies Cumulative; Delay or Omission Not Waiver.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Except as otherwise provided in Section 2.07, all powers and remedies given by this Article
      to the Trustee or to the Securityholders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any other powers and remedies available to the Trustee or the holders of the Securities, by judicial proceedings or otherwise,
      to enforce the performance or observance of the covenants and agreements contained in this Indenture or otherwise established with respect to such Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) No delay or omission of the Trustee or of any holder of any of the Securities to exercise
      any right or power accruing upon any Event of Default occurring and continuing as aforesaid shall impair any such right or power, or shall be construed to be a waiver of any such default or an acquiescence therein; and, subject to the provisions of
      Section 6.04, every power and remedy given by this Article or by law to the Trustee or the Securityholders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Securityholders.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0pt"></td>
        <td style="width: 96px; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 6.6</b></font></td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Control by Securityholders.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of a majority in aggregate principal amount of the Securities of any series at
      the time Outstanding, determined in accordance with Section 8.04, shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the
      Trustee with respect to such series; provided, however, that such direction shall not be in conflict with any rule of law or with this Indenture. Subject to the provisions of Section 7.01, the Trustee shall have the right to decline to follow any
      such direction if the Trustee in good faith shall, by a Responsible Officer or officers of the Trustee, determine that the proceeding so directed, subject to the Trustee&#8217;s duties under the Trust Indenture Act, would involve the Trustee in personal
      liability or might be unduly prejudicial to the Securityholders not involved in the proceeding. The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding affected thereby, determined in accordance
      with Section 8.04, may on behalf of the holders of all of the Securities of such series waive any past default in the performance of any of the covenants contained herein or established pursuant to Section 2.01 with respect to such series and its
      consequences, except a default in the payment of the principal of, or premium, if any, or interest on, any of the Securities of that series as and when the same shall become due by the terms of such Securities otherwise than by acceleration (unless
      such default has been cured and a sum sufficient to pay all matured installments of interest and principal and any premium has been deposited with the Trustee (in accordance with Section 6.01(c)). Upon any such waiver, the default covered thereby
      shall be deemed to be cured for all purposes of this Indenture and the Company, the Trustee and the holders of the Securities of such series shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall
      extend to any subsequent or other default or impair any right consequent thereon.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 100%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 6.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Undertaking to Pay Costs.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All parties to this Indenture agree, and each holder of any Securities by such holder&#8217;s
      acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as
      Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys&#8217; fees, against any party litigant in such suit,
      having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section shall not apply to any suit instituted by the Trustee, to any suit instituted by any Securityholder, or group of
      Securityholders, holding more than 10% in aggregate principal amount of the Outstanding Securities of any series, or to any suit instituted by any Securityholder for the enforcement of the payment of the principal of (or premium, if any) or interest
      on any Security of such series, on or after the respective due dates expressed in such Security or established pursuant to this Indenture.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">18</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE VII</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONCERNING THE TRUSTEE</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain Duties and Responsibilities of Trustee.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The Trustee, prior to the occurrence of an Event of Default with respect to the Securities
      of a series and after the curing of all Events of Default with respect to the Securities of that series that may have occurred, shall undertake to perform with respect to the Securities of such series such duties and only such duties as are
      specifically set forth in this Indenture, and no implied covenants shall be read into this Indenture against the Trustee. In case an Event of Default with respect to the Securities of a series has occurred (that has not been cured or waived), the
      Trustee shall exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances
      in the conduct of his own affairs.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) No provision of this Indenture shall be construed to relieve the Trustee from liability for
      its own negligent action, its own negligent failure to act, or its own willful misconduct, except that:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) prior to the occurrence of an Event of Default with respect to the Securities of a series
      and after the curing or waiving of all such Events of Default with respect to that series that may have occurred: (A) the duties and obligations of the Trustee shall with respect to the Securities of such series be determined solely by the express
      provisions of this Indenture, and the Trustee shall not be liable with respect to the Securities of such series except for the performance of such duties and obligations as are specifically set forth in this Indenture, and no implied covenants or
      obligations shall be read into this Indenture against the Trustee; and (B) in the absence of bad faith on the part of the Trustee, the Trustee may with respect to the Securities of such series conclusively rely, as to the truth of the statements and
      the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture; but in the case of any such certificates or opinions that by any provision hereof are
      specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this Indenture;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) the Trustee shall not be liable for any error of judgment made in good faith by a
      Responsible Officer or Responsible Officers of the Trustee, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) the Trustee shall not be liable with respect to any action taken or omitted to be taken
      by it in good faith in accordance with the direction of the holders of not less than a majority in principal amount of the Securities of any series at the time Outstanding relating to the time, method and place of conducting any proceeding for any
      remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee under this Indenture with respect to the Securities of that series; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) none of the provisions contained in this Indenture shall require the Trustee to expend or
      risk its own funds or otherwise incur personal financial liability in the performance of any of its duties or in the exercise of any of its rights or powers if there is reasonable ground for believing that the repayment of such funds or liability is
      not reasonably assured to it under the terms of this Indenture or adequate indemnity against such risk is not reasonably assured to it.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.<b>Section 7.2</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain Rights of Trustee.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise provided in Section 7.01:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The Trustee may rely and shall be protected in acting or refraining from acting upon any
      resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, bond, security or other paper or document believed by it to be genuine and to have been signed or presented by the proper party or parties;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Any request, direction, order or demand of the Company mentioned herein shall be
      sufficiently evidenced by a Board Resolution or an instrument signed in the name of the Company by any authorized officer of the Company (unless other evidence in respect thereof is specifically prescribed herein);</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The Trustee may consult with counsel and the written advice of such counsel or, if
      requested, any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken or suffered or omitted hereunder in good faith and in reliance thereon;</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">19</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) The Trustee shall be under no obligation to exercise any of the rights or powers vested in
      it by this Indenture at the request, order or direction of any of the Securityholders pursuant to the provisions of this Indenture, unless such Securityholders shall have offered to the Trustee reasonable security or indemnity against the costs,
      expenses and liabilities that may be incurred therein or thereby; nothing contained herein shall, however, relieve the Trustee of the obligation, upon the occurrence of an Event of Default with respect to a series of the Securities (that has not been
      cured or waived), to exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and to use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the
      circumstances in the conduct of his own affairs;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) The Trustee shall not be liable for any action taken or omitted to be taken by it in good
      faith and believed by it to be authorized or within the discretion or rights or powers conferred upon it by this Indenture;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) The Trustee shall not be bound to make any investigation into the facts or matters stated
      in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, bond, security, or other papers or documents, unless requested in writing so to do by the holders of not less than a majority in
      principal amount of the Outstanding Securities of the particular series affected thereby (determined as provided in Section 8.04); provided, however, that if the payment within a reasonable time to the Trustee of the costs, expenses or liabilities
      likely to be incurred by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded to it by the terms of this Indenture, the Trustee may require reasonable indemnity
      against such costs, expenses or liabilities as a condition to so proceeding. The reasonable expense of every such examination shall be paid by the Company or, if paid by the Trustee, shall be repaid by the Company upon demand; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) The Trustee may execute any of the trusts or powers hereunder or perform any duties
      hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Trustee shall not be deemed to have knowledge of any Default or Event of
      Default except (1) any Event of Default occurring pursuant to Sections 6.01(a)(1) and 6.01(a)(2) or (2) any Default or Event of Default of which the Trustee shall have received written notification in the manner set forth in this Indenture or a
      Responsible Officer of the Trustee shall have obtained actual knowledge. Delivery of reports, information and documents to the Trustee under Section 5.03 is for informational purposes only and the information and the Trustee&#8217;s receipt of the
      foregoing shall not constitute constructive notice of any information contained therein, or determinable from information contained therein including the Company&#8217;s compliance with any of their covenants thereunder (as to which the Trustee is entitled
      to rely exclusively on an Officer&#8217;s Certificate).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.3</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trustee Not Responsible for Recitals or Issuance or Securities.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The recitals contained herein and in the Securities shall be taken as the statements of the
      Company, and the Trustee assumes no responsibility for the correctness of the same.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The Trustee makes no representations as to the validity or sufficiency of this Indenture or
      of the Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The Trustee shall not be accountable for the use or application by the Company of any of
      the Securities or of the proceeds of such Securities, or for the use or application of any moneys paid over by the Trustee in accordance with any provision of this Indenture or established pursuant to Section 2.01, or for the use or application of
      any moneys received by any paying agent other than the Trustee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.4</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>May Hold Securities.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Trustee or any paying agent or Security Registrar, in its individual or any other
      capacity, may become the owner or pledgee of Securities with the same rights it would have if it were not Trustee, paying agent or Security Registrar.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.5</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Moneys Held in Trust.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the provisions of Section 11.05, all moneys received by the Trustee shall, until
      used or applied as herein provided, be held in trust for the purposes for which they were received, but need not be segregated from other funds except to the extent required by law. The Trustee shall be under no liability for interest on any moneys
      received by it hereunder except such as it may agree with the Company to pay thereon.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">20</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.6</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation and Reimbursement.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The Company covenants and agrees to pay to the Trustee, and the Trustee shall be entitled
      to, such reasonable compensation (which shall not be limited by any provision of law in regard to the compensation of a trustee of an express trust) as the Company and the Trustee may from time to time agree in writing, for all services rendered by
      it in the execution of the trusts hereby created and in the exercise and performance of any of the powers and duties hereunder of the Trustee, and, except as otherwise expressly provided herein, the Company will pay or reimburse the Trustee upon its
      request for all reasonable expenses, disbursements and advances incurred or made by the Trustee in accordance with any of the provisions of this Indenture (including the reasonable compensation and the expenses and disbursements of its counsel and of
      all Persons not regularly in its employ), except any such expense, disbursement or advance as may arise from its negligence or bad faith and except as the Company and Trustee may from time to time agree in writing. The Company also covenants to
      indemnify the Trustee (and its officers, agents, directors and employees) for, and to hold it harmless against, any loss, liability or expense incurred without negligence or bad faith on the part of the Trustee and arising out of or in connection
      with the acceptance or administration of this trust, including the reasonable costs and expenses of defending itself against any claim of liability in the premises.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The obligations of the Company under this Section to compensate and indemnify the Trustee
      and to pay or reimburse the Trustee for reasonable expenses, disbursements and advances shall constitute additional indebtedness hereunder. Such additional indebtedness shall be secured by a lien prior to that of the Securities upon all property and
      funds held or collected by the Trustee as such, except funds held in trust for the benefit of the holders of particular Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.7</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reliance on Officer&#8217;s Certificate.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise provided in Section 7.01, whenever in the administration of the
      provisions of this Indenture the Trustee shall deem it reasonably necessary or desirable that a matter be proved or established prior to taking or suffering or omitting to take any action hereunder, such matter (unless other evidence in respect
      thereof be herein specifically prescribed) may, in the absence of negligence or bad faith on the part of the Trustee, be deemed to be conclusively proved and established by an Officer&#8217;s Certificate delivered to the Trustee and such certificate, in
      the absence of negligence or bad faith on the part of the Trustee, shall be full warrant to the Trustee for any action taken, suffered or omitted to be taken by it under the provisions of this Indenture upon the faith thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.8</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disqualification; Conflicting Interests.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Trustee has or shall acquire any &#8220;conflicting interest&#8221; within the meaning of Section
      310(b) of the Trust Indenture Act, the Trustee and the Company shall in all respects comply with the provisions of Section 310(b) of the Trust Indenture Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.9</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Trustee Required; Eligibility.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There shall at all times be a Trustee with respect to the Securities issued hereunder which
      shall at all times be a corporation organized and doing business under the laws of the United States of America or any state or territory thereof or of the District of Columbia, or a corporation or other Person permitted to act as trustee by the
      Securities and Exchange Commission, authorized under such laws to exercise corporate trust powers, having a combined capital and surplus of at least fifty million U.S. dollars ($50,000,000), and subject to supervision or examination by federal,
      state, territorial, or District of Columbia authority.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If such corporation or other Person publishes reports of condition at least annually,
      pursuant to law or to the requirements of the aforesaid supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such corporation or other Person shall be deemed to be its combined capital and
      surplus as set forth in its most recent report of condition so published. The Company may not, nor may any Person directly or indirectly controlling, controlled by, or under common control with the Company, serve as Trustee. In case at any time the
      Trustee shall cease to be eligible in accordance with the provisions of this Section, the Trustee shall resign immediately in the manner and with the effect specified in Section 7.10.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">21</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.10</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Resignation and Removal; Appointment of Successor.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The Trustee or any successor hereafter appointed may at any time resign with respect to the
      Securities of one or more series by giving written notice thereof to the Company and by transmitting notice of resignation by mail, first class postage prepaid, to the Securityholders of such series, as their names and addresses appear upon the
      Security Register. Upon receiving such notice of resignation, the Company shall promptly appoint a successor trustee with respect to Securities of such series by written instrument, in duplicate, executed by order of the Board of Directors, one copy
      of which instrument shall be delivered to the resigning Trustee and one copy to the successor trustee. If no successor trustee shall have been so appointed and have accepted appointment within 30 days after the mailing of such notice of resignation,
      the resigning Trustee may petition any court of competent jurisdiction for the appointment of a successor trustee with respect to Securities of such series, or any Securityholder of that series who has been a bona fide holder of a Security or
      Securities for at least six months may on behalf of himself and all others similarly situated, petition any such court for the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and
      prescribe, appoint a successor trustee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) in case at any time any one of the following shall occur:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) the Trustee shall fail to comply with the provisions of Section 7.08 after written
      request therefor by the Company or by any Securityholder who has been a bona fide holder of a Security or Securities for at least six months; or</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) the Trustee shall cease to be eligible in accordance with the provisions of Section 7.09
      and shall fail to resign after written request therefor by the Company or by any such Securityholder; or</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) the Trustee shall become incapable of acting, or shall be adjudged a bankrupt or
      insolvent, or commence a voluntary bankruptcy proceeding, or a receiver of the Trustee or of its property shall be appointed or consented to, or any public officer shall take charge or control of the Trustee or of its property or affairs for the
      purpose of rehabilitation, conservation or liquidation; then, in any such case, the Company may remove the Trustee with respect to all Securities and appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of
      Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or any Securityholder who has been a bona fide holder of a Security or Securities for at least six months may, on behalf of
      that holder and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and
      prescribe, remove the Trustee and appoint a successor trustee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The holders of a majority in aggregate principal amount of the Securities of any series at
      the time Outstanding may at any time remove the Trustee with respect to such series by so notifying the Trustee and the Company and may appoint a successor Trustee for such series with the consent of the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) Any resignation or removal of the Trustee and appointment of a successor trustee with
      respect to the Securities of a series pursuant to any of the provisions of this Section shall become effective upon acceptance of appointment by the successor trustee as provided in Section 7.11.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) Any successor trustee appointed pursuant to this Section may be appointed with respect to
      the Securities of one or more series or all of such series, and at any time there shall be only one Trustee with respect to the Securities of any particular series.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.11</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acceptance of Appointment By Successor.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) In case of the appointment hereunder of a successor trustee with respect to all Securities,
      every such successor trustee so appointed shall execute, acknowledge and deliver to the Company and to the retiring Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become
      effective and such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee; but, on the request of the Company or the successor trustee, such retiring
      Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor trustee all the rights, powers, and trusts of the retiring Trustee and shall duly assign, transfer and deliver to such successor trustee all
      property and money held by such retiring Trustee hereunder.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">22</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) In case of the appointment hereunder of a successor trustee with respect to the Securities
      of one or more (but not all) series, the Company, the retiring Trustee and each successor trustee with respect to the Securities of one or more series shall execute and deliver an indenture supplemental hereto wherein each successor trustee shall
      accept such appointment and which (i) shall contain such provisions as shall be necessary or desirable to transfer and confirm to, and to vest in, each successor trustee all the rights, powers, trusts and duties of the retiring Trustee with respect
      to the Securities of that or those series to which the appointment of such successor trustee relates, (ii) shall contain such provisions as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts and duties of the
      retiring Trustee with respect to the Securities of that or those series as to which the retiring Trustee is not retiring shall continue to be vested in the retiring Trustee, and (iii) shall add to or change any of the provisions of this Indenture as
      shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in such supplemental indenture shall constitute such Trustees co- trustees of the same
      trust, that each such Trustee shall be trustee of a trust or trusts hereunder separate and apart from any trust or trusts hereunder administered by any other such Trustee and that no Trustee shall be responsible for any act or failure to act on the
      part of any other Trustee hereunder; and upon the execution and delivery of such supplemental indenture the resignation or removal of the retiring Trustee shall become effective to the extent provided therein, such retiring Trustee shall with respect
      to the Securities of that or those series to which the appointment of such successor trustee relates have no further responsibility for the exercise of rights and powers or for the performance of the duties and obligations vested in the Trustee under
      this Indenture, and each such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series to which
      the appointment of such successor trustee relates; but, on request of the Company or any successor trustee, such retiring Trustee shall duly assign, transfer and deliver to such successor trustee, to the extent contemplated by such supplemental
      indenture, the property and money held by such retiring Trustee hereunder with respect to the Securities of that or those series to which the appointment of such successor trustee relates.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Upon request of any such successor trustee, the Company shall execute any and all
      instruments for more fully and certainly vesting in and confirming to such successor trustee all such rights, powers and trusts referred to in paragraph (a) or (b) of this Section, as the case may be.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) No successor trustee shall accept its appointment unless at the time of such acceptance
      such successor trustee shall be qualified and eligible under this Article.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) Upon acceptance of appointment by a successor trustee as provided in this Section, the
      Company shall transmit notice of the succession of such trustee hereunder by mail, first class postage prepaid, to the Securityholders, as their names and addresses appear upon the Security Register. If the Company fails to transmit such notice
      within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be transmitted at the expense of the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.12</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Merger, Conversion, Consolidation or Succession to Business.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Any corporation into which the Trustee may be merged or converted or with which it may be consolidated, or any
      corporation resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to the corporate trust business of the Trustee, including the administration of the trust created by this
      Indenture, shall be the successor of the Trustee hereunder, provided that such corporation shall be qualified under the provisions of Section 7.08 and eligible under the provisions of Section 7.09, without the execution or filing of any paper or any
      further act on the part of any of the parties hereto, anything herein to the contrary notwithstanding. In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion or
      consolidation to such authenticating Trustee may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself authenticated such Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.13</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferential Collection of Claims Against the Company.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Trustee shall comply with Section 311(a) of the Trust Indenture Act, excluding any
      creditor relationship described in Section 311(b) of the Trust Indenture Act. A Trustee who has resigned or been removed shall be subject to Section 311(a) of the Trust Indenture Act to the extent included therein.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">23</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 7.14</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notice of Default</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any Default or any Event of Default occurs and is continuing and if such Default or Event
      of Default is known to a Responsible Officer of the Trustee, the Trustee shall mail to each Securityholder in the manner and to the extent provided in Section 313(c) of the Trust Indenture Act notice of the Default or Event of Default within the
      earlier of 90 days after it occurs and 30 days after it is known to a Responsible Officer of the Trustee or written notice of it is received by the Trustee, unless such Default or Event of Default has been cured; provided, however, that, except in
      the case of a default in the payment of the principal of (or premium, if any) or interest on any Security, the Trustee shall be protected in withholding such notice if and so long as the board of directors, the executive committee or a trust
      committee of directors and/or Responsible Officers of the Trustee in good faith determine that the withholding of such notice is in the interest of the Securityholders.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE VIII</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONCERNING THE SECURITYHOLDERS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 8.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evidence of Action by Securityholders.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever in this Indenture it is provided that the holders of a majority or specified
      percentage in aggregate principal amount of the Securities of a particular series may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the
      time of taking any such action the holders of such majority or specified percentage of that series have joined therein may be evidenced by any instrument or any number of instruments of similar tenor executed by such holders of Securities of that
      series in person or by agent or proxy appointed in writing.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company shall solicit from the Securityholders of any series any request, demand,
      authorization, direction, notice, consent, waiver or other action, the Company may, at its option, as evidenced by an Officer&#8217;s Certificate, fix in advance a record date for such series for the determination of Securityholders entitled to give such
      request, demand, authorization, direction, notice, consent, waiver or other action, but the Company shall have no obligation to do so. If such a record date is fixed, such request, demand, authorization, direction, notice, consent, waiver or other
      action may be given before or after the record date, but only the Securityholders of record at the close of business on the record date shall be deemed to be Securityholders for the purposes of determining whether Securityholders of the requisite
      proportion of Outstanding Securities of that series have authorized or agreed or consented to such request, demand, authorization, direction, notice, consent, waiver or other action, and for that purpose the Outstanding Securities of that series
      shall be computed as of the record date; provided, however, that no such authorization, agreement or consent by such Securityholders on the record date shall be deemed effective unless it shall become effective pursuant to the provisions of this
      Indenture not later than six months after the record date.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 8.2</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proof of Execution by Securityholders.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the provisions of Section 7.01, proof of the execution of any instrument by a
      Securityholder (such proof will not require notarization) or his agent or proxy and proof of the holding by any Person of any of the Securities shall be sufficient if made in the following manner:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The fact and date of the execution by any such Person of any instrument may be proved in
      any reasonable manner acceptable to the Trustee.<br>
      <br>
    </font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The ownership of Securities shall be proved by the Security Register of such Securities or
      by a certificate of the Security Registrar thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Trustee may require such additional proof of any matter referred to in this Section as it
      shall deem necessary.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 8.3</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Who May Be Deemed Owners.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the due presentment for registration of transfer of any Security, the Company, the
      Trustee, any paying agent and any Security Registrar may deem and treat the Person in whose name such Security shall be registered upon the books of the Company as the absolute owner of such Security (whether or not such Security shall be overdue and
      notwithstanding any notice of ownership or writing thereon made by anyone other than the Security Registrar) for the purpose of receiving payment of or on account of the principal of, premium, if any, and (subject to Section 2.03) interest on such
      Security and for all other purposes; and neither the Company nor the Trustee nor any paying agent nor any Security Registrar shall be affected by any notice to the contrary.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">24</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 8.4</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain Securities Owned by Company Disregarded.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining whether the holders of the requisite aggregate principal amount of Securities
      of a particular series have concurred in any direction, consent or waiver under this Indenture, the Securities of that series that are owned by the Company or any other obligor on the Securities of that series or by any Person directly or indirectly
      controlling or controlled by or under common control with the Company or any other obligor on the Securities of that series shall be disregarded and deemed not to be Outstanding for the purpose of any such determination, except that for the purpose
      of determining whether the Trustee shall be protected in relying on any such direction, consent or waiver, only Securities of such series that the Trustee actually knows are so owned shall be so disregarded. The Securities so owned that have been
      pledged in good faith may be regarded as Outstanding for the purposes of this Section, if the pledgee shall establish to the satisfaction of the Trustee the pledgee&#8217;s right so to act with respect to such Securities and that the pledgee is not a
      Person directly or indirectly controlling or controlled by or under direct or indirect common control with the Company or any such other obligor. In case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel
      shall be full protection to the Trustee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 8.5</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actions Binding on Future Securityholders.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At any time prior to (but not after) the evidencing to the Trustee, as provided in Section
      8.01, of the taking of any action by the holders of the majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection with such action, any holder of a Security of that series
      that is shown by the evidence to be included in the Securities the holders of which have consented to such action may, by filing written notice with the Trustee, and upon proof of holding as provided in Section 8.02, revoke such action so far as
      concerns such Security. Except as aforesaid any such action taken by the holder of any Security shall be conclusive and binding upon such holder and upon all future holders and owners of such Security, and of any Security issued in exchange therefor,
      on registration of transfer thereof or in place thereof, irrespective of whether or not any notation in regard thereto is made upon such Security. Any action taken by the holders of the majority or percentage in aggregate principal amount of the
      Securities of a particular series specified in this Indenture in connection with such action shall be conclusively binding upon the Company, the Trustee and the holders of all the Securities of that series.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE IX</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUPPLEMENTAL INDENTURES</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 9.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplemental Indentures Without the Consent of Securityholders.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to any supplemental indenture otherwise authorized by this Indenture, the Company
      and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect), without the consent of the Securityholders, for one
      or more of the following purposes:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) to cure any ambiguity, defect, or inconsistency herein or in the Securities of any series;<br>
      <br>
    </font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) to comply with Article Ten;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) to provide for uncertificated Securities in addition to or in place of certificated
      Securities;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) to add to the covenants, restrictions, conditions or provisions relating to the Company for
      the benefit of the holders of all or any series of Securities (and if such covenants, restrictions, conditions or provisions are to be for the benefit of less than all series of Securities, stating that such covenants, restrictions, conditions or
      provisions are expressly being included solely for the benefit of such series), to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default,
      or to surrender any right or power herein conferred upon the Company;</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">25</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) to add to, delete from, or revise the conditions, limitations, and restrictions on the
      authorized amount, terms, or purposes of issue, authentication, and delivery of Securities, as herein set forth;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) to make any change that does not adversely affect the rights of any Securityholder in any
      material respect;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) to provide for the issuance of and establish the form and terms and conditions of the
      Securities of any series as provided in Section 2.01, to establish the form of any certifications required to be furnished pursuant to the terms of this Indenture or any series of Securities, or to add to the rights of the holders of any series of
      Securities;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) to evidence and provide for the acceptance of appointment hereunder by a successor trustee;
      or</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) to comply with any requirements of the Securities and Exchange Commission or any successor
      in connection with the qualification of this Indenture under the Trust Indenture Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Trustee is hereby authorized to join with the Company in the execution of any such
      supplemental indenture, and to make any further appropriate agreements and stipulations that may be therein contained, but the Trustee shall not be obligated to enter into any such supplemental indenture that affects the Trustee&#8217;s own rights, duties
      or immunities under this Indenture or otherwise.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any supplemental indenture authorized by the provisions of this Section may be executed by
      the Company and the Trustee without the consent of the holders of any of the Securities at the time Outstanding, notwithstanding any of the provisions of Section 9.02.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 9.2</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplemental Indentures With Consent of Securityholders.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With the consent (evidenced as provided in Section 8.01) of the holders of not less than a
      majority in aggregate principal amount of the Securities of each series affected by such supplemental indenture or indentures at the time Outstanding, the Company, when authorized by a Board Resolution, and the Trustee may from time to time and at
      any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect) for the purpose of adding any provisions to or changing in any manner or eliminating any of the
      provisions of this Indenture or of any supplemental indenture or of modifying in any manner not covered by Section 9.01 the rights of the holders of the Securities of such series under this Indenture; provided, however, that no such supplemental
      indenture shall, without the consent of the holders of each Security then Outstanding and affected thereby, (a) extend the fixed maturity of any Securities of any series, or reduce the principal amount thereof, or reduce the rate or extend the time
      of payment of interest thereon, or reduce any premium payable upon the redemption thereof or (b) reduce the aforesaid percentage of Securities, the holders of which are required to consent to any such supplemental indenture.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It shall not be necessary for the consent of the Securityholders of any series affected
      thereby under this Section to approve the particular form of any proposed supplemental indenture, but it shall be sufficient if such consent shall approve the substance thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 9.3</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect of Supplemental Indentures.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the execution of any supplemental indenture pursuant to the provisions of this Article
      or of Section 10.01, this Indenture shall, with respect to such series, be and be deemed to be modified and amended in accordance therewith and the respective rights, limitations of rights, obligations, duties and immunities under this Indenture of
      the Trustee, the Company and the holders of Securities of the series affected thereby shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments, and all the terms and conditions of
      any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this Indenture for any and all purposes.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 9.4</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities Affected by Supplemental Indentures.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities of any series affected by a supplemental indenture, authenticated and delivered
      after the execution of such supplemental indenture pursuant to the provisions of this Article or of Section 10.01, may bear a notation in form approved by the Company, provided such form meets the requirements of any securities exchange upon which
      such series may be listed, as to any matter provided for in such supplemental indenture. If the Company shall so determine, new Securities of that series so modified as to conform, in the opinion of the Board of Directors, to any modification of this
      Indenture contained in any such supplemental indenture may be prepared by the Company, authenticated by the Trustee and delivered in exchange for the Securities of that series then Outstanding.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">26</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 9.5</b></font></td>
        <td style="font: 10pt Times New Roman,Times,serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution of Supplemental Indentures.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the request of the Company, accompanied by its Board Resolutions authorizing the
      execution of any such supplemental indenture, and upon the filing with the Trustee of evidence of the consent of Securityholders required to consent thereto as aforesaid, the Trustee shall join with the Company in the execution of such supplemental
      indenture unless such supplemental indenture affects the Trustee&#8217;s own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion but shall not be obligated to enter into such supplemental
      indenture. The Trustee, subject to the provisions of Section 7.01, may receive an Officer&#8217;s Certificate or, if requested, an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant to this Article is authorized or
      permitted by, and conforms to, the terms of this Article and that it is proper for the Trustee under the provisions of this Article to join in the execution thereof; provided, however, that such Officer&#8217;s Certificate or Opinion of Counsel need not be
      provided in connection with the execution of a supplemental indenture that establishes the terms of a series of Securities pursuant to Section 2.01 hereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promptly after the execution by the Company and the Trustee of any supplemental indenture
      pursuant to the provisions of this Section, the Trustee shall transmit by mail, first class postage prepaid, a notice, setting forth in general terms the substance of such supplemental indenture, to the Securityholders of all series affected thereby
      as their names and addresses appear upon the Security Register. Any failure of the Trustee to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE X</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUCCESSOR ENTITY</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 10.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company May Consolidate, Etc.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in
      an Officer&#8217;s Certificate, or established in one or more indentures supplemental to this Indenture, nothing contained in this Indenture shall prevent any consolidation or merger of the Company with or into any other Person (whether or not affiliated
      with the Company) or successive consolidations or mergers in which the Company or its successor or successors shall be a party or parties, or shall prevent any sale, conveyance, transfer or other disposition of the property of the Company or its
      successor or successors as an entirety, or substantially as an entirety, to any other corporation (whether or not affiliated with the Company or its successor or successors) authorized to acquire and operate the same; provided, however, (a) the
      Company hereby covenants and agrees that, upon any such consolidation or merger (in each case, if the Company is not the survivor of such transaction), sale, conveyance, transfer or other disposition, the due and punctual payment of the principal of
      (premium, if any) and interest on all of the Securities of all series in accordance with the terms of each series, according to their tenor, and the due and punctual performance and observance of all the covenants and conditions of this Indenture
      with respect to each series or established with respect to such series pursuant to Section 2.01 to be kept or performed by the Company shall be expressly assumed, by supplemental indenture (which shall conform to the provisions of the Trust Indenture
      Act, as then in effect) reasonably satisfactory in form to the Trustee executed and delivered to the Trustee by the entity formed by such consolidation, or into which the Company shall have been merged, or by the entity which shall have acquired such
      property and (b) in the event that the Securities of any series then Outstanding are convertible into or exchangeable for shares of common stock or other securities of the Company, such entity shall, by such supplemental indenture, make provision so
      that the Securityholders of Securities of that series shall thereafter be entitled to receive upon conversion or exchange of such Securities the number of securities or property to which a holder of the number of shares of common stock or other
      securities of the Company deliverable upon conversion or exchange of those Securities would have been entitled had such conversion or exchange occurred immediately prior to such consolidation, merger, sale, conveyance, transfer or other disposition.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 10.2</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Successor Entity Substituted.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition
      and upon the assumption by the successor entity by supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the obligations set forth under Section 10.01 on all of the Securities of all series
      Outstanding, such successor entity shall succeed to and be substituted for the Company with the same effect as if it had been named as the Company herein, and thereupon the predecessor corporation shall be relieved of all obligations and covenants
      under this Indenture and the Securities.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">27</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition,
      such changes in phraseology and form (but not in substance) may be made in the Securities thereafter to be issued as may be appropriate.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Nothing contained in this Article shall require any action by the Company in the case of a
      consolidation or merger of any Person into the Company where the Company is the survivor of such transaction, or the acquisition by the Company, by purchase or otherwise, of all or any part of the property of any other Person (whether or not
      affiliated with the Company).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 10.3</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evidence of Consolidation, Etc. to Trustee.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Trustee, subject to the provisions of Section 7.01, may receive an Officer&#8217;s Certificate
      and, if requested, an Opinion of Counsel as conclusive evidence that any such consolidation, merger, sale, conveyance, transfer or other disposition, and any such assumption, comply with the provisions of this Article.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE XI</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SATISFACTION AND DISCHARGE</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 11.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Satisfaction and Discharge of Indenture.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If at any time: (a) the Company shall have delivered to the Trustee for cancellation all
      Securities of a series theretofore authenticated and not delivered to the Trustee for cancellation (other than any Securities that shall have been destroyed, lost or stolen and that shall have been replaced or paid as provided in Section 2.07 and
      Securities for whose payment money or Governmental Obligations have theretofore been deposited in trust or segregated and held in trust by the Company and thereupon repaid to the Company or discharged from such trust, as provided in Section 11.05);
      or (b) all such Securities of a particular series not theretofore delivered to the Trustee for cancellation shall have become due and payable, or are by their terms to become due and payable within one year or are to be called for redemption within
      one year under arrangements satisfactory to the Trustee for the giving of notice of redemption, and the Company shall deposit or cause to be deposited with the Trustee as trust funds the entire amount in moneys or Governmental Obligations or a
      combination thereof, sufficient in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered to the Trustee, to pay at maturity or upon redemption all Securities of that
      series not theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay
      or cause to be paid all other sums payable hereunder with respect to such series by the Company then this Indenture shall thereupon cease to be of further effect with respect to such series except for the provisions of Sections 2.03, 2.05, 2.07,
      4.01, 4.02, 4.03 and 7.10, that shall survive until the date of maturity or redemption date, as the case may be, and Sections 7.06 and 11.05, that shall survive to such date and thereafter, and the Trustee, on demand of the Company and at the cost
      and expense of the Company shall execute proper instruments acknowledging satisfaction of and discharging this Indenture with respect to such series.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 11.2</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Discharge of Obligations.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If at any time all such Securities of a particular series not heretofore delivered to the
      Trustee for cancellation or that have not become due and payable as described in Section 11.01 shall have been paid by the Company by depositing irrevocably with the Trustee as trust funds moneys or an amount of Governmental Obligations sufficient to
      pay at maturity or upon redemption all such Securities of that series not theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for
      redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder by the Company with respect to such series, then after the date such moneys or Governmental Obligations, as the case may be, are
      deposited with the Trustee the obligations of the Company under this Indenture with respect to such series shall cease to be of further effect except for the provisions of Sections 2.03, 2.05, 2.07, 4,01, 4.02, 4,03, 7.06, 7.10 and 11.05 hereof that
      shall survive until such Securities shall mature and be paid.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">28</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter, Sections 7.06 and 11.05 shall survive.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 11.3</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deposited Moneys to be Held in Trust.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All moneys or Governmental Obligations deposited with the Trustee pursuant to Sections 11.01
      or 11.02 shall be held in trust and shall be available for payment as due, either directly or through any paying agent (including the Company acting as its own paying agent), to the holders of the particular series of Securities for the payment or
      redemption of which such moneys or Governmental Obligations have been deposited with the Trustee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 11.4</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment of Moneys Held by Paying Agents.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the satisfaction and discharge of this Indenture all moneys or
      Governmental Obligations then held by any paying agent under the provisions of this Indenture shall, upon demand of the Company, be paid to the Trustee and thereupon such paying agent shall be released from all further liability with respect to such
      moneys or Governmental Obligations.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 11.5</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Repayment to Company.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any moneys or Governmental Obligations deposited with any paying agent or the Trustee, or
      then held by the Company, in trust for payment of principal of or premium, if any, or interest on the Securities of a particular series that are not applied but remain unclaimed by the holders of such Securities for at least two years after the date
      upon which the principal of (and premium, if any) or interest on such Securities shall have respectively become due and payable, or such other shorter period set forth in applicable escheat or abandoned or unclaimed property law, shall be repaid to
      the Company on May 31 of each year or upon the Company&#8217;s request or (if then held by the Company) shall be discharged from such trust; and thereupon the paying agent and the Trustee shall be released from all further liability with respect to such
      moneys or Governmental Obligations, and the holder of any of the Securities entitled to receive such payment shall thereafter, as a general creditor, look only to the Company for the payment thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE XII</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 12.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No Recourse.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No recourse under or upon any obligation, covenant or agreement of this Indenture, or of any
      Security, or for any claim based thereon or otherwise in respect thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Company or of any predecessor or successor corporation, either
      directly or through the Company or any such predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly understood that this
      Indenture and the obligations issued hereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or shall be incurred by, the incorporators, stockholders, officers or directors as such, of the
      Company or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the
      Securities or implied therefrom; and that any and all such personal liability of every name and nature, either at common law or in equity or by constitution or statute, of, and any and all such rights and claims against, every such incorporator,
      stockholder, officer or director as such, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom,
      are hereby expressly waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issuance of such Securities.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">29</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE XIII</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MISCELLANEOUS PROVISIONS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.1</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect on Successors and Assigns.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All the covenants, stipulations, promises and agreements in this Indenture made by or on
      behalf of the Company shall bind its successors and assigns, whether so expressed or not.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.2</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actions by Successor.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any act or proceeding by any provision of this Indenture authorized or required to be done or
      performed by any board, committee or officer of the Company shall and may be done and performed with like force and effect by the corresponding board, committee or officer of any corporation that shall at the time be the lawful successor of the
      Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.3</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Surrender of Company Powers.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company by instrument in writing executed by authority of its Board of Directors and
      delivered to the Trustee may surrender any of the powers reserved to the Company, and thereupon such power so surrendered shall terminate both as to the Company and as to any successor corporation.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.4</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notices.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise expressly provided herein, any notice, request or demand that by any
      provision of this Indenture is required or permitted to be given, made or served by the Trustee or by the holders of Securities or by any other Person pursuant to this Indenture to or on the Company may be given or served by being deposited in first
      class mail, postage prepaid, addressed (until another address is filed in writing by the Company with the Trustee), as follows:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="font: 10pt Times New Roman, Times, Serif">
        <td style="width: 30%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 2pt">&#160;</font></td>
        <td style="width: 70%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 2pt">&#160;</font></td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif">
        <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 2pt">&#160;</font></td>
        <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 2pt">&#160;</font></td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif">
        <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 2pt">&#160;</font></td>
        <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 2pt">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">Any notice, election, request or demand by the Company or any Securityholder or by any other Person pursuant to
      this Indenture to or upon the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if given or made in writing at the Corporate Trust Office of the Trustee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.5</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governing Law.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Indenture and each Security shall be deemed to be a contract made under the internal
      laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said State, except to the extent that the Trust Indenture Act is applicable.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.6</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Treatment of Securities as Debt.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is intended that the Securities will be treated as indebtedness and not as equity for
      federal income tax purposes. The provisions of this Indenture shall be interpreted to further this intention.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.7</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certificates and Opinions as to Conditions Precedent.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Upon any application or demand by the Company to the Trustee to take any action under any
      of the provisions of this Indenture, the Company shall furnish to the Trustee an Officer&#8217;s Certificate stating that all conditions precedent provided for in this Indenture (other than the certificate to be delivered pursuant to Section 13.12)
      relating to the proposed action have been complied with and, if requested, an Opinion of Counsel stating that in the opinion of such counsel all such conditions precedent have been complied with, except that in the case of any such application or
      demand as to which the furnishing of such documents is specifically required by any provision of this Indenture relating to such particular application or demand, no additional certificate or opinion need be furnished.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Each certificate or opinion provided for in this Indenture and delivered to the Trustee
      with respect to compliance with a condition or covenant in this Indenture shall include (i) a statement that the Person making such certificate or opinion has read such covenant or condition;(ii) a brief statement as to the nature and scope of the
      examination or investigation upon which the statements or opinions contained in such certificate or opinion are based; (iii) a statement that, in the opinion of such Person, he has made such examination or investigation as is reasonably necessary to
      enable him to express an informed opinion as to whether or not such covenant or condition has been complied with; and (iv) a statement as to whether or not, in the opinion of such Person, such condition or covenant has been complied with.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">30</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.8</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payments on Business Days.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in
      an Officer&#8217;s Certificate, or established in one or more indentures supplemental to this Indenture, in any case where the date of maturity of interest or principal of any Security or the date of redemption of any Security shall not be a Business Day,
      then payment of interest or principal (and premium, if any) may be made on the next succeeding Business Day with the same force and effect as if made on the nominal date of maturity or redemption, and no interest shall accrue for the period after
      such nominal date.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.9</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conflict with Trust Indenture Act.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If and to the extent that any provision of this Indenture limits, qualifies or conflicts with
      the duties imposed by Sections 310 to 317, inclusive, of the Trust Indenture Act, such imposed duties shall control.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.10</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Counterparts.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Indenture may be executed in any number of counterparts, each of which shall be an
      original, but such counterparts shall together constitute but one and the same instrument.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.11 Separability.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In case any one or more of the provisions contained in this Indenture or in the Securities of
      any series shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Indenture or of such Securities, but this Indenture and such
      Securities shall be construed as if such invalid or illegal or unenforceable provision had never been contained herein or therein.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
        <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 13.12</b></font></td>
        <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compliance Certificates.</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall deliver to the Trustee, within 120 days after the end of each fiscal year
      during which any Securities of any series were outstanding, an officer&#8217;s certificate stating whether or not the signers know of any Default or Event of Default that occurred during such fiscal year. Such certificate shall contain a certification from
      the principal executive officer, principal financial officer or principal accounting officer of the Company that a review has been conducted of the activities of the Company and the Company&#8217;s performance under this Indenture and that the Company has
      complied with all conditions and covenants under this Indenture. For purposes of this Section 13.12, such compliance shall be determined without regard to any period of grace or requirement of notice provided under this Indenture. If the officer of
      the Company signing such certificate has knowledge of such a Default or Event of Default, the certificate shall describe any such Default or Event of Default and its status.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; font-weight: normal; font-style: normal;">31</font></div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed all as of the day and year
      first above written.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AQUESTIVE THERAPEUTICS, INC.</font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: bottom; width: 10%; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
        <td style="vertical-align: top; width: 90%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: bottom; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
        <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: bottom; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
        <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>
      <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
        <td colspan="2" style="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>
      <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
        <td colspan="2" style="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[TRUSTEE], as Trustee</font></p>
        </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: bottom; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
        <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: bottom; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
        <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif">
        <td style="vertical-align: bottom; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
        <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.75pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ny20010746x1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font style="font-weight: bold;">Exhibit 5.1</font><br>
    </div>
    <div><br>
    </div>
    <div>
      <table id="z890c7eed7d194d6a9252601def8868af" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 70%; padding-bottom: 2px;"><img src="ny20010746x1_logo01.jpg"></td>
            <td style="border-bottom: 1px solid #000000; width: 30%;">
              <div><font style="font-size: 8pt;">1095 Avenue of the Americas<br>
                  New York, NY&#160; 10036-6797<br>
                  +1&#160; 212&#160; 698&#160; 3500&#160; Main<br>
                  +1&#160; 212&#160; 698&#160; 3599&#160; Fax<br>
                  www.dechert.com</font><br>
              </div>
              <div><font style="font-size: 8pt;"> <br>
                </font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>April 3, 2024</div>
    <div> <br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z55794be5fba94517a84bca9d1ac69147" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 79.22%; vertical-align: top;">
            <div>Aquestive Therapeutics, Inc.</div>
            <div>30 Technology Drive</div>
            <div>Warren, New Jersey 07059</div>
          </td>
          <td style="width: 20.78%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 79.22%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 20.78%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z70dab12098e5446b98f5ac1aa2290766" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top;">Re:</td>
          <td style="width: auto; vertical-align: top;">
            <div><u>Registration Statement on Form S-3</u></div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div>Ladies and Gentlemen:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">We have acted as counsel to Aquestive Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), in connection with the preparation and filing by the Company of a registration statement on Form S-3
      (the &#8220;Registration Statement&#8221;), filed today with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), relating to the proposed public offerings by the Company from time to
      time of up to $250,000,000 aggregate amount of the following securities of the Company: (1) shares of common stock, par value $0.001 per share, of the Company (&#8220;Common Stock&#8221;); (2) shares of preferred stock, par value $0.001 per share, of the Company
      (&#8220;Preferred Stock&#8221;); (3) warrants of the Company to purchase Common Stock, Preferred Stock, Debt Securities or Units (each as defined below) (&#8220;Warrants&#8221;); (4) debt securities (&#8220;Debt Securities&#8221;) to be issued pursuant to an indenture between the
      Company and a trustee to be named therein (the &#8220;Trustee&#8221;) (such indenture, as may be amended or supplemented from time to time, the &#8220;Indenture&#8221;); (5) rights of the Company to purchase Common Stock, Preferred Stock, Debt Securities, or Units
      (&#8220;Rights&#8221;); and (6) units of the Company consisting of any combination of Common Stock, Preferred Stock, Warrants, Debt Securities or Rights (&#8220;Units&#8221;). The Common Stock, Preferred Stock, Warrants, Debt Securities, Rights and Units are collectively
      referred to herein as the &#8220;Securities.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The Registration Statement provides that the Securities may be offered separately or together, in separate series, in amounts, at prices and on terms as set forth in a prospectus, which was included
      in the Registration Statement, and which forms a part of the Registration Statement, or to be set forth in one or more supplements to the prospectus included in the Registration Statement (each, a &#8220;<u>Prospectus Supplement</u>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">This opinion letter is being furnished to the Company in accordance with the requirements of Item 601(b)(5) under Regulation S-K of the Securities Act, and no opinion is expressed herein as to any
      matter pertaining to the contents of the Registration Statement, other than as to the validity of the Securities as set forth below.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; text-align: right;"> Aquestive Therapeutics, Inc.<br>
      April 3, 2024<br>
      Page 2<br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">
      <div><br>
      </div>
      <div>In rendering the opinion expressed below, we have examined and relied on originals or copies, certified or otherwise identified to our satisfaction, of such documents, corporate records and other instruments and such agreements, certificates and
        receipts of public officials, certificates of officers or other representatives of the Company and others, and such other documents as we have deemed necessary or appropriate as a basis for rendering the opinion set forth below, including the
        following documents:</div>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zfe2912b8f1874a22a1a36da827e2a57e" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div>(i)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div>the Registration Statement;</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: auto; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div>(ii)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div>the Company&#8217;s Amended and Restated Certificate of Incorporation, as originally filed with the Secretary of State of the State of Delaware on July 27, 2018 (the &#8220;Certificate&#8221;);</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: auto; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div>(iii)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div>the Company&#8217;s Amended and Restated Bylaws, effective as of February 2, 2023 (together with the Certificate, the &#8220;Charter&#8221;);</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: auto; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div>(iv)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div>a Certificate of Good Standing with respect to the Company issued by the Secretary of State of the State of Delaware, as of a recent date; and</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 36pt; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: auto; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div>(v)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div>the resolutions of the board of directors of the Company, relating to, among other things, the authorization and approval of the preparation and filing of the Registration Statement.</div>
            <div>&#160;</div>
            <div>&#160;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">As to the facts upon which this opinion is based, we have relied, to the extent we deem proper, upon certificates of public officials and certificates and written statements of agents, officers,
      directors, employees and representatives of, and accountants for, the Company and we have assumed in this regard the truthfulness of such certifications and statements. We have not independently established the facts so relied on.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as original documents, the conformity to original documents of all documents
      submitted to us as copies, the legal capacity of natural persons who are signatories to the documents examined by us and the legal power and authority of all persons signing on behalf of the parties to all documents (other than the Company). We have
      further assumed that there has been no oral modification of, or amendment or supplement (including any express or implied waiver, however arising) to, any of the agreements, documents or instruments used by us to form the basis of the opinion
      expressed below.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">On the basis of the foregoing and subject to the assumptions, qualifications and limitations set forth in this letter, we are of the opinion, as of the date hereof, that:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zad7ebb6031334990bd4133fdb4efff13" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: middle;">&#160;</td>
          <td style="width: 36pt; vertical-align: top;">
            <div>1.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify;">The Common Stock, when (a) duly issued and sold in accordance with the Registration Statement and applicable Prospectus Supplement, or upon conversion or exchange of Debt Securities or Preferred Stock or upon
              exercise of Rights or Warrants as contemplated by the Registration Statement and applicable Prospectus Supplement, and (b) delivered to the purchaser or purchasers thereof against receipt by the Company of such lawful consideration therefor
              as the Board of Directors (or a duly authorized committee thereof) may determine and at a price per share not less than the per share par value of the Common Stock, will be validly issued, fully paid and non-assessable.</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: middle;">&#160;</td>
          <td style="width: 36pt; vertical-align: top;">
            <div>2.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify;">The Preferred Stock, when (a) duly issued and sold in accordance with the Registration Statement and applicable Prospectus Supplement, or upon conversion or exchange of Debt Securities or upon exercise of
              Rights or Warrants as contemplated by the Registration Statement and applicable Prospectus Supplement, and (b) delivered to the purchaser or purchasers thereof against receipt by the Company of such lawful consideration therefor as the Board
              of Directors (or a duly authorized committee thereof) may determine and at a price per share not less than the per share par value of the Preferred Stock, will be validly issued, fully paid and non-assessable.</div>
            <div style="text-align: justify;"> <br>
            </div>
          </td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: right;"> Aquestive Therapeutics, Inc.<br>
      April 3, 2024<br>
      Page 3</div>
    <div> <br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: middle;">&#160;</td>
          <td style="width: 36pt; vertical-align: top;">
            <div>3.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify;">The Warrants, when (a) duly executed, issued and sold in accordance with the Registration Statement and applicable Prospectus Supplement and the provisions of an applicable, valid and binding warrant agreement
              and (b) delivered to the purchaser or purchasers thereof against receipt by the Company of such lawful consideration therefor as the Board of Directors (or a duly authorized committee thereof) may determine, will be valid and binding
              obligations of the Company enforceable against the Company in accordance with their respective terms.</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: middle;">&#160;</td>
          <td style="width: 36pt; vertical-align: top;">
            <div>4.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify;">The Debt Securities, when (a) duly executed by the Company and authenticated by the applicable Trustee in accordance with the provisions of the valid and binding Indenture (including any amendments or
              supplements thereto) and issued and sold (x) in accordance with the Registration Statement and applicable Prospectus Supplement or (y) upon conversion or exchange of Preferred Stock or upon exercise of Rights or Warrants as contemplated by
              the Registration Statement and applicable Prospectus Supplement, and (b) delivered to the purchaser or purchasers thereof against receipt by the Company of such lawful consideration therefor as the Board of Directors (or a duly authorized
              committee thereof) may determine, will be valid and binding obligations of the Company enforceable against the Company in accordance with their respective terms.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc1018c1cdc914781a598907c13c94bcf" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: middle;">&#160;</td>
          <td style="width: 36pt; vertical-align: top;">
            <div>5.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify;">The Rights, when (a) duly issued in accordance with the Registration Statement and applicable Prospectus Supplement and the provisions of an applicable subscription certificate and any applicable and valid and
              binding subscription agreement, and (b) delivered to the purchaser or purchasers thereof against receipt by the Company of such lawful consideration therefor as the Board of Directors (or a duly authorized committee thereof) may determine,
              will be validly issued and binding obligations of the Company enforceable against the Company in accordance with their respective terms.</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: middle;">&#160;</td>
          <td style="width: 36pt; vertical-align: top;">
            <div>6.</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify;">The Units, when (a) duly executed, issued and sold in accordance with the Registration Statement and applicable Prospectus Supplement and the provisions of any applicable and valid and binding unit agreement,
              and (b) delivered to the purchaser or purchasers thereof against receipt by the Company of such lawful consideration therefor as the Board of Directors (or a duly authorized committee thereof) may determine, will be valid and binding
              obligations of the Company enforceable against the Company in accordance with their respective terms.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The opinions set forth herein are subject to the following assumptions, qualifications, limitations and exceptions being true and correct at or before the time of the delivery of any Securities
      offered pursuant to the Registration Statement and appropriate Prospectus Supplement: (i) the Board of Directors, including any appropriate committee appointed thereby, shall have (x) duly established the terms of the Securities (and in the case of
      the Units, the Securities that are the components thereof), and (y) duly authorized and taken any other necessary corporate or other action to approve the creation, if applicable, issuance and sale of the Securities and related matters (including
      with respect to Preferred Stock, the execution, acknowledgment and filing of a Certificate of Designation stating the designation and voting rights, preferences, limitations and special rights, if any, of any such Preferred Stock in accordance with
      the applicable provisions of the General Corporation Law of the State of Delaware) and any Securities consisting of Common Stock or Preferred Stock, and any Common Stock or Preferred Stock for or into which any other Securities are exercisable,
      exchangeable or convertible, shall have been duly reserved for issuance and such authorizations and actions have not been rescinded; (ii) the resolutions establishing the definitive terms of and authorizing the Company to register, offer, sell and
      issue the Securities shall remain in effect and unchanged at all times during which the Securities are offered, sold or issued by the Company; (iii) the definitive terms of each class and series of the Securities not presently provided for in the
      Registration Statement or the certificate of incorporation of the Company, and the terms of the issuance and sale of the Securities (x) shall have been duly established in accordance with all applicable law and the Charter, the Indenture (including
      any amendments or supplements thereto), underwriting agreement, warrant agreement, subscription agreement, unit agreement and any other relevant agreement relating to the terms and the offer and sale of the Securities (collectively, the &#8220;<u>Documents</u>&#8221;)
      and the authorizing resolutions of the Board of Directors, and reflected in appropriate documentation reviewed by us, and (y) shall not violate any applicable law, the Charter or the Documents (subject to the further assumption that such Charter and
      Documents have not been amended from the date hereof in a manner that would affect the validity of any of the opinions rendered herein), or result in a default under or breach of any agreement or instrument binding upon the Company and so as to
      comply with any restriction imposed by any court or governmental body having jurisdiction over the Company; (iv) upon issuance of any shares of Preferred Stock or Common Stock, or, in the case of Units, of which shares of Preferred Stock or Common
      Stock are components, including upon exercise, conversion or exchange of Securities, the total number of shares of Preferred Stock or Common Stock issued and outstanding shall not exceed the total number of shares of Preferred Stock or Common Stock
      that the Company is then authorized to issue under its certificate of incorporation; (v) the interest rate on the Debt Securities shall not be higher than the maximum lawful rate permitted from time to time under applicable law; (vi) the Securities
      (including any Securities issuable upon exercise, conversion or exchange of other Securities and, in the case of any Units, the Securities that are components thereof), and any certificates or instruments representing the relevant Securities
      (including any Securities issuable upon exercise, conversion or exchange of other Securities and, in the case of any Units, the Securities that are components thereof), have been duly authenticated, executed, countersigned, registered and delivered
      upon payment of the agreed-upon legal consideration therefor and have been duly issued and sold in accordance with any relevant agreement, approved by us and, if applicable, duly executed and delivered by the Company and any other appropriate party;
      (vii) the Indenture (including any amendments or supplements thereto), warrant agreement, subscription agreement, unit agreement and any other relevant agreement has been duly authorized, executed and delivered by, and will constitute a valid and
      binding obligation of, each party thereto (other than the Company); (viii) the Registration Statement, as amended (including all necessary post-effective amendments), and any additional registration statement filed under Rule 462, shall be effective
      under the Securities Act, and such effectiveness shall not have been terminated or rescinded; (ix) an appropriate Prospectus Supplement shall have been prepared, delivered and filed in compliance with the Securities Act and the applicable rules and
      regulations thereunder describing the Securities offered thereby; (x) the Securities shall be issued and sold in compliance with all federal and state securities laws and solely in the manner stated in the Registration Statement and the applicable
      Prospectus Supplement and there shall not have occurred any change in law affecting the validity of the opinions rendered herein; (xi) if the Securities will be sold pursuant to a firm commitment underwritten offering, the underwriting agreement with
      respect to the Securities in the form filed as an exhibit to the Registration Statement or any post-effective amendment thereto, or incorporated by reference therein, has been duly authorized, executed and delivered by the Company and the other
      parties thereto; (xii) the Indenture (including any amendments or supplements thereto) shall have been duly qualified under the Trust Indenture Act of 1939, as amended; (xiii) each agreement or contract referred to herein but not filed as an exhibit
      to the Registration Statement as of the date hereof shall be governed by the laws of the State of New York; and (xiv) in the case of an agreement or instrument pursuant to which any Securities are to be issued, there shall be no terms or provisions
      contained therein which would affect the validity of any of the opinions rendered herein.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; text-align: right;"> Aquestive Therapeutics, Inc.<br>
      April 3, 2024<br>
      Page 4</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Any opinion set forth herein as to enforceability of obligations of the Company is subject to: (i) bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar laws now or
      hereinafter in effect affecting the enforcement of creditors&#8217; rights generally, and by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or at law) and the discretion of the court or other body before
      which any proceeding may be brought; (ii) provisions of law that may require that a judgment for money damages rendered by a court in the United States be expressed only in United States dollars; (iii) requirements that a claim with respect to any
      Debt Securities denominated other than in U.S. dollars (or a judgment denominated other than in U.S. dollars in respect of such claim) be converted into U.S. dollars at a rate of exchange prevailing on a date determined pursuant to applicable law;
      and (iv) governmental authority to limit, delay or prohibit the making of payments outside the United States or in foreign currency or composite currency.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">We express no opinion as to the validity, legally binding effect or enforceability of any provision in any agreement or instrument that (i) requires or relates to payment of any interest at a rate or
      in an amount that a court would determine in the circumstances under applicable law to be higher than the maximum lawful rate permitted from time to time or (ii) relates to governing law and submission by the parties to the jurisdiction of one or
      more particular courts.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The opinion expressed herein is limited to the General Corporation Law of the State of Delaware. We are members of the bar of the State of New York. We express no opinion concerning the laws of any
      other jurisdiction, and we express no opinion concerning any state securities or &#8220;blue sky&#8221; laws, rules or regulations, or any federal, state, local or foreign laws, rules or regulations relating to the offer and/or sale of the Securities. The
      opinions expressed herein are based upon the law as in effect and the documentation and facts known to us on the date hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">This opinion letter has been prepared for your use solely in connection with the Registration Statement. We assume no obligation to advise you of any changes in the foregoing subsequent to the
      effectiveness of the Registration Statement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the use of our name in the base prospectus contained therein, under the caption &#8220;Legal Matters.&#8221; In
      giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act and the rules and regulations of the Commission thereunder.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3fc7e39aefb94abb8857b498e83dcedf" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">
            <div>Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">
            <div>/s/ Dechert LLP</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>4
<FILENAME>ny20010746x1_ex5-2.htm
<DESCRIPTION>EXHIBIT 5.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">


  <div>
    <div style="text-align: right;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font style="font-weight: bold;">Exhibit 5.2</font><br>
    </div>
    <div><br>
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 70%; padding-bottom: 2px;"><img src="ny20010746x1_logo01.jpg"></td>
              <td style="border-bottom: 1px solid #000000; width: 30%;">
                <div><font style="font-size: 8pt;">1095 Avenue of the Americas<br>
                    New York, NY 10036-6797<br>
                    +1 212 698 3500 Main<br>
                    +1 212 698 3599 Fax <br>
                    www.dechert.com</font><br>
                </div>
                <div><font style="font-size: 8pt;"> <br>
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><font style="font-weight: bold;"> <br>
      </font></div>
    <div>April 3, 2024</div>
    <div><br>
    </div>
    <div>Aquestive Therapeutics, Inc.</div>
    <div>30 Technology Drive</div>
    <div>Warren, New Jersey 07059</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3826d39775e74b0a84d7949633cebe42" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Re:</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div><u>Registration Statement and Equity Distribution Agreement Prospectus on Form S-3</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>Ladies and Gentlemen:</div>
    <div style="text-align: justify;"><br>
    </div>
    <div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">We have acted as counsel to Aquestive Therapeutics, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), in connection with the preparation and filing by the Company of a registration statement on Form S-3 (the &#8220;<u>Registration
            Statement</u>&#8221;), filed today with the U.S. Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), relating to the sale from time to time of shares of the Company&#8217;s common stock, par value $0.001 per share, having an aggregate offering price of up to
        $100,000,000 (the &#8220;<u>Offered Shares</u>&#8221;), as set forth in the prospectus dated April 3, 2024, which is included in the Registration Statement, and which forms a part of
        the Registration Statement (the &#8220;<u>Prospectus</u>&#8221;), and as may be set forth from time to time in one or more supplements to the Prospectus (each, a &#8220;<u>Prospectus Supplement</u>&#8221;).</div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The Offered Shares are to be sold by the Company pursuant
        to the equity distribution agreement, dated September 11, 2019, by and between the Company and Piper Jaffray &amp; Co. (n/k/a Piper Sandler &amp; Co.),<font style="font-family: 'Times New Roman',Times,serif;">&#160;as amended to date (the &#8220;<u>Equity Distribution Agreement</u>&#8221;).</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">This opinion letter is being furnished to the Company in accordance with the requirements of Item 601(b)(5) under Regulation S-K of the
      Securities Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement, other than as to the validity of the Offered Shares as set forth below.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">In rendering the opinion expressed below, we have examined and relied on originals or copies, certified or otherwise identified to our
      satisfaction, of such documents, corporate records and other instruments and such agreements, certificates and receipts of public officials, certificates of officers or other representatives of the Company and others, and such other documents as we
      have deemed necessary or appropriate as a basis for rendering the opinion set forth below, including the following documents:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z52d6fa6b28bf473297f6334c05511649" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">(i)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">the Registration Statement;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">(ii)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">the Prospectus;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">(iii)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">the Company&#8217;s Amended and Restated Certificate of Incorporation, as originally filed with the Secretary of State of the State of Delaware on July 27, 2018;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">(iv)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">the Company&#8217;s Amended and Restated Bylaws, effective as of February 2, 2023;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">(v)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">a Certificate of Good Standing with respect to the Company issued by the Secretary of State of the State of Delaware, as of a recent date;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">(vi)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">the Equity Distribution Agreement; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 36pt; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">(viii)</div>
          </td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">the resolutions of the board of directors of the Company, relating to, among other things, (a) the authorization and approval of the preparation and filing of
              the Registration Statement and the Prospectus and (b) the authorization to enter into and amend the Equity Distribution Agreement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">As to the facts upon which this opinion is based, we have relied, to the extent we deem proper, upon certificates of public officials
      and certificates and written statements of agents, officers, directors, employees and representatives of, and accountants for, the Company and we have assumed in this regard the truthfulness of such certifications and statements. We have not
      independently established the facts so relied on.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as original
      documents, the conformity to original documents of all documents submitted to us as copies, the legal capacity of natural persons who are signatories to the documents examined by us and the legal power and authority of all persons signing on behalf
      of the parties to all documents (other than the Company). We have further assumed that there has been no oral modification of, or amendment or supplement (including any express or implied waiver, however arising) to, any of the agreements, documents
      or instruments used by us to form the basis of the opinion expressed below.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; text-align: right;"> Aquestive Therapeutics Inc.<br>
      April 3, 2024<br>
      Page 2<br>
      <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">On the basis of the foregoing and subject to the assumptions, qualifications and limitations set forth in this letter, we are of the
      opinion, as of the date hereof, that the Offered Shares have been duly authorized for issuance by the Company and, when the Offered Shares have been (i) duly issued and sold in accordance with the Registration Statement, the Prospectus and any
      applicable Prospectus Supplement and (ii) delivered to the purchaser or purchasers thereof against receipt by the Company of such lawful consideration therefor in accordance with the terms of the Equity Distribution Agreement and at a price per share
      not less than the per share par value of the Company&#8217;s common stock, the Offered Shares will be validly issued, fully paid and non-assessable.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The opinion expressed herein is limited to the General Corporation Law of the State of Delaware. We are members of the bar of the State
      of New York. We express no opinion concerning the laws of any other jurisdiction, and we express no opinion concerning any state securities or &#8220;blue sky&#8221; laws, rules or regulations, or any federal, state, local or foreign laws, rules or regulations
      relating to the offer and/or sale of the Offered Shares. The opinions expressed herein are based upon the law as in effect and the documentation and facts known to us on the date hereof.</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">This opinion letter has been prepared for your use solely in connection with the Registration Statement. We assume no obligation to advise you
        of any changes in the foregoing subsequent to the effectiveness of the Registration Statement.</div>
    </div>
    <div><br>
    </div>
    <div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the use of our name in the Prospectus
        contained therein, under the caption &#8220;Legal Matters.&#8221; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act and the rules and regulations of the
        Commission thereunder.</div>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf99992700f6b43b5ac89060e1c19c5e7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top; text-align: right;">/s/ Dechert LLP</td>
        </tr>

    </table>
    <div style="text-align: right;"><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ny20010746x1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font style="font-weight: bold;">Exhibit 23.1</font><br>
  </div>
  <div><br>
  </div>
  <div>
    <div style="text-align: center; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
    <div><br>
    </div>
    <div>We consent to the use of our report dated March&#160;5,&#160;2024, with respect to the consolidated financial statements of Aquestive Therapeutics, Inc., incorporated
      herein by reference, and to the reference to our firm under the heading "Experts" in the prospectus.</div>
    <div><br>
    </div>
    <div style="text-align: center;">/s/ KPMG LLP</div>
    <div><br>
    </div>
    <div>Short Hills, New Jersey<br>
      April&#160;3,&#160;2024</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>ny20010746x1_ex107.htm
<DESCRIPTION>EXHIBIT 107
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="text-align: right; color: #000000; font-weight: bold;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 107</div>
  <div>&#160;</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">Calculation of Filing Fee Tables</div>
  <div>&#160;</div>
  <div style="text-align: center; color: #000000;"><font style="font-weight: bold;">Form S-3</font><br>
    (Form Type)</div>
  <div>&#160;</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">Aquestive Therapeutics, Inc.</div>
  <div style="text-align: center; color: #000000;">(Exact Name of Registrant as Specified in its Charter)</div>
  <div>&#160;</div>
  <div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7c2c72aab44d474896241dfd464090a9" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.12%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Security Type</div>
          </td>
          <td style="width: 7.12%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Security Class Title</div>
          </td>
          <td style="width: 9.71%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Fee Calculation or Carry Forward Rule</div>
          </td>
          <td style="width: 8.14%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Amount Registered(1)</div>
          </td>
          <td style="width: 8.69%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Proposed Maximum Offering Price Per Unit(2)</div>
          </td>
          <td style="width: 8.42%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Maximum Aggregate Offering Price(3)</div>
          </td>
          <td style="width: 7.12%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Fee Rate</div>
          </td>
          <td style="width: 7.77%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Amount of Registration Fee</div>
          </td>
          <td style="width: 6.47%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Carry Forward Form Type</div>
          </td>
          <td style="width: 6.47%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Carry Forward File Number</div>
          </td>
          <td style="width: 6.47%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Carry Forward Initial Effective Date</div>
          </td>
          <td colspan="2" style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Filing Fee Previously Paid In Connection with Unsold Securities to be Registered</div>
          </td>
        </tr>
        <tr>
          <td colspan="14" style="width: 100%; vertical-align: top; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Newly Registered Securities</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Fees to be Paid</div>
          </td>
          <td style="width: 7.12%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Equity</div>
          </td>
          <td style="width: 7.12%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Common Stock, par value $0.001 per share (the &#8220;Common Stock&#8221;)</div>
          </td>
          <td style="width: 9.71%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.14%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.69%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.77%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td colspan="2" style="width: 10%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Equity</div>
          </td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Preferred Stock</div>
          </td>
          <td style="width: 9.71%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.14%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.69%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.77%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td colspan="2" style="width: 10%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Debt</div>
          </td>
          <td style="width: 7.12%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Debt Securities</div>
          </td>
          <td style="width: 9.71%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.14%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.69%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.77%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td colspan="2" style="width: 10%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Other</div>
          </td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Warrants</div>
          </td>
          <td style="width: 9.71%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.14%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.69%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.77%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td colspan="2" style="width: 10%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Other</div>
          </td>
          <td style="width: 7.12%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Rights</div>
          </td>
          <td style="width: 9.71%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.14%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.69%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.77%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td colspan="2" style="width: 10%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Other</div>
          </td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Units</div>
          </td>
          <td style="width: 9.71%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.14%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.69%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.77%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td colspan="2" style="width: 10%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Unallocated (Universal) Shelf</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 9.71%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Rule 457(o)</div>
          </td>
          <td style="width: 8.14%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.69%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">$132,721,077</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">0.00014760</div>
          </td>
          <td style="width: 7.77%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">$19,590</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td colspan="2" style="width: 10%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Fees Previously Paid</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 9.71%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.14%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.69%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.77%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td colspan="2" style="width: 10%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
        </tr>
        <tr>
          <td colspan="14" style="width: 100%; vertical-align: middle; background-color: #D9E2F3;">
            <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Carry Forward Securities</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Carry Forward Securities</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">Unallocated (Universal) Shelf</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 9.71%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">415(a)(6)</div>
          </td>
          <td style="width: 8.14%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.69%; vertical-align: middle;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">$117,278,923</div>
          </td>
          <td style="width: 7.12%; vertical-align: middle; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 7.77%; vertical-align: middle; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">S-3</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">333-254775</div>
          </td>
          <td style="width: 6.47%; vertical-align: middle; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">April 5, 2021</div>
          </td>
          <td colspan="2" style="width: 10%; vertical-align: middle; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">$12,796</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 9.71%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 8.14%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="background-color: #D9E2F3; margin: 0px 0px 0px 0px; vertical-align: top; width: 8.69%; padding: 0px 6pt 0px 0px;">
            <div style="text-align: right; color: #000000; font-size: 8pt; font-weight: bold;">Total Offering Amounts</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">$250,000,000</div>
          </td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 7.77%; vertical-align: middle; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">$19,590</div>
          </td>
          <td style="width: 6.47%; vertical-align: top; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.47%; vertical-align: top; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.47%; vertical-align: top; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td colspan="2" style="width: 10%; vertical-align: top; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top;">&#160;</td>
          <td style="width: 9.71%; vertical-align: top;">&#160;</td>
          <td style="width: 8.14%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top; width: 8.69%; padding: 0px 6pt 0px 0px;">
            <div style="text-align: right; color: #000000; font-size: 8pt; font-weight: bold;">Total Fees Previously Paid</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 7.12%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 7.77%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: top; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.47%; vertical-align: top; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.47%; vertical-align: top; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td colspan="2" style="width: 10%; vertical-align: top; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 9.71%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="width: 8.14%; vertical-align: top; background-color: #D9E2F3;">&#160;</td>
          <td style="background-color: #D9E2F3; vertical-align: top; width: 8.69%; padding: 0px 6pt 0px 0px;">
            <div style="text-align: right; color: #000000; font-size: 8pt; font-weight: bold;">Total Fee Offsets</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 7.12%; vertical-align: middle; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 7.77%; vertical-align: middle; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">&#8212;</div>
          </td>
          <td style="width: 6.47%; vertical-align: top; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.47%; vertical-align: top; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.47%; vertical-align: top; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 2.24%; vertical-align: top; background-color: #D9E2F3; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="background-color: #D9E2F3; vertical-align: top; width: 7.76%;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top;">&#160;</td>
          <td style="width: 7.12%; vertical-align: top;">&#160;</td>
          <td style="width: 9.71%; vertical-align: top;">&#160;</td>
          <td style="width: 8.14%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top; width: 8.69%; padding: 0px 6pt 0px 0px;">
            <div style="text-align: right; color: #000000; font-size: 8pt; font-weight: bold;">Net Fees Due</div>
          </td>
          <td style="width: 8.42%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 7.12%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 7.77%; vertical-align: middle; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-size: 8pt;">$19,590</div>
          </td>
          <td style="width: 6.47%; vertical-align: top; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.47%; vertical-align: top; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 6.47%; vertical-align: top; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          <td colspan="2" style="width: 10%; vertical-align: top; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>

    </table>
  </div>
  <div> <br>
  </div>
  <div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7cb66676c5a943b2b6c25d9f9cbe3df4" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 8pt; text-align: center;">(1)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-size: 8pt;"><font style="color: #000000;">There are being registered hereunder an indeterminate
                  number of each identified class of securities of Aquestive Therapeutics, Inc., which securities may be offered and sold, on a primary basis, in such amount as shall result in an aggregate public offering price for all securities of $</font>250,000,000
                <font style="color: #000000;">after the date hereof. The securities registered hereunder also include such indeterminate amount of debt securities and shares of Common Stock and
                  shares of preferred stock as may be issued upon conversion or exchange for any other debt securities or preferred stock that provide for conversion or exchange into other securities being registered hereunder. Any securities registered
                  hereunder may be sold separately or as units with other securities registered hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this Registration Statement shall be deemed to cover an
                  indeterminate number of additional securities to be offered as a result of share splits, share dividends or similar transactions.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z10649843d43d4e708e96b374190a63fc" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 8pt; text-align: center;">(2)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-size: 8pt;">With regard to the securities included in the offering made hereby, the proposed maximum offering price per security will be
                determined from time to time by the registrant in connection with the issuance of the securities registered by this Registration Statement. Prices, when determined, may be in U.S. dollars or the equivalent thereof in one or more foreign
                currencies, foreign currency units or composite currencies. If any debt securities or shares of preferred stock are issued at an original issue discount, then the amount registered will include the principal or liquidation amount of such
                securities measured by the initial offering price thereof.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z90b5c87e45e04e0d8ec3d54b5f6760a5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 8pt; text-align: center;">(3)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-size: 8pt;">Pursuant to Rule 415(a)(6) under the Securities Act, the securities registered pursuant to this registration statement include
                $117,278,923 of unsold securities (the &#8220;Carry Forward Securities&#8221;) previously registered pursuant to the shelf registration statement on Form S-3 (File No. 333-254775), which was declared effective by the U.S. Securities and Exchange
                Commission on April 5, 2021 (the &#8220;Prior Registration Statement&#8221;). In connection with the filing of the Prior Registration Statement, the registrant paid a filing fee of $27,275. Of this amount, $12,796 is associated with the Carry Forward
                Securities. The filing fees associated with the Carry Forward Securities are hereby carried forward to be applied to the Carry Forward Securities registered hereunder, and no additional filing fee is due with respect to the Carry Forward
                Securities in connection with the filing of this registration statement. To the extent that, after the filing date hereof and prior to the effectiveness of this registration statement, the registrant sells any Carry Forward Securities
                pursuant to the Prior Registration Statement, the registrant will identify in a pre-effective amendment to this registration statement the updated number of Carry Forward Securities from the Prior Registration Statement to be included in
                this registration statement pursuant to Rule 415(a)(6) and the updated amount of new securities to be registered on this registration statement. The registrant is also registering new securities on this registration statement with an
                aggregate maximum offering price of $132,721,077 (the &#8220;New Securities&#8221;), which aggregate offering price is not specified as to each class of securities in reliance upon Rule 457(o) promulgated under the Securities Act. A filing fee of
                $19,590 with respect to the New Securities is being paid in connection with the filing of this registration statement. Pursuant to Rule 415(a)(6), the offering of the Carry Forward Securities under the Prior Registration Statement will be
                deemed terminated as of the date of effectiveness of this registration statement.</div>
            </td>
          </tr>

      </table>
    </div>
  </div>
  <div> <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo_aquestivex1.jpg
<TEXT>
begin 644 logo_aquestivex1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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ML)<UZJ5GK?F25N;I;S\^FJOZ#12*054@Y! (/'((X/''(]./2EKX ]L****
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M#9M3L/,U;2-'M_#VN^*+O3_L6I3:%9Z)J>G:O);=M6!^YM%?YTOQ,_X.V_\
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MM=\-7'@7PI8_# ^*+GP1X'\,:A>VFH>)KE=:\2Z;X5OO$^M>([K3-(BC>_\
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M:1;^)M'L;X_\(_XNTRRN?@?+(FD>)]&:PU[3=TTA;2]1A(89R?TN_P""-O\
MP6NTS_@J[??&?PWJ/P3@^!/C;X00>%M9M]#MOB*/'UIXI\,^*EU2S2_M[FZ\
M&>![RSETG5=(,%_:?8)55-0TQS+N<DM--VOKKWZ"U[?T[6_/[D?O+117\TG_
M  5N_P"#A;3/^"9_[2>D?LX^$OV>M'^/^M'X:>'/&WC/6)/C%+X#/@W6?%&J
M:[%I?A.]T>T^'GC-[O4&\-Z=H7B[[9)J&DYTGQ9HY$>"7+NEN[+Y_I=C_P"'
M^5TNO:ZN?TMT5_,9_P $HO\ @OS\3O\ @J'^U!<? ;2OV-="^&/AC0O ?B?X
MA>.OB&WQPU/Q=-X>T?2+BPT31M/M-!/PH\/6E]K>K^(-<TVRCL9/$6D Z6FL
MZP@E\@6Y_1G_ (*5_P#!77]E#_@F'X2MW^+VM77C/XS>)]$U76/AQ\ _!+6U
MQXY\5PVERMG::GK^J$-IOPZ\&M?W?E_\)/XG/]H:LD&N_P#""Z)XYUOP]J^A
M*KJU^G=JW;OZAKT5]OSMV_K8_5JBO\Z/XR_\':_[?WC'6M47X._"K]G3X*>$
M9KKSM"L[W0O$_P 3_'=G:  &TU?Q;J_BO1?"FMDGDWVG?#30AV"@<GO_ -F7
M_@[A_:Q\(^(]&T[]JSX)_"?XQ?#_ .T^1K6M_#&TUGX8_%"WMKN[P^JVKWFN
M^)/A_KATNR9CIGAM/#7AQM8:../5O$NB OK#3[2.F]O3OMH!_H.T5\=_L9_M
MK_LZ_M[?!/P_\??V;_&D?BKPSK$:6NO^&M1%I:^//A]XJ6W+:EX&^(GA6.^O
MF\+^+-.9V4I]ON-'US2'M]?\-:UK_@VYT37;O[$J_02?R^=^B?\ 7WD1A0DD
MHI))).3R3WZ5D:AI6CZC&\&J6%E>P'(,=Y:0W*8)Y!6>W="..I)SZ]Z_@7_X
M*D_\%2/^"FOP%_;C_:<^ >A_M3^(?#'@SP#\5]4F\!Z+X<\(_"O2[O1/!/B6
MQM/&G@/2+C6]-^']KJNK1Z9X1\6:98P+JVKZE?SM;I?Z[>7>N>==/^1FL?\
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MYO=3U)X-,T^&-Y)Y;9BLE?T$_P#!U?XN\9:Q_P %+;+PGK-R]QX2\%_ _P
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M'!\0O8C4AH+>-_%6D^&#K/\ 9/\ :FC?VB-+.K&^.D?;=/\ MX3^S_[43?\
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MNRN[*\-C?VD=^$U"P?2V*X=64E3$M+1[)?C:[U=[W^:]7J]--]]?^!_6[/\
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MM)U6P%S,+36+6]M&D<PLU?R.?\%-OV:K[]GK]I?Q3=V=D8_ /Q3O[_QSX.N
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MEL^M_#[Q*D7_ " ?%EK:7"6<MS C1M=:5J$4[6.IV:$'[-*9K5[>]C6XLO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ny20010746x1_logo01.jpg
<TEXT>
begin 644 ny20010746x1_logo01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  I '@# 2(  A$! Q$!_\0
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J&XM!#J37SH;+]S&QVQ 8;N<< DX/%%=CX9_Y'/QC_P!?5M_Z31T4 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
